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Abstract
Since bile acids are m ajor excretion products o f  cholesterol in the body, changes 
in rates o f  production w ill affect the turnover rate o f  cholesterol in the body. 7 a -  
hydroxycholesterol is the product o f  the rate-lim iting reaction in the biosynthesis o f 
bile acids and it has been suggested that its concentration in serum is a good 
parameter for establishing disorders involving the m etabolic conversion o f  7 a- 
hydroxycholesterol towards bile acids.
The objectives o f  the project w ere to validate the m ethodology towards 
measurement o f  7a-h ydroxych olesterol in serum - to investigate serum levels o f  this 
analyte in human and rat sera and to develop  a m ethodology based on discoidal 
com plexes for esterification studies o f  7a-h ydroxych olesterol. The method involved 
the extraction o f  lipids from  serum using the F olch  method, hydrolysis o f  the sample 
to yield total amounts present, enzym atic conversion o f  7a-h ydroxych olesterol to its 
enone derivative w hich w as then detected and m easured at 240 nm using reverse 
phase H PLC .
A  significant amount o f  7a-hydroxycholesteroI w as found to be esterified, which 
resulted in studies being carried out on (a) its possible esterification in the liver by 
acyl coenzym e A  : cholesterol-O -acyltransferase, or (b) in the plasm a by lecithin : 
cholesterol acyltransferase, which was facilitated by the synthesis o f  discoidal 
com plexes, containing 7a-hydroxycholesterol, by the sodium cholate dialysis method 
and w hich resem bled native high density lipoproteins. Electron m icroscopy w as 
carried out to exam ine the physical structures o f  these com plexes.
The biological significance o f  serum 7a-h yd roxych olesterol w ill be discussed in 
the thesis.
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CHAPTER 1 
INTRODUCTION
“ Cholesterol is the most highly decorated sm all m olecule in biology. Thirteen N obel 
prizes have been awarded to scientists who devoted m ajor parts o f  their careers to 
cholesterol. Ever since it was isolated from gallstones in 1784, cholesterol has exerted an 
alm ost hypnotic fascination for scientists from the m ost diverse areas o f  science and 
medicine. Cholesterol is a Janus-faced m olecule. The very property that m akes it useful 
in cell membranes, nam ely its absolute insolubility in water also makes it lethal” . These 
are the celebrated words o f  M ichael Brown and Joseph Goldstein who received the Nobel 
prize in medicine in 1985 for their pioneering studies o f  fam ilial hypercholesterolaemia, a 
genetic disorder associated with defective cellular uptake.
M uch has since been learned concerning cellular uptake o f  cholesterol in health and 
disease. Furtherm ore, m uch o f  the current p ersp ective  on atherosclerosis is now  
focussing on the role o f  oxysterols as species ‘beyond cholesterol’ that act as homeostatic 
signals for nuclear control o f  the many cholesterol utilising pathways in mammalian cells. 
In specialised tissues such as the adrenal glands, gonads and liver, cholesterol undergoes 
a variety o f oxidation steps w hich increase its polarity and permit its transit through the 
aqueous fluids o f  the body. The parent sterol m olecu le  lacks this fa cility  and must 
therefore be solubilised by interaction with a number o f  amphipathic agents. In plasma, it 
exists in association w ith phospholipid and certain proteins to form  the lipid-protein 
com p lexes that w e call lipoproteins. In b ile , on the other hand, b ile  salts and 
phospholipid act as its em ulsify ing agents, lead ing to the production o f  m icellar 
aggregates. B ile  acids are the major metabolites o f  cholesterol in humans being formed in 
the liver via  pathw ays involving a large number o f  oxygenated steroid interm ediates, 
many o f  w hich appear in blood also. The occurrence, identification and quantitation in 
serum o f oxygenated steroid intermediates o f  both cholesterol and bile acid biosynthetic 
pathways is being seen to provide a diagnostic aid to liver and gastrointestinal diseases 
and during dietary, hormonal and pharm acological m anipulation o f  plasm a cholesterol 
levels.
The oxysterol at the centre o f  this study was 7a-hydroxycholesterol, the product o f  the 
rate-lim iting reaction in bile acid biosynthesis. M ost o f  our know ledge regarding the 
regulation o f  bile acid production has been gathered in the rat. The absence o f  a gall 
bladder in this species, coupled with an unusually long sm all intestine results in high 
levels  o f  b ile  acid  b iosynthesis. N otw ithstanding this h ow ever and despite the 
applications o f  modem chromatographic and spectroscopic methods to steroid analysis in 
serum, it appears that only one such investigation o f  levels o f  oxysterols in rat serum has
ever been reported. The study, published earlier this year reported le v e ls  o f  7 a -  
hydroxycholesterol in portal blood (Fukushima et  al . , ) .  One o f  the objectives o f  this 
study w as to v a lid a te  a procedure for the accu rate d eterm in ation  o f  7 a -  
hydroxycholesterol in rat serum. The second phase o f  the study compared the levels o f
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7 a-hydroxycholesterol in serum o f  rat and man and to ascertain w hether levels o f  this
m etabolite in serum reflected alterations in cholesterol m etabolism . Increased flow  
through a m etabolic pathway sometimes leads to an increased leakage o f  intermediates 
from the pathw ay into the circulation. It is w ell docum ented that the serum levels o f  
different methyl sterols, intermediates in cholesterol biosynthesis are increased under 
conditions o f  increased biosynthesis o f  cholesterol. This study also investigated the
possibility that the serum concentration o f  7 a-hydroxycholesterol m ay reflect the hepatic
concentration o f  7 a -h y d ro x y ch o le ste ro l form ed by ch o lestero l 7a -h yd ro x ylase . 
U nequivocable demonstration o f the mode o f  transport o f  oxysterols in plasm a has been 
elusive. H ow ever, several studies have reported and confirm ed an oxidative nature to
lipoproteins, 7a-h ydroxych olesterol being one such oxysterol belon gin g to a broad 
spectrum o f oxysterols identified within the major circulating lipoproteins. D ifferences in 
the m etabolism  o f these oxidatively m odified lipoproteins have been im plicated in the
initiation o f  atherosclerosis. H aving investigated the extent o f  esterification  o f  7 a -
hydroxycholesterol in human and rat sera, the third and final phase o f  this study involved
investigating serum as a possible site for its further m etabolism . The reactivity o f  7 a -
h yd roxych olesterol w ith  a serum  ch olestero l acy ltran sferase e n zy m e dem anded 
development o f an exquisite substrate vehicle and partially purified enzym e source devoid 
o f  contaminating acceptor lipoproteins and exchange/transfer proteins. The extent o f  its 
interaction w ith this enzym e was com pared w ith that o f  its reaction w ith  the hepatic 
equivalent sterol-esterifying enzyme.
The aim o f  this chapter is to introduce the elements o f  plasm a lipoprotein m etabolism  
prior to review ing the occurence and biological effects o f  plasm a oxysterols. V alidation
o f  the preparative and chrom atographic procedures necessary for quantifying 7 a -
hydroxycholesterol in serum together w ith a species com parison survey o f  the sterol in 
serum paved the w ay forward for a study to determine a possible putative lipoprotein- 
mediated pathway for its m etabolism. These three studies form  the basis for the w ork 
described in this thesis.
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1.1 Cholesterol and its metabolism:
From a biochem ical perspective, cholesterol is a necessary constituent for eukaryotic 
cell growth and developm ent. The biosynthesis o f  cholesterol provides crucial building 
blocks for cell membranogenesis and membrane fluid regulation and for the synthesis o f  
sterol and non sterol products that are important for norm al cell function. P revailin g 
interest in cholesterol has revolved around its role in the developm ent in atherosclerosis 
and cholelithiasis and m uch research energy has been directed tow ard id en tify in g  
m echanisms to decrease elevated serum cholesterol levels. M ore recent developm ents 
have underscored the essential nature o f cholesterol in cell growth and developm ent and 
have begun to elucidate the mechanisms governing cholesterol homeostasis.
Cholesterol m ay be obtained for cellular m etabolism  either via  uptake m ediated by 
members o f  the low  density lipoprotein (LD L) receptor fam ily  or through biosynthesis. 
The uptake pathway involving the lipoprotein receptors m ay be further subdivided into an 
exogenous (dietary) pathw ay and an endogenous pathw ay (Fig 1.1). A lth ou gh  uptake 
and biosynthesis are interdependent, cellular cholesterol requirements can be met equally 
w ell through either supply pathway. Cholesterol hom eostasis in mammals is through the 
coordinate regulation o f  these supply pathways in the liver and by a third pathway in liver 
which involves the catabolism o f cholesterol to hydrophilic bile acids. This latter pathway 
involving cholesterol conversion to bile acid accounts for approxim ately 50%  o f  total 
cholesterol excreted from the body per day (Fielding and Fielding, 1985).
1.1.2: The plasma lipoproteins
D ue to its insolubility in an aqueous medium, cholesterol is transported in plasm a in 
lipoproteins, w hich are m ultim olecular com plexes o f  triglycerides, phospholipids, free 
fatty acids, cholesterol free and esterified and protein. T h ey are classified on the basis o f  
their lipid or protein com position. They can be divided into five  m ajor classes, shown in 
Table 1 . The larger lipoproteins usually have a h igher content o f  lipids, esp ecia lly  
neutral lipids and as a consequence, their density decreases with increasing size. The fatty 
acid composition o f  the lipids vary in the different human lipoproteins. U sually, a strong 
similarity exists between the fatty acid compositions o f  specific lipid classes (Gotto et  al.,  
1986). This m ay be attributed to the various lipid exchange proteins in plasm a. The 
protein components o f  these com plexes are termed apolipoproteins. T w o major fam ilies 
o f  these proteins- apolipoprotein A  and apolipoprotein B , are intim ately involved  in the 
transport o f cholesterol (Fig 1.1). Apo A  is the main protein o f  plasm a H D Ls, w hich by 
accepting cholesterol, is involved in the transport o f  cholesterol from peripheral tissues 
back to the liver in what is known as “ reverse cholesterol transport” . A p o B is an integral 
com ponent o f  V L D L , ID L , L D L  and chylom icrons. It is involved in the transport o f  
cholesterol and triglyceride to peripheral parenchym al cells. These cells then utilise the 
cholesterol for structural and m etabolic purposes. Thus, apolipoproteins stabilise the 
surface o f  the lipoproteins, w hile also providing “address labels” that govern which cells 
in the body receive and metabolise these lipoproteins (Fielding and Fielding, 1985).
3
F ig  1 .1  : Schem atic representation o f  the major elements o f  human plasm a lipoprotein 
m etabolism  illustrating the flow  o f exogenous/dietary and endogenous cholesterol. 
A bbreviations: A C A T  = acyl C o A -ch o lestero l acyltransferase; L C A T  = lecithin- 
cholesterol acyltransferase; H M G R  = H M G  C o A  reductase; P A P  = phosphatidic acid 
phosphatase; C E T P  = cholesteryl ester transfer protein; F A  = fatty acids. (Shepherd 
and Packard, 1992).
D ie lo r y  c h o ie j fe r o l  
a n d  I r ig ly c e r id «
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The largest lipoproteins are the chylom icrons, w hich  are synthesised in the gut during 
intestinal assimiliation o f exogenous lipid and carry dietary triglycerides and cholesterol. 
T hey acquire apo E and C  from HDL. The form er apolipoprotein acts as a cofactor for 
lipoprotein lipase which is located on the surface o f  various extrahepatic tissues including 
adipose tissue, cardiac m uscle and skeletal tissue. This enzym e is synthesised by the cells 
that underlie the capillaries o f such tissues. It metabolises the chylom icrons such that they 
becom e depleted o f  triglyceride. The fatty acids w hich are released from  triacylglycerol 
hydrolysis are used in storage or as a means o f  energy. The body can then direct 
chylom icrons and V L D L  to particular organs through its tissu e-specific control o f  
lipoprotein lipase (Fielding and Fielding, 1985). T rig lycerid es are off-loaded into the 
adipose tissue and m uscle w hile the cholesterol-containing remnants are taken up by the 
liver, so that 12-14 hours after fat digestion, chylom icra virtually disappear from  plasm a 
(Ireland et  al.,  1980).
The remnant is formed as the chylomicron shrinks progressively, shedding its surface 
phospholipid and small molecular weight proteins into the H D L  density interval, leaving 
a remnant w hich  by virtue o f  the apo E on its surface, is rapidly cleared  b y  the 
parenchymal cells o f  the liver (Shepherd and Packard, 1992). These remnants m ay be 
m ore com p letely  h yd ro lysed  to form  L D L  (G rum m er and C arro ll, 1988). T his 
metabolism o f remnant particles is extensive in humans, w hile in rats, V L D L  remnants or 
ID L  are largely cleared by the liver (Eisenberg and L e v y , 1975).
V ery-low -d en sity  lipoproteins (V L D L ), although being sligh tly  sm aller, have a 
structure and composition similar to that o f chylom icrons, but differ mainly due to apo B - 
100 o f  V L D L  reacting w ith the apo B , E  receptor, w h ich  is not the case  w ith  
chylom icrons (Fielding and Fielding, 1985). This apolipoprotein activates lipoprotein 
lipase, thereby facilitating the triglyceride switch from  carrier to tissue depot (Ireland et  
al.,  1980). This results in the formation o f  relatively cholesteryl-ester-rich, intermediate- 
density, remnant lipoprotein particles, ID L. These m ay be m etabolised further to y ie ld  
L D L , or they may be taken up directly by the L D L  receptor, which reacts with apo B  and 
apo E.
Low-density lipoproteins (LD L) are the main carriers o f  cholesterol, being cholesteryl 
ester-rich lipoproteins which are metabolised by the liver and peripheral tissues. Human 
L D L  contains apo B -100 as the major or only apolipoprotein. This apoprotein, on the 
L D L  particle’ s surface, facilitates the transport process by interacting w ith specific high- 
affinity receptors on ce ll membranes. The L D L  receptor also binds apo E, w hich  is 
present in certain subclasses o f  H D L in some species (Grum m er and C arroll, 1988). 
Consequently, L D L  reacts with the apo B , E receptor and its cholesterol is interiorised 
along with other com ponents o f  the lipoprotein. The protein com ponent o f  L D L  is 
hydrolysed to amino acids and cholesteryl esters are hydrolysed by acid lipase, w ith free 
cholesterol being released for the c e ll ’ s needs. T h ey are, essentially, slim m ed down
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versions o f  V L D L s. After V L D L s have delivered triglyceride to peripheral tissue, they 
come in contact with HDLs thereby taking on cholesteryl esters in a mid-stream switch.
Table 1: Lipoprotein classification
Family name Synonym s 
(based on 
electrophoretic 
mobility)
Density range 
(g/ml)
Com position Major
Function
Protein
(% )
Lipid
(% )
Major
Lipid
Chylom icrons < 0 .9 5 0 .5-2.0 98-
99.5
T G Transport 
exogenous T G
V LD L Pre-beta
lipoproteins
0.95-1.006 7.7 90.1 T G
Transport
endogenous
T G
IDL Slow  pre-beta 
lipoproteins
1.006-1.1019 19.0 81.0 T G
Intermediate in 
the
transformation 
o f V L D L -L D L
L D L Beta
lipoproteins
1.019-1.063 22.3 78.3 C H O
Transport 
C H O  and P L  
to peripheral 
cells
H DL Alpha
lipoproteins
1.063-1.21 51.9 48.6 C H O  
and PL
Transport 
C H O  and othei 
lipids from 
tissues - liver
V L D L : V ery  low  density lipoproteins TG: Triglyceride 
IDL: Intermediate density lipoproteins CH O : Cholesterol
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High-density lipoproteins (H DL), which function as initiators o f  “ reverse cholesterol 
transport” , promote the clearance o f  sterol from peripheral tissues to the liver. T hey are 
considered to be the m ost important cholesterol carriers as low  H D L  ch olesterol 
concentration has been established as a major risk factor for the developm ent o f  coronary 
heart disease (M iller, 1990). Nascent disc-shaped H D L  are secreted by the intestine and 
liver and are rich in cholesterol. The apolipoproteins o f  H D Ls activate lecithin:cholesterol 
actyltransferase (L C A T ) w hich  esterifies ch olestero l and a llo w s for the further 
metabolism o f lipids. Upon the occurrence o f  this enzym atic reaction, the H D Ls becom e 
more spherical in appearance. H D L s are the on ly know n system  for transporting 
cholesterol out o f peripheral tissue back to the liver for excretion in the bile  (Ireland et  
al.,).  This process where cholesterol from peripheral cells can be returned to the liver for 
catabolism is termed “reverse-cholesterol transport” .
1.1.3: Cholesterol transport between the tissues in humans
A bsorbed cholesterol, from  food, enters the intestinal lym ph as a com ponent o f  
ch ylom icrons (Fig 1.1). U pon entering the blood stream, lipoprotein lipase (L P L ) 
hydrolyses the triglyceride and concomitantly, there is an interaction with H D Ls, with the 
resu ltin g  transfer o f  som e su rface  m aterial and a ch an ge o ccu rs  in their 
apolipoproteins.The chylom icron remnant is then taken up by the liver.
On the surface o f  the liver, is found an A po-E  receptor, w hich allow s for the uptake o f  
the chylom icron remnant. This cholesterol then becom es available for cellular m etabolism 
or re cy c lin g  as plasm a lipoproteins. Patients w ith  the gen etic  disorder, fa m ilia l 
lecithin:cholesterol acyltransferase deficiency, have a reduction in the clearance o f  these 
remnants. Cholesterol from the diet, w hich is not rem oved by the chylom icron remnant 
pathway, enters the pools o f cholesterol in peripheral tissues, with cholesterol o f  L D L s.
In order to prevent the build up o f  free and esterified  cholesterol in ce lls, excess 
cholesterol must be recycled through the plasm a to the liver, where it can be degraded. 
The m echanism  by w hich  those tissues not secreting lipoprotein  particles return 
cholesterol to the liver is termed “reverse cholesterol transport” , due to the opposing 
m ovement o f  cholesterol from  peripheral cells to the liver. Cholesterol is m obilised from  
tissues when H D L binds to the cell membrane and incorporates excess unesterified 
cholesterol into its surface monolayer. Glomset (1964) proposed as free cholesterol in the 
ce ll becam e esterified outside (by L C A T ), then this “ reverse cholesterol transport” 
pathway w as an active transport system  (Fig 1.2). The cholesterol that is recycled  is 
present in new ly synthesised plasm a lipoproteins, w hile part appears in the bile as bile 
acids or unesterified cholesterol. The cholesterol that passes through the intestine, is 
reabsorbed in the intestine and m ixes with dietary cholesterol to be m etabolised via  the 
chylom icron degradation pathway (Fielding and Fielding, 1995).
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The peripheral tissues in volved  in reverse cholesterol transport, transfer cholesterol 
only in its unesterified form (Fielding and Fielding, 1995). There is strong evidence that 
the net transport o f  cholesterol from nonhepatic cells into the circulation is maintained by 
a chem ical reaction, that is catalysed by L C A T  (D obiasova, 1983). T his enzym e is 
responsible for the maturation o f  nascent H D L, the transform ation o f  sm aller H D L  
subclasses (H D L 3) into larger ones (H D L 2), the rem oval o f  excess cholesterol and
phospholipids from L D L , V L D L , chylom icrons and the flux o f  cholesterol from  cell 
membranes into H D L (Jonas, 1991). A s free cholesterol m oves rapidly between different 
lipoproteins and between ce ll surfaces and lipoproteins, such different potential sources 
w ill com pete for transfer o f  free cholesterol to H D L , dow n the ch em ical gradient 
generated by the L C A T  reaction (R eichl and M iller, 1989). C h olesteryl ester transfer 
protein (CETP) and phospholipid transfer protein (P L TP ) are tw o plasm a lipid transfer 
proteins that act in the metabolism o f plasma lipoproteins. U nlike enzym es, these proteins 
are energy-independent and they must work down preexisting concentration gradients.
The former facilitates both the exchange and net transfer o f  triglyceride and cholesteryl 
ester. The net transfer process proceeds by a reciprocal exchange o f  trig lyceride and 
cholesteryl ester without net transfer o f core lipids between lipoproteins, i.e., net transfer 
is mediated by a hetero-exchange process. The latter is able to mediate transfer o f a w ide 
v a r ie ty  o f  p h o sp h o lip id s  in c lu d in g  p h o s p h a tid y lc h o lin e s , d ia c y lg ly c e r o l,  
phosphatidylethanolam ine, phosphatidylserine and p hosphatidylglycerol (Tall, 1986). 
These tw o lipid transfer proteins contribute to the further m odelling o f  H D L. P L T P  
supplies lecithin to H DL, while C E TP can move cholesteryl ester made by L C A T  to other 
lipoproteins, particulary triglyceride rich lipoproteins and L D L  (Fielding and Fielding, 
1995).
Although cholesterol has been implicated in atherogenesis, much evidence now  exists 
that cholesterol oxidation products m ay be more atherogenic than cholesterol itself. Thus, 
the study o f  cholesterol oxidation products is im portant- w hether they result from  
cholesterol autoxidation or are m etabolites o f  ch olesterol itse lf. Studies on their 
identification and metabolism may provide further insight into problems such as disorders 
in bile acid metabolism or aid in studies on atherosclerosis.
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Fig 1.2 The role o f  H D L  in reverse ch olesterol transport. L C A T  circu latin g  in 
association with H D L, traps tissue cholesterol within the particle by esterifying the sterol, 
increasing its hydrophobicity and promoting its m igration to the core o f  the lipoprotein. 
The mature H D L generated in the process, is then capable o f  transferring its cholesteryl 
ester load into chylom icrons and V L D L  via the agen cy o f  C E T P . These particles m ay 
thus represent the final pathway for sterol excretion into bile. Adapted from  (Shepherd 
and Packard, 1992).
9
I1.2: Cholesterol oxidation
Cholesterol, an unsaturated alcohol being insoluble in water, undergoes autoxidation in 
the presence o f  m olecular oxygen  through a free radical reaction, predom inantly at 
position C -7 . M any primary and secondary oxidation products are therefore form ed 
(Nourooz-Zadeh, 1990). Such oxidation products are formed as a result o f  heat, light and 
radiation (Smith, 1981) and also by peroxidation in vivo  and m etabolism  (Smith, 1987). 
They are also observed in various foodstuffs o f  animal origin after processing under a 
variety o f conditions (Kumar and Singhal, 1991). Structural characteristics o f  cholesterol 
relevent to the process o f its autoxidation are the B ring unsaturation and positions allylic 
to it and also the presence o f  two tertiary carbons in the side chain (M aerker, 1987). Due 
to the possible influence o f  the C 3 h yd roxyl group and the tertiary C 5 atom, the C 4
(allylic) position rarely gets attacked by m olecular oxygen . Therefore, it is the other 
allylic carbon atom, C 7 , which is more sensitive to m olecular attack by  oxygen, resulting 
in the form ation o f  a series o f  A  and B ring oxidation products (K um ar and Singhal, 
1991), fo llo w in g  hydrogen abstraction at position C 7 (M a erk er, 1987). Resulting 
products are hydroperoxides in the B-ring and the side chain and to a lesser extent, the 
dehydrogenation o f  the 36-alcoh ol group. Secondary p rocesses then produce a 
multiplicity o f  derivatives (Bosinger et a l . ,  1993). Various hydroxylations take place on 
the side chain, such as at C 2 0 , C 25 and at C 7 on the B-ring (Bosinger et  al.,  1993). The 
former tw o are seen in the autoxidation o f  solid or crystalline cholesterol, as such side 
chain oxidations are not observed in cholesterol in solution or in aqueous dispersions 
(M aerker, 1987). The abstraction o f  a hydrogen atom from  position 7, results in the 
formation o f  epimers o f  7-hydroperoxide (F ig  1.3 ) w hich, due to their instability, form
7 - a  and 7B-hydroxycholesterol and also 7-ketocholesterol (Smith, 1987). The tertiary
carbons, such as that at position 25, tend to yield  the corresponding hydroxysterol upon 
reduction o f peroxides which are form ed at the position o f  the tertiary carbon atom. This 
is due to the fact that such structures tend to form  relatively stable radicals (Finocchiaro 
and Richardson, 1983).
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Fig 1.3: M echanism s and major products o f  cholesterol oxidation.
I
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1.2.1: Location of cholesterol oxidation products in animal tissues
Since cholesterol is found in many biological membranes and tissues, it is reasonable 
to expect to find its oxidation products in such tissues also (Table 2). Som e o f  these 
oxidation products o f  cholesterol have been identified in the body and are important 
intermediates in the metabolism o f cholesterol (Kumar and Singhal, 1991). It appears that 
some o f  them are products o f  lipid peroxidation reactions, w hile those from  cholesterol 
m etabolism  are formed by enzym atic oxidation (Bernheimer et al . ,  1987). The form er 
involves the attack o f any species that has sufficient reactivity to abstract a hydrogen atom 
from a m ethylene (-C H 2-) group from a polyunsaturated fatty acid. Such radicals as the 
hydroxyl radical can carry this out (H alliwell and Gutteridge, 1989).
Table 2: Occurence o f some cholesterol oxides in human and animal tissues (Bôsinger 
et  al.,  1993)
Cholesterol oxide Found in
7a-hydroxycholesterol Renal cortex, arteries, brain, human meconium, pregnant 
mare serum, bovine testes, pig liver, sheep’ s w ool, rat 
faeces, rat liver, skin o f toads
7J3-hydroxycholesterol Renal cortex, brain, human meconium, pregnant 
mare serum, bovine liver and testes, foetal ca lf serum, 
pig spleen, rat faeces and liver, skin o f  toads
7-ketocholesterol Human fatty tissue, aorta, brain, heart, erythrocytes, 
kidney, liver, lung, m econium, m uscle, pancreas, spleen, 
urine, renal blood and aorta o f  baboons, renal vein blood 
in rhesus m onkeys, equine aorta, bovine testes, aorta and 
brain, kidney, testes, fat, liver and blood o f  pigs, sheep’ s 
w ool, feline aortas, rat kidney, aortas, faeces and liver, 
hen ovaries
25-hydroxycholesterol Human fatty tissue, arteries, brain, heart, liver, lung, 
muscle, pancreas and spleen, baboon aorta, equine aorta, 
bovine renal cortex and aorta, feline aorta, rat aorta and 
liver mitochondria, pigeon aorta, porifera
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Smith et  al. ,  (19 8 1) reported that 7a-h yd ro xych olestero l, 7B -hydroxycholesterol, 7-
k e to c h o le s te r o l, 2 4 - h y d r o x y c h o le s te r o l, 2 5 - h y d r o x y c h o le s te r o l and 26 - 
hydroxycholesterol were found to be most abundant in aortic tissue w hile hepatic levels 
o f  these oxides w ere much lower. T hey found these oxides to be esterified  in such 
tissues. 24-hydroxycholesterol was found in significant amounts in the brain (Lin and
Sm ith, 1974). 7 a -h y d ro x y ch o le ste ro l has been show n to increase, as has 25-
hydroxylated bile alcohols, in patients o f cerebrotendinous xanthomatosis (O ftebro et al.,  
1980; Bjorkhem  et  al.,  1981).
27-hydroxycholesterol was found to be present in atherosclerotic human fem oral 
arteries. This oxide is a potent inhibitor o f  H M G -C o A  reductase (Bjorkhem  et  al . ,  1994). 
Several reports have been published on the identification o f cholesterol oxides in human 
atherosclerotic aortic tissues. There w as found to be an association o f  le v e ls  o f  the 
oxides- 26-hydroxycholesterol and 7-ketocholesterol with an increase in the progression 
o f atherosclerosis (Brooks et  al. ,  1966; Sm ith and V an Lier, 1970). O f  the sixty  
cholesterol oxidation products identified (Sm ith, 1987), tw elve oxidation products o f  
cholesterol have been identified in human atheromata (Smith and V an Lier, 1970; V an 
Lier and Smith, 1967) which include the above mentioned.
Oxysterols (together with their fatty acyl esters) occur at appreciable levels distributed 
among the plasm a lipoproteins (Smith and Johnson, 1989). A n alysis  o f  endogenous
human plasma oxysterols suggest that 7-ketocholesterol and isom eric cholesterol 5 a , 606- 
epoxide and the corresponding 13-epoxide, are present in equal amounts in L D L . Streuli et 
al. (1981), found that whenabout 7 a-hydroxycholesterol was incubated w ith the major 
lipoprotein classes o f  human serum 40% w as subsequently recovered in H D L  and L D L , 
w hile 23%  o f 25-hydroxycholesterol added was carried by H D L and L D L .
1.2.2: Biological effects of cholesterol oxides
Several important biological activities m ay be attributed to cholesterol being present in 
cells and cell membranes. The cytotoxic effects o f  cholesterol autoxidative products have 
dominated studies o f  biological activities (Kum ar and Singhal, 1991).
1.2.2.1: Effect on cell membranes
O xygen ated  sterols have been shown to alter membrane m orphology and function. 
They are taken up by skin fibroblasts (Khachadurian et  al.,  1981) and are incorporated 
into the cell membrane o f  red blood cells (Hsu et  al.,  1980). They have been found to be 
capable o f altering the structure and function o f  mammalian cell membranes (Streuli and 
Chung, 1979). The structure o f  the red cell mem branes changed shape to take on the 
“ spiny” appearance o f  echinocytes. H ow ever, w hen selected oxysterols w ere incubated 
with red cells, in the presence o f lipoproteins, there was an im pedem ent o f  oxysterol
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insertion into the cells, suggesting that lipoproteins bind oxysterols (Streuli e t a l . ,  198 1). 
Their mechanism o f action is not clearly understood, how ever, it is thought that due to 
their inhibitory e ffect on H M G  C oA -reductase, the rate-lim iting enzym e controlling 
cholesterol synthesis, the cholesterol in the cell membrane is lacking, thereby resulting in 
it liquefying and having altered functions.
1.2.2.2: Effect on cholesterol metabolism/Cytotoxicity
The exact m echanism  through w hich these com pounds inhibit ce ll grow th  and 
eventually result in cell death is not w ell defined. T he inhibition o f  the biosynthesis o f  
cholesterol by oxygenated derivatives o f  cholesterol and lanosterol was demonstrated by 
Kandutsch et  a i ,  (1978) to be a result o f  a decrease in cellular levels o f  H M G -C o A  
reductase activity. T hey found that oxysterols inhibited cholesterol synthesis, both in- 
v i vo  and in vitro  at concentrations between 10 -9 and 10 -6 M . T his, in turn, a ffects the 
cholesterol content o f  mem branes. Upon suppression o f  H M G -C o A  reductase, the 
concentration o f  cellular sterol content declined as did the rate o f  D N A  synthesis. The 
oxysterols seem to block cell division in the G 1 phase o f  the cell cycle.
Sm ith and Johnson (1989) suggested that the process o f  peroxidation o f  sterols 
involving oxyl, peroxyl and carbon-centered radicals, as w ell as stable oxysterol products 
may contribute to toxic effects. The presence o f cholesterol in cell surface membranes can 
influence their susceptibility to peroxidation, probably by intercepting som e o f  the 
radicals present and also by affecting the internal structure o f  the membrane by interaction 
o f  its large hydrophobic ring structure w ith fatty acid  side chains (H alliw ell and 
Gutteridge, 1989).
O xysterols m im ic all the effects o f  L D L  in cholesterol metabolism: the suppression o f  
L D L  receptor activity; the stimulation o f  acyl C oA :cholesterol acyltransferase (A C A T ) 
and the suppression o f  other enzym es o f  cholesterol synthesis as w ell as H M G -C o A  
reductase (Fielding and Fielding, 1985). A lso , a cy to so lic  oxysterol carrier protein has 
been identified. The affinities o f  oxysterols for this protein reflect their relative ability to 
suppress reductase. The reductase inhibitory activity o f  a large number o f  oxysterols is 
proportional to their affinity for the oxysterol carrier protein (Fielding and F ield in g, 
1985). A  sch em atic representation o f  the in h ib itory  action o f  o x y stero ls  on 
cholesterogenesis is depicted in Fig 1.4.
W ork carried out by T aylor et  a i ,  (1984) on a cyto solic  binding protein (in m ouse 
fibroblast cell cultures) being a mediator o f  the actions o f  oxysterols on H M G -C o A  
reductase indicated that many sterols did bind this protein. They reported that no sterol 
was found that w ould bind the binding protein w ith high affinity yet that w ould  not 
repress H M G -C oA  reductase activity.
Peng et  al. ,  (1985) carried out studies on the effects o f  oxysterols on the uptake o f
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cholesterol, in aortic smooth muscle cells. T hey found that, in the presence o f  oxygenated 
derivatives o f  cholesterol, cholesterol uptake was severly  im paired. Cholestane-3B-
5a,68-trio l inhibited cholesterol uptake as much as 90%  and other oxystero ls tested
show ed inhibitions o f  betw een 30% to 60%. 7 a -h yd ro x ych o le ste ro l w as found to 
inhibit cholesterol uptake in these cultured cells by levels by approxim ately 40%  when 
incubated at 50fi.g/ml medium , w hile at concentrations o f  -1 0 0  fig/m i m edium , 7 a -  
hydroxycholesterol w as found to be more potent in this inhibition o f  cholesterol uptake 
than 7-ketocholesterol.
It has been proposed that 25-hydroxycholesterol m ay influence A C A T  activity, since 
its incubation with human fibroblasts resulted in an accum ulation o f  cholesteryl esters 
(B row n et  a l . ,  1975). L ichtenstein  and B rech er (19 8 3 ), later sh ow ed  that 25- 
hydroxycholesterol itself was esterified by rat liver m icrosom es, in a sim ilar reaction to 
that which esterified cholesterol, thereby proposing a stimulatory effect on A C A T .
The cytotoxicity o f  oxysterols on cultured aortic smooth muscle cells, m ay not be only 
due to their potent inhibition o f  cholesterogenesis, but m ay also be attributed to their 
capability for inhibiting exogenous cholesterol uptake, particularly in arterial cells, which 
synthesise cholesterol at a very slow  rate (Peng et  al.,  1985). A  possible explanation for 
this event occuring is that cholesterol and oxysterols com pete for identical and specific 
binding sites on the cell surface. M ore recent studies carried out by Zhang et  al. ,  (1990) 
report that different oxysterols in oxidised L D L  seem  to have d ifferin g  e ffects  on 
cholesterol esterification in cultured m acrophages. 7-ketoch olesterol resulted in an 
enhancement o f  cholesterol esterification, whereas 7-hydroxycholesterol resulted in a 
m uch sm aller effect. D epending on the extent o f  oxidation o f  L D L  and the relative 
proportions o f  oxystero ls used in the study, the net result o f  o xystero ls  on the 
esterification o f cholesterol could be either inhibitory or stim ulatory. M any reports are 
available on oxygenated sterols which are found to be suppressive o f  sterol synthesis and 
H M G -C o A  reductase activity. Som e are know n m etabolites o f  cholesterol, som e are 
autoxidative products o f  cholesterol, w hile som e precursors o f  ch olesterol are also 
reported (Kudo et  al.,  1989).
In general, the overall structure o f  the oxysterol seems to determine the potency o f  its 
inhibitory effects. Greatest potency has been shown to be when the side chain is intact, 
w hile the presence o f  oxygen  groups in the D -ring and the iso-o ctyl side chain also 
contribute to the inhibitory effect. Parish et  al . ,  (1987) noted that as the distance betw een 
the second oxygen and the C-3, increased, so too did the activity.
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F ig  1 .4 : R egulation o f  cholesterogenesis by external or internal oxystero ls v ia  the 
activity o f  oxysterol-binding protein. This scheme summarises results w hich suggest that 
a common signal derived from either external or internal oxysterols mediates H M G -C o A  
reductase activity (Fielding and Fielding, 1985).
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1.2.2.3: Mutagenicity and carcinogenicity
The m utagenicity o f  5 ,6-epoxycholestanols has been im plicated in som e studies. 
Sevanian and Peterson, (1984) dem onstrated that 5 ,6-ep oxycholestan ols possessed 
mutagenic properties when incubated with V -79  Chinese hamster lung fibroblasts.
Carcinogenic properties have also been attributed to cholesterol oxides. B isch o ff (1969) 
reported that, o f  numerous cholesterol analogues, 5 a ,6 a -  epoxycholestanol w as the only 
cholesterol oxide that resulted in carcinogenic properties upon administration to rats and 
mice. This oxidation product was later found to be implicated in the developm ent o f  colon 
cancer (Reddy et  al.,  1977), where its breakdown product- cholestanetriol, was identified 
in the faeces o f  such patients. Hill e t a l . ,  (19 7 1) reported that d eoxych olic acid, w hich is 
recognised to be produced by bacterial degradation o f  b ile  salts, is in certain cases, a 
carcinogen.
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1.2.2.4: Atherogenicity of oxysterols
Much evidence exists indicating that lipid oxidation products both initiate and promote 
atherosclerosis and that one particular group of these products- cholesterol oxidation 
products are far more atherogenic than cholesterol itself. There are two differing 
hypotheses to atherosclerosis- one which suggests that atherosclerosis results from 
hypercholesterolemia-induced deposition of lipid in the vessel wall, which is known as 
the “lipid hypothesis” the second theory is known as the “response-to-injury” hypothesis, 
where it is thought that cholesterol oxides are involved in the injury to the vessel wall. 
Cholesterol plays a major role in the former hypothesis, while oxysterols do not. The 
angiotoxic and cytotoxic properties of oxysterols may explain their role as initators of 
atherosclerotic lesions. Oxysterols have a reported role in the injury of the arterial wall 
(Imai et al., 1980), thereby, initiating the atherosclerotic lesions.
Peng et al., (1985) intravenously administered cholestanetriol and 25- 
hydroxycholesterol to New Zealand white rabbits. The injury to the endothelium was 
examined by means of transmission electron microscopy. The aorta of rabbits 
administered with 25-hydroxycholesterol showed 67% of the endothelium with some 
subendothelial edema. Those that received cholestanetriol indicated more damage to the 
endothelium of the aorta, approximately 90%.
On the contrary, Higley et al., (1986) found that feeding cholesterol to rabbits resulted 
in six times more arterial lesions when compared to those fed a mixture of oxysterols (a-
and B-epoxides; 7a-hydroxyperoxide and 7-ketocholesterol). However, it must be noted 
that these oxysterols were different to those used in the previously described 
experiments, which were mainly 25-hydroxycholesterol and cholestanetriol. He thus 
concluded that cholesterol was more atherogenic than oxysterols. It would appear from 
these studies that oxysterols have varying atherogenic potential.
Faggiotto et al., (1984), described the pathological sequence of events in the 
development of a mature atheromatous plaque. Methods used included scanning electron 
microscopy and transmission electron microscopy. The various stages included:
* The adhering of monocytes and endothelium; the migration of monocytes into the 
subendothelium; accumulation of lipid; foam cell formation- after twelve days.
* Formation of fatty streaks from foam cells; pathological changes due to discontinuity in 
the endothelium; the addition of monocytes to the fatty streaks in the intima and the final 
egression of foam cells into the circulation- after two months.
* A mural thrombus develops upon platelets and macrophages adhering to the denuded 
artery. Arterial smooth muscle cells proliferate due to stimulation caused by the secretion 
of a growth factor from platelets or cells which are local in the wall of the artery. Such 
smooth cells of the artery are converted into foam cells by LDL, which results in the wall 
of the artery thickening.
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One area where lipid oxidation products may be affecting atherosclerosis is through 
oxidised LDL. Goldstein et al., (1979) were the first to describe that a modified form of 
LDL could be taken up by macrophages to convert them into foam cells. They chemically 
modified LDL by acetylation which converted LDL to a form which could be recognised 
by the monocyte/macrophage and taken up at a rate several times that of native LDL. 
Thus, as this receptor does not recognise native LDL, it may be termed the “scavenger 
receptor”. Macrophages express a specific scavenger receptor site reactive with LDL in 
which apo B has been chemically modified (Fielding and Fielding, 1985).
The molecular mechanisms of the oxidation processes and the reaction pathway leading 
to the modification of LDL is largely unknown. Aldehydes, such as malonaldehyde, 
generated by lipid peroxidation from PUFA contained in the phospholipids of LDL, 
interact with apo B and interfere with the binding of LDL with the apo B/E receptor (of 
fibroblasts) by modifing lysine residues of apo B. Evidence exists indicating that lipid 
oxidation by endothelial cells is responsible for the alteration of structural and biological 
properties of LDL (Esterbauer et al., 1987), in human plasma. They found a surprisingly 
high resistance of the polyunsaturated fatty acids- 18:2 and 20:4, in LDL against 
oxidation.
It has been suggested that hydrolysed cholesteryl ester may be trapped in the lysosomal 
compartment of the macrophage, resulting in the accumulation of free cholesterol in the 
macrophage, when oxidised LDL are incubated with macrophages. This affects the 
amount cholesterol available, as substrate, for esterification. Native LDL, on the 
otherhand, unlike oxidised LDL, does not cause the accumulation of cholesterol in the 
macrophage. It binds and internalises to the cell by means of the LDL receptor, which is 
regulated by the levels of free cholesterol in the cell (Maor and Aviram, 1994).
The oxidative nature of LDL was examined recently by Hodis et al., (1994) by 
determining the cholesterol and cholesterol oxide content of LDL. A similar array of 
oxysterols were identified in both types of LDL, thereby suggesting that a free radical 
mediated process was involved, in the oxidation of cholesterol. Again, some of the
typical oxidative products of cholesterol were identified such as 7 a-hydroxycholesterol, 
76-hydroxycholesterol, 7-ketocholesterol, 25-hydroxycholesterol and 5a-cholestane-
3B,5a,6B-triol. They concluded that LDL- (the more negatively charged LDL), an
oxidatively modified lipoprotein, is a subfraction of total LDL, which is enriched in 
oxysterols. Upon separation from unmodified LDL, oxidised LDL shows cytotoxic 
effects on aortic endothelial cells, which was not the case with normal LDL.
It has well been established that LDL plays a major role in atherosclerosis, primarily by 
promoting the accumulation of lipid in the lesion. Thin-layer chromatography analysis of 
oxidised LDL lipids identified 7-ketocholesterol, 5,6-epoxycholesterol and 7-
18
hydroxycholesterol, in studies carried out on cholesterol esterification (Zhang et a l . ,
1990). Also, Bascoul etal., (1990) reported that 7a-hydroxycholesterol was carried by
LDLs. This may have serious implications in atherogenesis as oxidised LDLs are 
cytotoxic. This may induce functional changes in the endothelial cells that favour the 
penetration of circulating monocytes or favour the movement of LDL into the 
subendothelial space and thereby accelerate the formation of the fatty streak (Steinberg et 
al,  1989).
Finally, atherosclerosis has been described as the basic lesion leading to the high 
morbidity and mortality in diabetes (Tomkin and Owens, 1991). Morel and Chislom
(1989), were the first to demonstrate that a relationship existed between the in vivo 
oxidation of lipoproteins in diabetes and the potential for tissue damage as monitored by 
in vitro cytotoxicity, thus suggesting that the mechanism for the characteristic damage of 
tissues in the arteries and organs of diabetics, may be attributed, in part, to the activity of 
lipid peroxidation products.
1.2.3: Parameters influencing cholesterol autoxidation
As referred to in 1.2, there are structural features of cholesterol that contribute to its 
autoxidation. Cadenhead et al., (1982) reported the relative stabilty of crystalline 
cholesterol, as regards autoxidation, when compared to cholesterol in the liquid state. 
This was also reported by Kim and Nawar, (1993). Ozone, dioxygen species, 
superoxides and peroxides also result in the autoxidation of cholesterol.
Cholesterol oxidation is system dependent. Such factors as buffer type, form of 
substrate, presence of water, pH, temperature and oxidation time, influence the products 
of cholesterol oxidation and the relative amounts formed. In aqueous suspensions, the 
differences in the resistance of cholesterol to oxidation, were not significant within the 
pH range 6 .0-7.4, except for the early stages of oxidation (Kim and Nawar, 1993). 
Their results also showed that only traces of side-chain derivatives, i.e., 20- and 25- 
hydroxycholesterols and triols were detected in the dry-state oxidation.
1.2.4: Lipid oxidation and antioxidants
Oxidation of LDL causes multiple changes in both the lipid and protein constituents of 
the particles thereby facilitating recognition by the scavenger receptor. Peroxidation of the 
lipid components of LDL and the oxidative degradation of apo B occurs, results in the 
formation of several oxidation products (Esterbauer et al., 1987 and Fong et al., 1987). 
Lipid peroxidation has been reported in plasma of aging humans and also in subjects with 
diabetes (Nishigaki etal., 1981).
As more than 75% of 7a-hydroxycholesterol is carried by LDLs, (Bascoul et al., 1990) 
and as LDLs contain polyunsaturated fatty acids, (conjugated bonds rendering them
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susceptible to free-radical-mediated peroxidation), the stability of such esterified form of 
oxysterols poses a worthwhile question. A second aspect of the possible suceptibility of 
cholesterol to oxidation, involves the fact that it is the C7 position of cholesterol which is 
most sensitive to attack by molecular oxygen (Kumar and Singhal, 1991), thereby 
rendering cholesterol susceptible to autoxidation in air and peroxidation in vivo. 
However, free cholesterol has been reported to be more stable to autoxidation than its 
esters (Korahani et al., 1982).
Smith (1981) found that polyunsaturated fatty acids were much more easily oxidised 
than cholesterol. The first step in the oxidative modification of lipoproteins is 
peroxidation of polyunsaturated, long-chain fatty acids (Step 1):
(1) RH  ► R« + H*
(2) R* + 0 2  ► ROO
(3) ROO- + RH -----► ROOH + R*
(4) ROOH ---- ► RO* + *OH
This step is initiated by the abstraction of a hydrogen atom (adjacent to a double bond) 
from a polyunsaturated fatty acid (RH), to form a fatty acid free radical (Step 1). The 
double bond rearranges to form a conjugated diene, which combines with O 2 to produce 
a peroxyl radical (Step 2). This then can react with more polyunsaturated fatty acid to 
form hydroperoxide and another free radical (Step 3).
Steps 1-3 are self propagating. The primary reaction products are hydroperoxides, 
which are unstable and break down in several steps to produce numerous secondary 
breakdown products. Such secondary products include carbonyl compounds, both 
unsaturated and saturated fatty acids, aldehydes, ketones and alcohols.
Such free radicals are formed in the reduction of oxygen to water during normal 
metabolism. Whether or not a free radical will act as a chain propagator (by attacking a 
stable molecule) or as a chain terminator (by combining with another free radical) 
depends on subtle numerical proportions and unpredictable affinities (Dormandy, 1969). 
Oxygen free radicals act on tissue unsaturated lipids, specifically on cholesterol (Smith 
and Johnson, 1989).
The cell has evolved many mechanisms to reduce the damage caused by prooxidants. 
Such enzymes as catalase, superoxide dismutase and glutathione transferase all act so as 
to inactivate the potentially damaging prooxidants which arise from the metabolism of 
biological materials. In addition, there are several natural dietary components, such as 
vitamins E and C and selenium, called “antioxidants”. When present, they can reduce,
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inhibit or significantly delay the oxidation of a substance that is susceptible to oxidation, 
by acting as “free-radical scavengers”. Vitamin E, from the diet, acts preferentially by 
preventing the peroxidation of PUFA in cell membranes. Vitamin C, again adsorbed from 
the diet, acts by scavenging radicals in the water-soluble section of the cell. Selenium, 
combined in an amino acid, is an essential component of the prosthetic groups of several 
enzymes- particularly glutathione peroxidase. This enzyme acts in the protection of cells 
against the effects of hydrogen peroxide (Lehninger, 1982).
Synthetic additives to the diet, such as 2-(3)-tert-butyl-4-hydroxyanisole (BHA) and 
3,5-di-tert-buytl-4-hydroxytoluene (BHT), have been shown to act effectively as 
antioxidants, having anticarcinogenic properties. The structure of these compounds are 
shown below (Fig 1.5).
Fig 1.5 Structures of BHA and BHT
O H  O H
BHA BHT
(mixture of 2- and 2- tert- 
butyl- 4- methoxyphenonl)
BHT is frequently added as an antioxidant in sample biological preparations, where 
cholesterol is present and autoxidation is minimised (Bjorkhem et al., 1987). Both of 
these compounds are phenolic antioxidants. They are commonly used as preservatives in 
the food and drug industry, owing to their usefulness to the comparative ease with which 
they undergo 2-stage oxidation. Between loosing the first and second electron, they pass 
through a free radical phase; and by combining with a chain-initiating or chain- 
propagating free-radical, this intermediate can block or break an autocatalytic chain 
(Dormandy, 1969).
As referred to above, lipid peroxidation has been reported in plasma of subjects with 
diabetes (Nishigaki et al., 1981). Treatment of diabetic rats with the lipophilic 
antoxidants- vitamin E and probucol- after the establishment of diabetes, inhibited both 
the in vivo oxidation and the in vitro cytotoxicity of diabetic LDL and VLDL, without 
altering hyperglycemia (Morel and Chislom, 1989). This suggests that the frequently 
observed tissue damage in experimental diabetes may be explained, in part, by the 
mechanism of action of lipid peroxidation products and simultaneously highlighting the
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importance of antioxidants in such studies.
Several therapeutic approaches have been tested in the attempt to inhibit the oxidative 
modification of lipoproteins in vivo, which include:
* Lowering of plasma LDL to reduce the amount of LDL available for oxidation
* Inhibition of cellular mediated mechanisms with 15-lipoxygenase inhibitiors
* Protection of LDL directly with lipid soluble antioxidants, such as Vitamin E or 
probucol
* Enhancement of the antioxidant capacity of endogenous antioxidants with ascorbate 
etc., (Rosenfeld, 1991).
1.2.5: Metabolism of oxysterols
Human subjects have some capacity to absorb cholesterol oxidation products from 
food sources. Upon administration of these compounds in powdered egg meal to human 
subjects, plasma levels of the selected oxysterols were found to be elevated. Upon 
entering into the circulation, their presence was detected in chylomicrons. After a period 
of up to 30 minutes, the oxysterols had cleared from the chylomicrons, thereby 
suggesting their rapid transfer among lipoprotein fractions and/or clearance from plasma 
(Emanuel etal., 1991).
The detection of oxysterols in various lipoprotein fractions was demonstrated upon 
incubation of oxysterols with red blood cells earlier in 1981 by Streuli et al., where it was 
found that lipoproteins, by binding oxysterols, may act in a protective manner against the 
potential damaging effect which the latter have on cell membranes. Results from their 
experiments showed that upon incubation of human serum with oxysterols, namely 2 0 -
hydroxycholesterol, 25-hydroxycholesterol and 7 a-hydroxycholesterol, the isolated
lipoprotein fractions had the following constituents (% of oxysterols recovered are 
expressed with respect to the total amount of sterol recovered, as 60[ig sterols were 
added to 3ml serum):
VLDL: 12.2+1.7% 2Q-OHCHO LDL: 39.5+7.2% 7a-OHCHO
8.0±1.1% 7oc-OHCHO 
4.5 ±2.7% 25-OHCHO
38.2±2.1% 2Q-OHCHO
38.1% CHO
4.4% CHO 21.6±2.7% 25-OHCHO
HDL: 40.8±5.9% 7a-OHCHO BOTTOM: 49.6±10.6% 25-OHCHO
29.7% CHO FRACTION 27.8% CHO
2Q-OHCHO24.3±3.3% 2Q-OHCHO 25.3±2.7%
24.3+5.1% 25-OHCHO 11.7+5.9% 7a-OHCHO
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From these results, it is observed that approximately equal amounts of 7a- 
hydroxycholesterol (-40%) and 25-hydroxycholesterol (-23%) were present in HDL and 
LDL. This suggests that oxysterols are metabolised by transfer between plasma 
lipoprotein fractions, as suggested by Emanuel et al., (1991), in a fashion similar to
cholesterol. The percentage of 7a-hydroxycholesterol found in LDL differs significantly 
from more than 75% reported by Bascoul et al., (1990) for circulating LDLs.
Other suggestions to the further metabolism of oxysterols indicate that cells, which 
have greater amounts of esterified cholesterol, may utilise oxysterols in preference to
cholesterol as substrate for the enzyme- 7a-hydroxylase. This was shown in studies
carried out by Dueland et al., (1992) on transfected non-hepatic cells, which had an
induction of LDL receptor mRNA. They concluded that 7a-hydroxylase indirectly
induces the LDL receptor gene by metabolising/inactivating oxysterol repressors.
As regards the metabolism of esterified oxysterols, metabolic studies are also difficult 
to carry out, as oxidised cholesteryl esters apparently do form artifically in tissues subject 
to long term storage (Smith et al., 1981). Very high levels of esterified cholesterol oxides 
have been reported in human liver which has been stored for years in the frozen state 
(Assmann etal., 1975). Smith and Johnson (1989) recorded oxysterols to be subject to 
esterifications in vivo and in vitro, but that it is uncertain as to the functions of the storage 
form of these oxysterols, suggesting, perhaps, their role in transport.
More recent work by Kishinaka et al., (1992) on the administration and subsequent 
metabolism of esterified 7a-hydroxycholesterol in the hamster model, revealed that this 
form of the oxide could be effectively taken up by the liver, hydrolysed by the enzyme- 
cholesterol esterase and further metabolised to taurine- or glycine-conjugated primary bile 
acids via the normal bile acid biosynthetic pathway, to bile acids. Their work was in
agreement with that of Ogura and Yamasaki (1970), suggesting that 7 a -  
hydroxycholesterol ester is taken up into the microsomal fraction for metabolism. The 
main metabolites in both cases were cholic acid.
7a-hydroxycholesterol-[14C] (free) in rats was preferentially taken up by the
mitochondrial fraction of liver cells (Ogura and Yamasaki, 1970). The main bile acid 
which formed from this oxide was shown to be chenodeoxycholic acid. Finally, the
metabolism of labelled 7 a-hydroxycholesterol differed to that of labelled cholesterol,
much more radioactivity from the former was excreted in the bile than from the latter.
Serum esterified 7 a-hydroxycholesterol is considered to be under an equilibrium with a
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rapid turnover, as the biological half-life of intravenously injected 7a-
hydroxycholesterol-stearate is about 6 hours and hepatic uptake and conversion to 
primary bile acids are very efficient (Kuroki, 1995 Personal communication).
Although most of the literature referred to above discusses the adverse affects of 
oxysterols, there are also possible advantages to the action of these compounds. Such in 
vitro cytotoxicities of oxysterols may be of possible use if manipulated for control of 
tumor cell growth, proliferation, survival and also in the suppression of de novo sterol 
biosynthesis (Kandutch et al., 1977) as a means of reducing plasma cholesterol levels in 
vivo. As 713-hydroxycholesterol was found to be toxic to cultured murine lymphoma cells 
but not to normal mouse lymphocytes, this may indicate that plasma oxysterols may, 
when present in plasma, act in order to protect against the survival of cancer cells (Smith 
and Johnson, 1989).
From the information presented here, it appears that oxysterols are of major importance 
in cholesterol metabolism and also in subsequent events which occur within the cell or
plasma. As regards oxysterols which are metabolites of cholesterol- such as 7a- 
hydroxycholesterol which is to be examined in this study- its measurement in serum is 
important as a possible diagnostical marker for disorders of bile acid metabolism, as its 
concentration in serum has been reported to be indicative of the activity of hepatic
cholesterol 7 a-hydroxylase. Also, the presence of these oxysterols has been detected in 
varying fractions of plasma lipoproteins, suggesting the similar transport and metabolism 
to that of cholesterol. As they are present in both the free and esterified form, various 
reports have been issued on the possible reactivity of AC AT towards them. To our 
knowledge, no report exists to date, on the possibility of these oxides serving as 
substrates for LCAT in plasma. Such studies may prove worthwhile in the further 
metabolism of these products of cholesterol oxidation/metabolism, produced either 
endogenously or from exogenous foodstuffs, as much evidence exists for the 
atherogenicity of oxidised LDL.
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CHAPTER 2 
MATERIALS AND METHODS
2.1 Reagents
[4-14C] Cholesterol (specific activty 52mCi/mmol) was purchased from Amersham Life 
Science, Buckinghamshire, U.K.
[1-'4C] oleoyl coenzyme A (specific activity 59.35 mCi/mmol) and [1,2,6,7-3H(N)]- 
cholesteryl oleate (specific activity 75.7 Ci/mmol) were obtained from NEN Research 
Products, Du Pont, Dreiech, W.Germany
Ammonium peroxodisulphate and N, N ’ methylenebisacrylamide (Electran molecular 
grade) and phosphotungstic acid were obtained from BDH, Poole, U.K.
The following reagents: Acrylamide, apolipoprotein A-I (bovine source), bovine serum 
albumin, boric acid, bromophenol blue, butylated hydroxytoluene (BHT), cholic acid- 
sodium salt, cholesterol, cholesteryl oleate, cholestyramine, dithiothreitol, ethylene- 
diamine-tetra-acetic acid (EDTA), EGTA, 76-hydroxycholesterol, 7-ketocholesterol and
20a-hydroxycholesterol were purchased from Sigma (all oxides were made up in 
methanol (HPLC grade)), 2-hydroxypropyl-B-cyclodextrin (2-HPBCD), glycine, lauryl 
sulfate, leupeptin, 2-mercaptoethanol, M.W-SDS-70L, SDS molecular weight markers 
(14000-70000), prestained molecular weight markers SDS-7B, potassium bromide, 
sodium  chloride, sodium  fluoride, sucrose, streptozotocin  (2-D eoxy 
2[([methylnitrosoamino]carbonyl)amino]-D-glucopyranose)- mixed anomers, tris
(hydroxymethyl)methylamine), tyloxapol (triton WR-1339), L -a -eg g  yolk
phosphatidylcholine (typical composition: 33% C 16, 31% C i8:l, 15% Ci8:2, 13% C i8 
(Sigma, Technical Services, U.K.) were purchased form Sigma Chemical Co., Poole, 
Dorset, U.K.
7a-hydroxycholesterol was purchased from Steraloids, Wilton, NH.
Cholesterol oxidase from Rhodococcus erythropolis (Nocardia erythropolis, 25U/mg, 
lmg/ml) was obtained from Boehringer Mannheim GmbH,.
Potassium chloride, potassium dihydrogen phosphate, di-potassium phoshate and 
sodium hydroxide were obtained from Riedel de Haen Chemical Co. (IRL).
All solvents: Acetonitrile, chloroform, diethyl ether, hexane, methanol and petroleum 
ether were HPLC grade and were purchased from Labscan Analytical sciences, Unit T26, 
Stillorgan Industrial Park, Dublin.
N, N, N ’, N’,-Tetra-methylethylenediamine and sodium chloride were obtained from
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Merck, FR Germany.
Sepharose CL 4B was purchased from Pharmacia Fine Chemicals AB, Uppsala, Sweden 
while DE-52 anion exchange resin was purchased from while Whatman (USA).
IIG, Bluebell, Dublin, supplied Oxygen free nitrogen (OFN) and Ecolite was obtained 
from Medical Supply Co., Dublin.
Test kits:
Test-combination free cholesterol was purchased from Boehringer Mannheim.
Cholesterol CHOD-PAP (total) was obtained from Randox, Antrim, U.K.
Protein determination:
Biochoninic acid assay (BCA) protein kit was purchased from Pierce and Warriner (UK) 
Ltd., 44 Upper Northgate St., Chester, Cheshire, CHI 4EF, England.
BioRad protein assay reagent was purchased from BioRad Laboratories, BioRad House, 
MAylands Ave, Hemel Hempstead, Hertfordshire, HP2 7TD, UK
Beckman (IRE) supplied silica gel thin layer chromatography 60A LK6D prescored plates 
(20cmx20cm) and polyallomer Quick-Seal centrifuge tubes (25x89mm).
2.1.1 Equipment
A C-18 Partisil PIO ODS-2 (4.6x250mm, 10(j,m) column was supplied by Whatman 
(USA), while Guard-Pak Precolumn Cartridges- (iBondapak C18 were purchased from 
Waters, Chromatographic division, Millipore Corporation, Milford, Mass 01757.
A density meter was supplied by DMA 35- Anton Paar K.G., Austria, Europe.
Labofuge 6000 (Hereus Christ).
LS-7500 Liquid Scintillation Counter (Beckman).
L8-70M Ultracentrifuge (Beckman).
Sorvall RC-5B centrifuge (Du-Pont Instruments).
Philips 201C transmisión electron microscope.
2.1.2 Subjects-
Human-Healthv control subjects
Two females and two males served as controls
Hypercholesterolemic subjects
Blood samples from three females and three males being treated for hypercholesterolemia 
were analysed.
All of the above samples were obtained from The Adelaide Hospital, Dublin 8 .
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Healthy control rats
Male Wistar rats (200-300g) were housed in a light controlled room for at least 14 days 
under reversed 12 hour dark/light cycle and had access to food and water ad libitum..
Cholestvramine-treated rats
Male Wistar rats were fed a 3% cholestyramine (w/w) (Sigma) diet mixed with pulverised 
chow for 7 days. Animals were starved overnight prior to being sacrificed the following 
morning in the middle of the dark cycle.
Streptozotocin-induced diabetes
Male Wistar rats were injected intraperitoneally with 1% (w/v) streptozotocin in 0 .1M 
sodium citrate buffer, pH 4.5 (150mg/kg body weight) i.e: 3 low dosages over a period 
of 5 days . Rats were housed as above, but received a restricted 20g chow daily. Diabetes 
was monitored daily, over a period of 11 days after the onset of diabetes, by urinary 
glucose measurements and for the absence of ketone bodies (Clinistix). Urinary glucose 
levels were between lOmM and 14mM. Rats were starved overnight and sacrificed the 
following morning, during the dark cycle.
All animals had blood samples taken from them while under anaesthetic prior to being 
sacrificed by cervical disslocation.
Bovine
Bovine plasma was obtained from Kepak abattoir, Clonea, Co.Meath.
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I2.2 Methods:
The methods described in 2.2.1 to 2.2.6 are illustrated in a flowchart (Fig 2.1).
2.2.1 Serum preparation
Blood was allowed to clot at 4°C and serum was isolated by centrifugation at 2500rpm 
for lOmin. Samples had BHT (butylated hydroxytoluene) added to yield a final 
concentration of 50|ig/ml, as an antioxidant.
2.2.2 Lipid extraction from serum - Folch method (1957)
0.5ml serum was mixed with 10ml chloroform-methanol (2:1). 2ml of 0.88% KC1 was 
added and vortexed again. The upper phase and interfacial band, containing most non 
lipid material, were removed after centrifugation at 2500rpm for 10 min. The lower 
chloroform layer was dried down under oxygen free nitrogen.
2.2.3 Alkaline hydrolysis of lipids (total amounts present) - Oda et al. ,
(1990)
2.0ml of 2.5% KOH in 90% ethanol was added to the dried sample, vortexed and 
hydrolysed at 55°C for 45min. 1.2ml distilled water was added and the sterols were 
extracted three times by the addition of n-hexane (3mlx3). The hexane layer was then 
washed with 1ml water-ethanol (1:1 (v/v)) twice. The organic layer was then dried down 
under oxygen-free nitrogen.
2.2.4 Cholesterol-oxidase reaction - Hylemon et al., (1989)
The residue was resuspended in 1ml 0.1M potassium phosphate buffer, pH7.4, 
containing ImM DTT, 50mM NaF, 0.015% CHAPS and ImM EDTA. To this, 30|il 
sodium cholate (20%) suspended in lOmM potassium phosphate buffer, pH7.4 
containing 20% glycerol was added and preincubated at 37°C for lOmin. Incubation with 
40(0,1 cholesterol oxidase (25U/mg, lmg/ml) was then carried out at 37°C for lOmin. 
Reaction was terminated with 2ml of 95% ethanol. Cholesterol metabolites were extracted 
by adding 6ml petroleum ether, vortexing for one minute, removing and drying down the 
upper layer under oxygen-free nitrogen. This ether extraction was repeated twice more 
and the final dried extract was resuspended in 100(il mobile phase. Samples were stored 
at 4°C until assayed.
2.2.5 HPLC analysis of cholesterol metabolites - Hylemon et al., (1989)
Analysis was carried out by reverse phase HPLC, using a C-18 Partisil P10 ODS-2 
(4.6x250mm, 10|im) Whatman column. HPLC was conducted on an LC-9A Schimadzu 
liquid chromatograph and an Axxiom 717 computing integrator. The mobile phase was 
acetonitrile:methanol (70:30 v/v) and elution was monitored at 240nm at a flow rate of 
0 .8ml/min for 2 0 min, which was then increased to 2 .0 ml/min to elute off cholesterol. 
The U.V. detector was set at 0.1 AUFS. 20(xl of sample was injected onto the column.
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I2.2.6 Standard curves for 7a-hydroxycholesterol and cholesterol:
Calibration curves for 7a-hydroxycholesterol and cholesterol were constructed, in the 
ranges 25.00 - 992 pmoles/20fil for the former and from 51.7 - 129.3 nmoles/20fll for 
the latter. Standards were brought through the whole procedure from the Folch
extraction, together with 2 0 a-hydroxycholesterol as internal standard, to the analysis by 
HPLC stage.
2.2.7 Recovery:
Control rat serum was spiked with varying amounts of 7a-hydroxycholesterol standard,
ranging from 40-120pmoles/0.5ml. Analysis was as above, carried out in duplicate. The 
percentage C.V. was calculated to measure the degree of precision obtained.
2.2.8 Intra/Inter assay variation:
Analyses were carried out in quadruplicate and assayed as above. Again, the percentage 
C.V. was measured to determine the precision of the method.
2.2.9 Measurement of Cholesterol 7a-hydroxylase in Rat Liver:
The preparation of rat liver microsomes and the subsequent measurement of Cholesterol 
7a-hydroxylase activity was carried out by J.Quinn in the laboratory as described by 
Hylemon et al., (1989):
The livers were cut up into small pieces prior to homogenisation in lOOmM potassium 
phosphate buffer, pH7.2 containing lOOmM sucrose, 50mM potassium chloride, 50mM 
sodium fluoride, 5mM EGTA, 3mM DTT, ImM EDTA, ImM PMSF and lOO^iM 
leupeptin. Each homogenate was centrifuged at 2500rpm fror lOmin and the supernatant 
fluid was centrifuged at lOOOOrpm for 2h. A microsomal pellet fraction was obtained 
after centrifugation of the supernatant fluid at 28000rpm for lh. The pellet was then 
homogenenised in the same buffer (4/1, w/v) and the protein content was determined as 
described by Lowry et al., (1951).
One milligram of microsomal protein was added to 0.1M potassium phosphate buffer, 
pH7.4 containing 50mM NaF, 5mM DTT, 5mM EDTA, 20% glycerol and 0.015% 
CHAPS and incubated for 5min at 370C. The reaction was initiated by the addition of the 
NADPH regeneration system whose final concentration were 5mM sodium isocitrate, 
5mM MgCl2, 0.5mM NADPH and 0.075 unit of isocitrate dehydrogenase. The final 
reaction volume was 1ml in a 15x125mm glass tube. The reaction mixture was incubated 
at 370C for 20 min in a shaking water bath. The reaction was terminatd by adding 30|ll of
20% sodium cholate and 1.9(J.g of 20a-hydroxycholesterol as an internal standard. Sterol 
conversion was initiated by the addition of 40fil of 0.1% cholesterol oxidase in lOmM
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potassium phosphate buffer, pH7.4 containig ImM DTT and 20% glycerol. This reaction 
mixture was incubated for lOmin at 37°C and the reaction was terminated and analysed 
by reverse-phase HPLC as described in 2.2.4 and 2.2,5.
Fig 2.1 Flow chart of sample preparation and treatment for subsequent sterol analysis 
by reverse-phase HPLC.
SERUM
(+ B.H.T. 50|ig/ml)
T
LIPID  EXTRACTION
(Chloroform : methanol 2:1 v/v) containing 0.88% KC1.
Lower layer dried down under N2 )
I
ALKALINE HYDROLYSIS
(2.5% KOH in 90% ethanol @ 55°C for 45 mins.
Washed with distilled water.)
I
EXTRACTION OF STEROLS
(3 X 3  mis n-Hexane extractions.
Organic layer washed twice with water:ethanol 
(1:1 v/v). Dried down under N2 ).
I
CHOLESTEROL OXIDASE ASSAY
I
H PLC ANALYSIS
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2.2.10 Partial purification of lecithin-cholesterol acyltransferase from  
Bovine plasma.
S tagel: d 1.21-1.25: Jonas, A., Personal communication
Bovine blood, containing lmg/ml EDTA was spun down for 30 mins at 3500rpm/40C. 
Plasma obtained had its density adjusted to 1.21g/ml with solid KBr and was checked 
using a densitometer (DMA 35, Anton Paar). The Beckman Quick Seal tubes were heat 
sealed as they are considered to be bio-hazardous (39.0ml capacity) and spun at 
54K/10°C/30hours in a 70 Ti rotor. The use of such tubes eliminates many of the 
problems that are inherent in the use of tube caps. On ice, the three layers were separated 
and an aliquot was of each layer was reserved for further analysis. The uppermost layer 
contains lipoproteins, middle layer- contains LCAT, while the lowest layer contains 
plasma proteins. Middle layer was dialysed against 0.01M Tris/5mM EDTA and 50mM 
NaCl, pH 7.6, changing buffer four times.
Stage 2: Butanol-Ammonium sulphate treatment: Doi and Nishida, (1981)
Solid sucrose was added to the dialysate, while slowly stirring on ice, to a concentration 
of lOOg/litre. Ammonium sulphate was then added to yield a final concentration of 40%. 
One volume of precooled butanol was added to two volumes of the solution and 
vortexed. Resultant mixture was centrifuged at 13000rpm/15mins/40C. The interface is 
collected, containing protein and suspended in precooled saturated ammonium-sulphate 
(40%) containing 10% sucrose (equivolume to middle dialysate of Stage 1). Precooled 1- 
butanol, (volume equal to half of middle dialysate), is added to the mixture, vortexed and 
centrifuged as above. This ammonium-sulphate/butanol treatment is repeated with one- 
half volumes of the solutions above. Resultant interface is resuspended in phosphate 
buffer, pH7.4 (containing 0.025% EDTA and 2mM NaN3), containing 10% sucrose. 
The solution was then mixed for 30mins under nitrogen.The enzyme mix was dialysed 
against 10mMTris/5mMEDTA/50mMNaCl, pH7.6 (4 x 1 litre) (Jonas, personal 
communication). The supernatant obtained by centrifuging the dialysate as above was 
treated as follows:
Stage 3: DE-52 Ion exchange chromatography: Jonas, A., Personal 
communication
An anion-exchange column was poured (2.5x6cm) with DE-52 anion resin, which had 
been prepared as follows:
Rinse resin with lOOmM Tris/50mM EDTA/500mM NaCl, pH7.6 (buffer 1) and leave to 
settle. Decant and repeat. Rinse resin with lOmM Tris/5mM EDTA/50mM NaCl, pH7.6 
(buffer 2). Repeat twice. Column was then poured and rinsed with buffer 2 prior to 
application of sample.
Sample was applied to column and the run-through peak was collected. Upon reaching a 
low, steady baseline, a linear gradient was applied (from 75mM NaCl-lOOmls to 200mM
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NaCl-lOOmls, lOmM Tris/5mM EDTA buffer, pH7.6, containing the above 
concentrations of salt). Flow rate was maintained at lml/min and 2ml fractions were
collected. This step was carried out at 4°C. Fractions were then assayed for LCAT
activity.
2 .2 .1 1  SDS-PAGE (polyacrylamide gel electrophoresis) of steps in the 
partial purification of LCAT from bovine plasma.
Sample aliquots of each of the above stages in the partial purification of LCAT were 
subjected to sodium dodecyl sulphate-poly aery lamide gel electrophoresis (SDS-PAGE) 
using the method of Laemmli (1970), as described by Bollag (1991). Proteins were 
separated on a resolving gel containing 7.5% (w/v) acrylamide, 0.20% (w/v) bis- 
acrylamide, 1.97M Tris-HCl pH 8 .8 , 1.25% (w/v) SDS, 0.15% (v/v) TEMED and 10% 
(w/v) ammonium persulphate. A stacking gel consisting of 2.85% (w/v) acrylamide, 
0.08% (w/v) bis-acrylamide, 0.5M Tris-HCl, pH 6 .8 , 2.5% (w/v) SDS, 0.05% (w/v) 
TEMED and 0.07% (w/v) ammonium persulphate was used. The electrode buffer 
contained 25 mm Tris, 192mM glycine and 0.1% SDS prepared in distilled water. 
Samples for electrophoresis were dissolved at a concentration of lmg/ml in solubilization 
buffer (equal ratio of sample to solubilization buffer) consisting of 60mM Tris-HCl, pH 
8 .8 , 25% (v/v) glycerol, 2% (w/v) SDS, 14.4mM 2-mercaptoethanol and 0.1% (w/v) 
bromophenol blue were used when reducing conditions were required. Samples were 
boiled for 2-3 minutes and 10-20(0.1 of these solutions were applied to the wells of the 
stacking gel. The gel was electrophoresed in electrode buffer, at 100mA for two gels, 
using an Atto vertical mini-system. Gels were stained for approximately 15 minutes in 
0.25% (w/v) Coomassie Brillant blue in methanol:acetic acid:water (5:1:4) and destained 
in methanol:acetic acid:water (25:7:68) while rotating gently. Markers were run in Lane 1 
and range from 32-195 kdal.
2.2.11.1 Concentration of DE-52 fraction for SDS-PAGE analysis:
T.C.A. (Trichloroacetic acid) precipitation: 20% T.C.A. was added in an equal volume to 
the sample. The mixture was left on ice for 30 mins. Sample is then centrifuged for three 
mins at 2000rpm (T.C.A. concentration is 10%). The supernatant is then removed, the 
pellet was washed twice with acetone and resuspended each time.
2.2.12 Synthesis and studies of discoidal com plexes- containing A) 
cholesterol and B) 7a-hydroxycholesterol as substrates for LCAT.
A) Cholesterol containing complexes: Jonas (1986a).
Micellar complexes of apolipoprotein A-I:egg phosphatidylcholine:cholesterol, in the 
molar ratio 1:100:9.1, were prepared as described by Jonas, A. (1986), but by varying 
the ratios of the three components of the discoidal complexes, using the detergent- 
mediated (sodium-cholate) method. Sodium cholate micelles with phosphatidylcholine
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form at a sodium cholate:phosphatidylcholine molar ratio of 1:2 to 2:1.
An aliquot of egg phosphatidylcholine was taken corresponding to 2.68mg (stock: 
50mg/lml ethanol). This, together with a total of 10 nmoles of cholesterol (comprising 
2.289 nmoles of [4-14C]Cholesterol (sp act, 52mCi/mmol) and 7.706 nmoles cold 
cholesterol,were dried down under a stream of oxygen-free nitrogen. Sodium cholate, in 
lOmM Tris-HCl, pH8.0, containing 150mM NaCl, 0.005% EDTA and ImM NaN3, was 
then added (2.68mg/total volume of complex=500|il) in order to disperse the lipids. The 
stock of sodium cholate is 30mg/ml. Such conditions result in the transformation of 
complex mixture from milky to translucent appearance. Incubation was carried out at 4°C 
for approximately 2 hours. If necessary, more sodium cholate may be added at this stage 
to ensure that the mixture becomes translucent, provided that the molar ratio of sodium 
cholate/phosphatidylcholine is no greater than 2/1. 870|i.g apolipoprotein A-I (was added 
lOmM Tris-HCl, pH 8.0, containing 150mM NaCl, 0.005% EDTA and ImM NaN3) 
next, in such an aliquot that the total volume of sodium cholate and apolipoprotein A-I is
500(11. The mixture was mixed thoroughly and incubated at 4°C for a period of 12-16 
hours, usually about 13 hours. Dialysis of the product was then carried out against 6 
changes of buffer, as above, in volumes of 500mls each in order to remove the sodium 
cholate. Such excessive dialysis was carried out over 3 days. Unreacted was removed
from the mixture by centrifugation for 70 minutes, 10°C at 13000rpm. Supernatant was 
transferred to a vial and stored at 4°C until required.
B) 7a-hydroxycholesterol containing complexes:
Discoidal complexes of apolipoprotein A-I:egg phosphatidylcholine: 7a-hydroxy- 
cholesterol, in the molar ratio 1:100:9.1,were prepared as above, except that 10 nmoles 
7a-hydroxycholesterol were dried down in the initial step, in place of cholesterol. The 
rest of the synthesis was as above.
2.2.13 Compositional analysis of discoidal complexes
a) Gel filtration of cholesterol-containing complexes- Chen and Albers, 
(1982)
The centrifuged preparation, containing 579(ig apo A-I, 84.848|lg cholesterol and 
1.785mg phosphatidylcholine, was chromatographed on a Sepharose CL-4B column 
(2.2x50cm), which was equilibrated and eluted with lOmM Tris, 150mM NaCl, ImM 
NaN3 and 0.05% EDTA, pH 7.4 buffer. Fractions of 2ml were collected at a flow rate of 
30ml/hour. Each fraction was assayed for each of its three components as described 
below. Markers run over the column were (Nichols et al., 1986)
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thyroglobulin- hydrated Stokes diametre 17.0nm, 6.69 x 105 daltons 
ferritin- hydrated Stokes diametre 12.2nm, 4.4 x 105 daltons 
eatalase- hydrated diametre 10.4nm, 2.1 x 105 daltons 
BSA- hydrated diametre 7.1nm, 6.7 x 104 daltons
Cholesterol elution was monitored by the addition of lOOjil of fraction to 10ml 
scintillation fluid and carrying out radioactive counting.
Phosphatidylcholine was measured using a kit for L-a-lecithin by Boehringer 
Mannheim.
Apolipoprotein A-I was measured by Bio-Rad protein assay.
b) Native Gradient gel electrophoresis (3-20%)
A linear gradient acrylamide gel (3-20%), pH 8.3 was made according to the method of 
(Walker, 1984). Fractions (cholesterol complexes) were concentrated by reverse dialysis 
against PEG-8000, to yield a final concentration of approximately 1.75mg/ml. Equal 
volumes of sample and tracker dye solution (40% sucrose and 0.05% bromophenol blue) 
were mixed and applied to the gel. A voltage of 160 was applied and the gel was left to 
run for approximately 90 minutes, in 50mM Tris and 0.38M glycine, pH8.3. An Atto 
mini system was employed. Staining and destaining were as described by Bollag and 
Edelstein (1991). Markers used were the same as those for the Sepharose CL-4B.
7a-hydroxy cholesterol complexes of equal concentration (approximately 10 |Xg protein)
were applied to the gel.
c) Electron microscopy of discoidal complexes
Electron microscopy was carried out by P.Costigan, Virus Reference Laboratory, 
University College Dublin. Transmission electron microscopy was used to determine the 
structure and approximate measure of diameter of the complexes. Samples were diluted to 
a final vlume of 4ml with “polished” water (reverse osmosis water which has been 
filtered and autoclaved), centrifuged at 2000g for 35min in an ultracentrifuge- Sorvall 
Combi. They were then negatively stained with 4% phosphotungstic acid, pH6 .8 , having 
been resuspended in 0.01% Bacitracin (a low molecular weight spreading agent which 
reduces the surface i.e., a “wetting” agent), for approximately lmin. A Philips 201C 
transmission electron microscope, operating at 80 kV, with an objective lens- aperature of 
20 microns and a condenser of 100 was used in this study. Grids were scanned 20,000 
times with a 9-fold magnification of the selected area (180,000- fold magnification). 
Prints were obtained for each sample. The diameters and widths were measured from the 
prints by utilisation of the bar indicated.
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2.2.14 Reaction of LCAT with substrate complexes
2.2.14.1 Reaction of LCAT source with discoidal complexes containing 
cholesterol: Jonas and Matz (1982)
An aliquot of complexes, containing lOnmoles substrate (7a-hydroxycholesterol or
cholesterol) incubated with 2mg defatted BSA, 4mM B-mercaptoethanol and lOmM Tris- 
HC1, 0.01% EDTA, ImM NaN3 buffer, pH 8.0, to a final volume of 500|il. The mixture
was preincubated for 30 minutes at 37°C. Then 100|jl of the pooled DE-52 fraction was 
added and further incubated for 30mins (Jonas and Matz, 1982). Reaction was terminated 
by the addition of 10ml chloroform/methanol (2/1). Carriers added for TLC were as 
described by (Steinmetz, 1985), 10jig/ml each of cholesterol and cholesteryl oleate were 
added. Cholesterol and cholesteryl ester were separated by thin layer chromatography on 
scored precoated silica gel 60 plates (20cmx20cm Whatman). The TLC plate was spotted 
and run with a mobile phase of petroleum ether:diethylether:acetic acid (76:20:1) (v/v/v). 
Spots were visualised after placing iodine crystals in the tank for a few minutes. Bands 
were scraped off and placed in scintillation vials with 10ml scintillation fluid (EcoLite). 
Counts were taken and calculations carried out as below. Controls were run which 
contained no enzyme source and they contributed to a minimal amount of enzyme 
activity.
Enzyme activity was measured by the conversion of [4-14C]cholesterol to [4-14C] 
cholesteryl ester. The ratio of cholesteryl ester to free unesterified cholesterol is measured 
and the percentage esterification is calculated based on the number of moles of cholesterol 
employed in the reaction mixture.
A.CE 
(CF+CE).v.t
where A = number of mole substrate added to the incubation mix, CE = cpm in the 
cholesterol ester band of the plate, CF = cpm in the unesterified cholesterol band, t = 
incubation time and v = volume of enzyme used (Mahedevan and Soloff, 1983).
2.2.14.2 Reaction of LCAT source with discoidal complexes containing 
7a-hydroxycholesteroI:
The procedure is as above, except, due to the fact that non-radioactive 7 a-
hydroxycholesterol was employed in the assay, scintillation counting could not be used 
as a quantitative method of analysis. Thus, using the procedure described above for the
hydrolysis and HPLC analysis of 7a-hydroxycholesterol, the following procedure was
used:
LCAT assay with discoidal complexes containing 7a-hydroxycholesterol (lOnmoles) 
was as described above.Upon termination of the reaction with 10ml chloroform/methanol
35
(2/1), 2ml of 0.88% KC1 was added and vortexed. The upper phase and interfacial band, 
containing most non-lipid material, were removed after centrifugation at 2500rpm for 10 
min. The lower chloroform layer was dried down under oxygen free nitrogen. Alkaline
hydrolysis was carried out on one sample, to measure total 7a-hydroxycholesterol
present, while a second sample was not hydrolysed, as the free amount of 7 a - 
hydroxycholesterol was to be measured. Thus, the amount that was esterified was 
calculated as the difference between the total and the free amounts of 7 a -  
hydroxycholesterol. Extraction with n-hexane, water:ethanol washing, cholesterol 
oxidase assay, petroleum ether extraction and finally, analysis by reverse-phase HPLC 
were carried out as in 2.2.5. Visual analysis by development on a TLC plate was also 
undertaken. Enzyme/substrate blanks and LCAT source samples were analysed, the latter
for endogenous 7a-hydroxycholesterol and cholesterol.
2.2.15 Preparation of liver microsomes- Einarsson et al., (1989)
Liver samples were homogenised with a Teflon-pestle in nine volumes of 50mM Tris- 
HC1 buffer, pH 7.4, containing 0.3M sucrose, ImM EDTA, 50 mM NaF, 5mM EGTA 
and 50(J.M leupeptin after being minced finely. The homogenate was centrifuged for 15 
min at 2500rpm. The supernatant fluid was centrifuged for 1 hour at 38000rpm. The 
microsomal pellet obtained was then resuspended in 0.1 M phosphate bufer, pH 7.4, 
containing ImM EDTA, to yield a final concentration of 10% (w/v). Protein content was 
determined by the method of Lowry et al., (1951).
2.2.16 Removal of microsomal cholesterol using 2-HPBCD- Martin et al., 
(1993)
Previous studies (De Caprio et al., 1992) have indicated that 2-hydroxypropyl-B- 
cyclodextrin, (2-HPBCD), is a molecule with a hydrophobic cavity capable of 
accomodating sterols and has been used in cell culture and in vivo studies. Results of 
Martin etal., (1993) indicate that this is also a suitable vehicle for the removal of 
cholesterol from microsomal preparations.
100(il aliquots of microsomal suspension (diluted) containing 3.42|_tg cholesterol, 
150|lg protein in lOOmM potassium phosphate buffer, containing ImM EDTA, pH 7.4, 
were incubated at 37°C for the duration of the experimental procedure. 2-HPBCD was 
added to the mixtures, in centrifuge tubes, to yield a final concentration of 30mM. Each 
assay was carried out at least in duplicate, while analysis was also carried out on 
replicates at time 45 (first incubation) and time 90 (second incubation), to measure the 
extent of cholesterol depletion. Upon completion of incubation of microsomal preparation 
with 30mM 2-HPBCD, the tube with its contents were immediately placed on ice and 
centrifuged at 150000g, at 40C for 40 min. Microsomal pellets were recovered and
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resuspended in their original buffer- lOOmM potassium phosphate buffer, containing 
ImM EDTA, pH 7.4 (100|il) and subsequently used in the assay of AC AT activity.
2.2.17 Assay of ACAT activity- Sahlin et al., (1994)
The above suspension, containing 150|ig protein and lmg of fatty acid-free bovine serum 
albumin, was made up a volume of 1ml (including the volumes of 7 a- 
hydroxycholesterol). Preincubation was carried out at 37°C for 5min. Varying amounts 
of 7a-hydroxycholesterol, ranging from 4-24 nmoles/assay, were added to the
mixture. [7a-hydroxycholesterol was made up as follows, using the principal as decribed 
by Billheimer et al. (1981):
Stock= 2.480mM 7a-hydroxycholesterol, in methanol. Aliquot dried down, under
oxygen free nitrogen, corresponding to 300jig 7 a-hydroxycholesterol (744.9nmoles). 
9mgTriton WR-1339 was added in 90fil methanol (10% solution of Triton WR-1339 in 
methanol). Thus, the stock solution of 7a-hydroxycholesterol/Triton WR- 
1339=300p.g/9mg in 90|il.
The working solution of 7a-hydroxycholesterol/Triton WR-1339 was as follows:
lml assay buffer is placed in a test tube, weighed and warmed gently. The stock solution
of 7a-hydroxycholesterol/Triton WR-1339 is also warmed gently, ensuring that the
cholesterol oxide is dissolved completely. 24.2^1 of the dissolved stock solution was 
then added to the buffer, with constant mixing. Oxygen-free nitrogen was used to 
evaporate off the solvent. If any loss in weight occured during the procedure, it was 
replaced at this stage with water, while vortexing. A transparent solution resulted, which
contained 200nmoles 7a-hydroxycholesterol and 2.416mg Triton WR-1339 in a final
volume of lml].
Thus, 20, 40, 60 and 120|il of the above mixture was added to the assay buffer, 
corresponding to 4, 8 , 12 and 24 nmoles 7a-hydroxycholesterol per assay mix. These
were further incubated for 20 min. 25nmoles (1.48[iCi) of [1-14C] oleoyl Co.A was 
added to initate the reaction. Reaction was terminated by the addition of 10ml 
chloroform/methanol [2/l(v/v)] after 6 min. [1,2,6,7-3H] cholesteryl oleate[0.01(iCi 
(0.132pmoles)] was added as internal standard, followed by the addition of lml 0.9% 
NaCl (w/v). Cholesteryl esters were recovered from the chloroform phase, which was 
evaporated under oxygen-free nitrogen. Having resuspended the residue in 
chloroform/methanol [2/l(v/v)], carried out thin layer chromatography on precoated 
Whatman silica gel 60 plates (20cmx20cm), with hexanerethyl acetate 95:5 (v/v) as 
mobile phase, the resulting spots were visualised with iodine vapour. Cold cholesterol 
and cold cholesteryl oleate were also run as markers. Resulting bands for analysis were
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scraped off and placed directly in scintillation vials with 10ml EcoLite scintillation fluid 
for radioactive counting. A substrate blank was also included in the assay. Enzyme 
activity was expressed as pmoles/min/mg protein.
A replicate of this procedure containing 24 nmoles 7a-hydroxycholesterol was 
produced and run on TLC. However, instead of being analysed quantitatively by 
radioactive counting, the bands of the TLC plate were scraped off, eluted 3 times with
2.5 ml diethyl ether as described by Nimmannit and Porter (1980). The combined 
extracts were subjected to hydrolysis, n-hexane extraction, cholesterol oxidase assay, 
petroleum ether extraction and finally, reverse HPLC analysis as described in 2.2.4 and
2.2.5. Each band of the TLC lane was analysed for its composition.
The amount of product formed was calculated using the following equation: 
nmoles esterified 7a-hydroxycholesterol produced/6min/mg protein=
dpm P4C]7a-hydroxycholesterol recovered x dpm [3H]cholesterol oleate added
specific activity [14C] oloeyl CoA dpm [3H]cholesterol oleate
(dpm/nmole) recovered
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Fig 2.2 Schematic representation of the procedure involved in the preparation and 
assay of ACAT, with respect to 7a-hydroxycholeserol as a potential substrate.
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2.2.18 Protein assays
2.2.18.1 Bicinchonic acid (BCA) protein assay
Cu2+ reacts with protein under alkaline conditions to yield a coloured product upon 
reaction with the BCA reagent. 200pi of commercial working BCA reagent (Pierce 
Chem.Co.,) was added to lOfil test sample or protein standard solution (10-2000(ig/ml), 
in 96-well microtitre plate wells. The plate was agitated to ensure thorough mixing and 
incubated for 30min at 370C. The absorbance was read at 560nm using a Titertek 
Twinreader® Plus microtitre plate reader. Protein concentrations were determined from a 
standard curve. Typically, BCA standard curves for protein determination gave r values 
of 0.999.
2.2.18.2 Bio-Rad assay
The Bio-Rad protein assay is based on the fact that the absorbance maximum for an acidic 
solution of Coomassie Brilliant Blue G-250 shifts from 465nm to 595nm, when binding 
to protein occurs. 40(il of commercial Bio-Rad reagent (Bio-Rad Laboratories) was 
added to 160 ,^1 of test sample or standard protein solution (5-25 fig/ml). Again, 96-well 
microtitre plates were used. Typically, BSA was the standard protein employed. The 
samples and reagent were mixed thoroughly using a micropipette as the reagent is viscous 
and does not mix readily with the sample or standard. Absorbance readings were 
measured on the Twinreader® Plus microtitre plate reader, at 620nm- 5-60min after 
sample mixing. Protein concentrations were obtained from a standard curve. Typical r 
values were 0.998
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CHAPTER 3 
VALIDATION OF PREPARATIVE AND 
CHROM ATOGRAPHIC PROCEDURES FOR  
THE M EASUREM ENT OF SERUM 7a- 
HYDROXYCHOLESTEROL
Introduction
This chapter discusses the concepts behind an efficient preparation of an analyte for 
subsequent analysis by a suitable chromatographic method. One of the problems that 
continually faces biochemists is the separation, purification and identification of one or 
more biological compounds from a mixture of such compounds. One of the most 
convenient methods for achieving such separations is the use of chromatographic 
techniques. The feature that distinguishes chromatography from most other physical and 
chemical methods of separation is that two mutually immiscible phases are brought into 
contact; one phase is stationary and the other mobile. It is possible to rationalise to some 
extent the type of system most likely to be applicable to the separation of compounds 
when the physical characteristics are known. An example of this would be the 
applicability of reverse-phase chromatography to the analysis of a polar compound such
as 7 a-hydroxycholesterol upon extraction from an aqueous environment, whereby the 
use of a mobile phase which is more polar relative to the stationary phase results in 
analytes being eluted from the column in order of decreasing polarity. Stationary phases 
which are frequently used in this form of chromatography are chemically bonded such as 
octadecylsilane (ODS), an alkane with 18 carbon atoms. C 8, shorter alkyl chains and also 
cyclohexyl and the more polar phenyl groups provide other alternatives.
Water is often described as the strongest elution medium for chromatography, but in 
fact this is only true for adsorption processes. Water may interact strongly with the active 
centres in silica gel and alumina, so that adsorption of sample molecules becomes highly 
restricted and they are rapidly eluted as a result. Exactly the opposite applies in reversed- 
phase systems: water cannot wet the non-polar alkyl groups and does not interact with 
them in any way. Hence, it is the weakest mobile phase of all and gives the slowest 
sample elution rate (Meyer, 1988). Before discussing HPLC applicability and 
methodology in detail, an introduction to sample cleanup will be given.
3.1.1: Sample collection
The first step in such biological analysis involves the collection of the sample. Such 
information as the expected concentration of the analyte to be found in the sample, the 
stability of the analyte, for example, to light, temperature, pH and biochemical changes 
due to enzymic reactions and the physiological variations of the analyte due to physical 
activity, stress or biological rhythms is required in order to maximise the efficiency of 
sample collection.
Plasma is obtained by centrifuging whole blood in a heparinised tube or tubes 
containing salts of EDTA to prevent clotting. It is rich in lipids and lipoproteins, since 
these compounds cannot be removed by centrifugation. Care must also be taken not to 
haemolyse the blood cells, as many compounds are present in different concentrations 
between red cells and plasma.
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Serum samples, which are produced by the natural clotting of fibrinogen, results from 
blood being drawn into tubes containing no anticoagulant. The clot is allowed to form
after standing for 10-15 mins at room temperature or longer if left at 4°C. A wooden stick 
may be used to remove the clot, if it adheres to the walls of the container. The clot is 
normally left to retract, before centrifugation, so as to release as much volume of serum 
as possible.
3.1.2: Sample storage
If the sample requires being transported from the site of collection to the site of 
analysis, then note should be taken of the possible effects of transport and storage on the 
analyte (Uihlein, 1986). Unless otherwise specified, the appropriate conditions for the 
sample during transport are freezing or freeze-drying. If required, an antioxidant such as 
butylated hydroxytoluene should be used. Under all conditions, stability is a time- 
dependent property. Care should also be taken if the sample is light sensitive, as it is well 
documented that certain substances, such as cholesterol are known to be light sensitive 
and break down under light. Containers themselves may also interact with the sample 
(lipids are known to react/adhere to glass), migration of plasticisers from the container 
into the sample may interfere with or adsorb the analyte (Steyn and Muller, 1980).
3.1.3: Sample preparation 
3.1.3.1: Deproteination
The choice of sample preparation method is dependent on the sample matrix, size 
availability, concentration of the analyte, stability of the analyte, whether or not the 
analyte is bound to proteins, sensitivity and specificity of the detector used and whether a 
qualitative or a quantitative analysis is to be performed. Such pretreatments of the sample 
include the disintegration of the sample where the matrix structure is destructed by 
homogenisation, grinding and blending in an appropriate solvent and secondly by 
deproteination which is necessary where high concentrations of protein are present which 
may form emulsions during organic extraction. Deproteination of a blood sample is 
generally associated with pH adjustment for the following extraction step into an organic 
solvent. Thus the method selected for deproteination depends on the pKa of the material
to be analysed. Common solvents used include acetone, acetonitrile and alcohols, which 
lower the solubility of proteins in aqueous solution. By deproteination and extraction, 
protein bonds must be broken in order to increase the recovery of the analyte (Christians 
and Sewing, 1989). Removal of protein is required whenever there is a hint of 
irreversible binding of the analyte to proteins. Extraction by means of solid-phase seems 
to avoid the formation of emulsions.
Proteins may also be precipitated by the formation insoluble salts. Acidic agents such as 
trichloroacetic acid and perchloric acid can form insoluble protein salts with the cationic 
form of proteins at low pH, thus precipitating them of solution. Alternatively, proteins,
42
being negatively charged in strongly alkaline solution, may be precipitated by the 
formation of insoluble salts with cationic précipitants such as Cu2+ and Zn2+ions.
Ultrafiltration may also be used to separate protein from an analyte. Here, filtration 
through a size-selective semipermeable membrane under pressure or by centrifugation in 
a membrane cone, results in a protein-free ultrafiltrate. An advantage of its applicability to 
small volumes over that of protein precipitation methods is that no dilution occurs during 
filtration.
3.1.3.2 Extraction procedures for blood samples
Many cleanup procedures for samples exist and include filtration, centrifugation, 
precipitation, freeze-drying, evaporation, extraction of solids/liquids by liquids and the 
extraction of liquids by adsorption on solids (Fig 3.1).
Fig 3.1: Methods involved in sample preparation
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Liquid-liquid extractions are usually followed by evaporation of the extraction solvent 
to concentrate the extracted analyte. Extraction is usually rapid, relatively simple and 
mostly results in high purification (Uihlein, 1986). The solvent is selected in order to 
provide maximum efficiency of extraction with the minimum amount of contamination. 
The least polar solvent that sufficiently extracts the analyte is selected for the extraction. 
By increasing the polarity of the extracting media one also increases the range of 
compounds extracted. Ideally, the solvent chosen should be volatile, as most samples are 
recovered, after solvent extraction by evaporation.
Ion-pair formation involves the extraction of samples into an organic solvent, by the 
suppression of their ionisation in the aqueous phase, by means of addition of acid, base, 
or a buffer of controlled pH. “Salting-out” results in the extraction of polar compounds 
into an organic phase, after decreasing their affinity for the aqueous phase, by the 
addition of buffer salts to the aqueous solution. Derivatisation is commonly used to 
improve the detectability of certain analytes. It may also be used in the analysis of 
compounds which are insufficiently soluble in organic solvents, but may be extracted 
after being derivatised to more organically-soluble derivatives. Formation of a complex 
allows the extraction of compounds which are hydrophilic, from the aqueous phase, by 
the formation of a hydrophobic complex with an appropriate complexing agent.
Solid-phase extraction involves the adsorption of the analyte onto the solid phase 
material. The adsorbent needs to be of suitable selectivity as does the solvent in which the 
analyte can be quantitatively recovered. Solid phases include- silica, silicic acid, alumina, 
Celite, talc, charcoal or ion-exchange, hydrophobic or hydrophilic resins. Silica gels have 
also been bonded with a wide variety of functional groups such as alkyl (C i, Cs and 
C i8), phenyl, aminopropyl and diol groups. Thus, these allow for the specific interaction 
between the analyte and the support. The cartridges (Fig 3.2) are disposable and the use 
of such a procedure results in the concentration of the sample on the cartridge as well as 
effecting at least a partial clean-up.
Fig 3.2 A disposable sorbent extraction cartridge
cz
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3.1.4 Modes of separation
As mentioned earlier it is possible to rationalise to some extent the type of system most 
likely to be applicable to the separation of compounds, based on such characteristics as 
their molecular weight, solubility in aqueous/non-aqueous systems and ionisability. The 
different modes of separation by HPLC may be divided into classes such as ion- 
exchange, reverse-phase, normal-phase (adsorption), partition and gel-permeation 
chromatography (Fig 3.3). In brief, these are discussed below:
Ion-exchange chromatography describes separation that is based on the relative 
molecular charges of the compounds being separated, i.e., the attraction between 
oppositely charged molecules. The charge on the stationary phase is opposite to that of 
the ion. The ion-exchange columns for HPLC include such packing material as silica 
bonded with ionic groups (cationic or anionic). Ion-exchange chromatography may also 
be performed on bare silica with methanol containing an ammonium salt, e.g., 
ammonium perchlorate (Law et al., 1984; Flanagan and Jane, 1985), as eluent.
Fig 3.3 Rationale for the choice of a chromatographic system (Wilson and Goulding, 
1986)
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Normal-phase chromatography also known as adsorption chromatography, allows the 
separation of components based on differences both in their degree of adsorption by the 
adsorbent and solubility in the solvent used for separation. The molecular structure of the 
compound governs these features. The eluents here are usually relatively non-polar 
organic solvents. Thus, the analytes are eluted off in order of increasing polarity, while 
retention decreases with increasing solvent polarity. Compounds that are highly soluble 
in organics, such as lipids and fat-soluble vitamins, are usually separated by normal- 
phase HPLC.
Partition chromatography especially in the high performance form, is used for the 
separation of a very wide range of biological compounds. It is based on the partition of 
the solute between the liquid stationary phase and the mobile phase. In normal phase 
partition chromatography, the stationary phase is water supported by a matrix. In reverse 
phase partition chromatography, the stationary phase is a non-polar compound such as 
liquid paraffin supported by a matrix similar to those employed in normal phase systems 
(cellulose, starch or silicic acid).
Gel permeation chromatography or size-exclusion chromatography, separates 
compounds on the basis of molecular size. Large molecules, outside the molecular weight 
cut-off range of the gel, are excluded from the gel, as they cannot enter the pores of the 
stationary phase. Elution occurs in order of decreasing size, the smallest molecules being 
eluted lastly.
Reverse-phase chromatography as the name suggests, is the opposite to normal-phase 
chromatography. Thus, the mobile phase is more polar than the stationary phase. The 
solute is retained mainly as a result of hydrophobic interactions between the solutes and 
the hydrophobic stationary phase surface. Solutes are normally eluted in order of 
decreasing polarity (increasing hydrophobicity) and increasing the content of the non­
polar component in the mobile phase, results in the decrease of the retention of the 
solutes. Various additives can be incorporated into the mobile phase to give special 
selectivities. Thus, reverse-phase chromatography may be extended to include ion- 
pairing, ionisation or ion-suppression.
3.1.5 Instrumentation for HPLC
The instrumentation for HPLC components for HPLC includes the following (Fig 
3 .4 ).
3.1.5.1 Solvent reservoir for the mobile phase:
The mobile phase (eluent) selected will depend on the type of separation that is to be 
achieved. Eluents for HPLC may comprise water, aqueous buffer solutions, 
aqueous/organic mixtures, organic liquids or mixtures of organic liquids. Only HPLC- 
quality products should be purchased or solvents must be subjected to preliminary
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purification procedures.
Fig 3.4 Taken from Wilson & Goulding (1986)
data system
Stabilisers may alter the solvent polarity completely, e.g. chloroform stabilised with 
ethanol is much more polar than the pure solvent. Solvents should be degassed or filtered 
prior to use. A gradient elution system is where the composition of the mobile phase 
changes continuously by use of a gradient programmer. This involves the use of two 
pumps. An isocratic system is where a single solvent, or two or more solvents mixed in 
fixed proportions are used. It is essential that the solvents used in mobile phases are 
specially purified of any impurities, which may interfere with the detection system or 
affect the column. If absorbance monitoring is below 200nm, these effects become 
noticable. The presence of air bubbles in the mobile phase may alter the resolution of the 
column and interfere with the effluent monitoring, thus the mobile phase must be 
degassed. This may be carried out by stirring the solvent with a magnetic stirrer, 
warming it, subjecting it to a vacuum, ultrasonic vibration or by bubbling helium gas 
through the solvent resevoir. The eluent viscosity is normally between 0.2xl(M (pentane) 
and 2x10-3 mN s m-2 (50:50 water:methanol). Table 3.1 lists such properties of 
commonly used organic solvents in chromatography as viscosity, refractive index and the 
solvent strength parameter, described by Snyder as X°. The latter is determined 
empirically and recorded numerically and is the hypothetical “energy of adsorption” of the 
eluent. The series of weak, medium strength and strong solvents thus derived is referred 
to as the eluotropic series. The table lists the solvents in order of increasing solvent 
strength- pentane being considered the weakest and water being the strongest. TLC may 
also be used in an attempt to determine the best mobile phase polarity for a specific 
separation.
Another factor to be considered in the selection of a suitable phase is the UV cut off
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value. Such values vary at random with the solvent strength- acetonitrile and methanol 
having relatively low UV cut off values of 190 and 205nm respectively when compared 
to carbon tetrachloride which has a cut off value of 265nm (Knox, 1978).
Table 3.1:
SOLVENT STRENGTH PARAMETRE, 1°, AND PHYSICAL PROPERTIES OF 
SELECTED SOLVENTS
1 ° 1 ° Viscosity, 20^C Refractive
Solvent (S i02) (AI2 O 3 ) (mN sec m'2) index,20^C
Pentane 0 .0 0 0 .0 0 0.230 1.358
Hexane 0 .0 0 0.313 1.375
Cyclohexane -0.05 0.04 0.980 1.426
Carbon disulphide 0.14 0.15 0.363 1.628
Carbon tetrachloride 0.14 0.18 0.965 1.460
1-Chlorobutane 0.26 0.470 1.402
Diisopropyl ether 0.28 0.379 1.368
2-Chloropropane 0.29 0.335 1.378
Benzene 0.25 0.32 0.650 1.501
Diethyl ether 0.38 0.38 0.230 1.353
Chloroform 0.26 0.40 0.570 1.443
Methylene dichloride 0.42 0.440 1.425
Methylene isobutyl ketone 0.43 1.394
Tetrahydrofuran 0.45 0.550 1.407
Acetone 0.47 0.56 0.320 1.359
1,4-Dioxane 0.49 0.56 1.540 1.422
Ethyl acetate 0.38 0.58 0.450 1.370
1-Pentanol 0.61 4.100 1.410
Acetoniltrile 0.50 0.65 0.375 1.344
Methanol 0.95 0.600 1.329
Water Large 1 .0 0 0 1.333
X°, solvent strength parameter values from Snyder (1968) 
Table reproduced from (Willard et al., 1988).
3.1.5.2 High pressure pump
The mobile phase must be delivered to the column over a wide range of flowrates and 
pressures. The pump, seals, all connections must be made from materials which are 
resistant to the mobile phase. A pump should, ideally, be able to operate to at least 100 
atm (1500 psi) which is a pressure suited to less expensive chromatographs. However, 
400 atm (6000 psi) is a more desirable pressure limit. There are different types of pumps-
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constant pressure, constant displacement and reciprocating piston-pumps.
The first of these, the constant pressure pump, operates by the introduction of high 
pressure gas into the pump. The gas forces the solvent from the pump chamber onto the 
column. These pumps result in pulseless and continous pumping and high flowrates 
through the column, for preparative purposes. However any decrease in the permeability 
of the column will result in lower flow rates which the pump will not compensate for.
With constant displacement a constant flow rate is maintained through the column, 
irrespective of changing conditions within the column. One type of constant displacement 
pump is a motor-driven syringe-type pump. These pumps work by means of a piston, 
which is driven mechanically at a constant rate. The rate of solvent delivery is controlled 
by the voltage being changed on the motor.
Reciprocating piston pumps are the most commonly used form of constant 
displacement pump. These pumps have advantages of permitting a wide range of 
flowrates and are relatively inexpensive. A small motor-driven piston moves rapidly back 
and forth in a hydraulic chamber that varies in size. On the backward stroke, the piston 
pulls in solvent from the mobile-phase reservoir, by means of check valves. The outlet to 
the separation column is closed at this stage and a forward stroke causes the pump to 
push solvent onto the column and the inlet from the reservoir is closed. All constant 
displacement pumps have built-in safety cut-out mechanisms so that if the pressure within 
the chromatographic system changes from the preset limits, then the pump is inactivated.
3.1.5.3 Sample injection loop / application of sample
Ideally, the sample should be introduced onto the column as an infinitely narrow band. 
The injection system itself, should have no dead volume. This is achieved by either of 
two methods:
1: Stop flow iniection. This method can be used up to very high pressures. Here the 
pump is turned off until the inlet column pressure becomes essentially atmospheric. The 
sample is injected through a septum in an injection port, either onto a plug of inert 
material immediately above the column or directly onto the column. Once the injection is 
made, the pump is switched on again.
2: Loop / valve iniection. This method is rapid and can operate at high pressures. 
Microsampling valves are the most widely used. An unnecessary solvent peak is avoided 
by dissolving the sample in the mobile phase. The sample is applied onto the metal loop, 
by means of a syringe. The valve, as shown in Fig 3.5, is then rotated, placing the 
sample-filled loop into the stream of mobile phase, resulting with the application of 
sample onto the top of the column. The interruption of flow is non-significant.
3.1.5.4 Columns
These are genarally made of stainless steel, to withstand the high pressures of HPLC
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and also the chemical action of the mobile phase. The preferred columns are precision 
bored with an internal mirror finish in order to allow efficient packing of the column. The 
packing material is retained within by the action of porous plugs of stainless steel/teflon.
Fig 3.5 Flow diagram of a six-port sample injection valve
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Radial compression columns have wider diameters. This allows the lowering of flow 
rates, due to lower pressures, which in turn allows the flow rate to be increased, resulting 
in the overall shortening of run-times. However, there is an associated decrease in 
response.The column is compressed by means of a radial-compression module. 
Separations are carried out when the column is under compression. After analysis, the 
column is decompressed and removed from the module. The internal diameter of standard 
columns is normally 4-5mm. Particles for packing are uniformly sized and mechanically 
stable (discussed below). By decreasing the internal diameter of the narrow bore column 
by a factor of two, there is an increase in the signal of the sample component by a factor 
of four. Packed columns with internal diameters of 1 .Omm or less impose limitations on 
extra-column effects. Columns of 3-6cm, being short columns, can save solvent costs 
and result in high sensitivity (higher than conventional columns). In brief, there are three 
types of packing- microporous where micropores ramify through the particles (5-10|im in 
diametre), pellicular where porous particles which are coated onto an inert solid core e.g., 
glass bead (40|nm diametre) and bonded phases- where the stationary phase is chemically 
bonded onto an inert support. All forms of HPLC column packing are characterised by 
their regular spherical shape which distinguishes them from conventional materials.
Reverse-phase chromatography uses a hydrophobic bonded packing, usually with an 
octadecyl (C-18) or octyl (C-8) functional group (Table 3.2) and a polar mobile phase, 
frequently a partially or fully aqueous mobile phase. Generally, the lower the polarity of 
the mobile phase, the higher it’s eluent strength.
Table 3.2 Silica-based column material and mobile-phase solvents for 
reverse-phase chromatography
Sample Column packing Mobile phase
Low Low/moderate Bonded C-18 Methanol/ High
polarity (soluble water
i { in aliphatic
hydrocarbons)
1 r
POLARITY Moderate polarity Bonded C-8 Acetonitrile/ POLARITY
soluble in methyl water
i i ethyl ketone)
1
High polarity Bonded C-2 1,4-Dioxane/ ’f
High (soluble in water Low
lower alcohols)
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3.1.5.5 Detector system The most common detecting system is a variable 
wavelength uv-visible spectrophotometer, fluorimeter, a refractive-index monitor or an 
electrochemical detector. Detectors based on the adsorption of UV-VIS radiation are 
virtually insensitive to variations in the temperature of the test liquid. However, such 
detectors are relatively inexpensive and are sensitive for such compounds that absorb in 
the ultraviolet or visible region of the spectrum. Detection by fluorimetry offers both 
sensitivity and selectivity. The former is improved as the signal produced is measured 
against a low background (assuming that the mobile phase does not fluoresce itself). The 
latter is enhanced as not all compounds absorb radiation fluoresce. A refractive-index 
monitors is limited by its poor detection sensitivity, lack of selectivity and its sensitivity 
to changes in flow and temperature. Finally, electrochemical detectors are used mainly 
when polar phases are employed. Sensitivity is very good and selectivity is also good as 
only certain compounds are likely to be electroactive.
In order to study the metabolism and biological significance of 7 a-hydroxycholesterol
in serum, it was necessary to validate the method of measurement of this sterol. Thus, the 
objective of the first phase of this study was to develop an efficient extraction for
cholesterol and 7 a-hydroxycholesterol from serum samples of animals and human
subjects. Upon extraction, measurement of 7 a-hydroxycholesterol was carried out using 
a reverse-phase HPLC method. Finally, the complete procedure, as described in the 
following section, was validated in terms of recovery, linearity and inter/intra assay 
variation.
Aims of Chapter 3 “Validation of preparative and chromatographic 
procedures for the measurement of serum 7a-hydroxycholesterol” :
* To develop an efficient extraction for 7a-hydroxycholesterol and cholesterol from 
human and animal sera
* To validate the developed method
* To measure levels of 7a-hydroxycholesterol in the selected sera samples
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Results
Prior to commencing a study to determine levels of l a -hydroxy cholesterol in human 
and animal sera, it was decided to carry out a preliminary study on the efficiency of 
solvent systems to extract cholesterol and 7 a-hydroxycholesterol from serum and to 
determine the performance characteristics of the chromatographic procedure used to assay 
7a-hydroxycholesterol in extracts of serum.
Therefore, organic solvent mixtures varying in degrees of polarity were compared with 
respect to their ability to extract cholesterol and 7a-hydroxycholesterol from a fixed 
aliquot of rat serum. This was followed by determining the optimal conditions for 
converting the sterols into derivatives having characteristic UV absorption profiles. 
Finally, this chapter will describe the characteristics of the chromatographic method of 
assay with respect to precision, linearity and recovery.
3.2.1 Efficiency of solvents in the extraction of 7 a -h y d r o x y ch o lestero l  
and cholesterol from rat serum.
0.5ml aliquots of rat serum, spiked with known amounts of cholesterol and 7a- 
hydroxycholesterol which ranged in concentrations across the standard curves, were 
mixed with 10ml of one of the following solvent mixtures: diethyl ether:methanol (2:1 
(v/v)), chloroform:methanol:diethyl ether (1:1:1 (v/v/v)), acetonitrile:methanol (2 :l(v/v)) 
or chloroform:methanol (2:1 (v/v)). After centrifugation at 2500rpm for lOmin as 
described in Chapter 2, the non-lipid material was removed from the biphasic system. 
The lower lipid-containing layer was dried down under nitrogen and subjected to alkaline 
hydrolysis treatment, in order to enable total amounts of lipid present (both free and 
esterified) to be quantitated using HPLC, as described previously in Chapter 2.
In order to estimate the amount of sterol recovered at each of the preparative stages, it 
was necessary to compare HPLC peak areas of each of these steps with those obtained 
when the corresponding standard was injected directly onto the HPLC column. Thus,
serum samples were spiked with 7 a-hydroxycholesterol and cholesterol and at the
various stages of sample preparation as in Fig 2.1 a 20 }il aliquot was analysed by 
HPLC and the resulting area units were compared with those obtained by direct injection 
onto the column. Absorption of 7 a-hydroxycholesterol and cholesterol was monitored at 
214nm and 205nm respectively. The overall efficiency was calculated for the extraction 
of 7 a-hydroxycholesterol and cholesterol from spiked serum samples using the above 
selection of organic solvents and are as illustrated in Fig 3.6.
53
hydroxycholesterol from serum samples. Cholesterol and 7 a - hydroxycholesterol, in the 
range of physiological concentrations, were added to samples of 0.5ml rat serum. 
Efficiencies of their extraction were quantified by comparing peak area HPLC units 
obtained, with those of corresponding standards injected directly onto the HPLC column.
The following organic solvents were tested in this study:
A: Diethyl ether : Methanol (2/1 (v /v ))
B: Chloroform : Methanol: Diethylether (1/1/1 (v /v /v ))
C: Acetonitrile : Methanol (2/1 (v /v ))
D: Chloroform : Methanol (2/1 ( v /v ))
Fig 3.6: Efficiency of various solvents in the extraction of cholesterol and 7a-
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It was apparent that the extent of lipid extraction (cholesterol and 7 a-
hydroxycholesterol) using these solvent mixtures, varied between 60.22 and 77.33%, the 
maximum being achieved using chloroformimethanol in the ratio 2:1 (v/v).
More in depth analysis of each preparative stage, indicated that approximately 17% of 
the standards was lost in the initial Folch extraction step, another 2% at the alkaline 
hydrolysis stage (this form of hydrolysis was preferred to the enzymatic hydrolysis by 
cholesterol esterase, as it resulted in slightly higher, though not significant, levels of total 
sterol) and finally a further 3.2% at the final cholesterol oxidase step. Thus, it would 
appear that the most significant loss occured at the inital extraction stage.
3.2.2 Optimisation of conditions for cholesterol oxidase activity
The conversion of 7 a-hydroxycholesterol into 7a-hydroxy-4-cholesten-3-one having 
an intense absorption at 240nm by cholesterol oxidase, was deemed critical in achieving a 
sensitive assay for 7 a-hydroxycholesterol. Hence, optimal conditions with respect to 
length of incubation time of substrate with cholesterol oxidase and extraction of 7 a-
hydroxy-4-cholesten-3-one were next determined. Authentic 7 a-hydroxycholesterol, (62 
pmoles in a final 20jxl HPLC injection) was incubated with 40(xl cholesterol oxidase 
(25U/mg, lmg/ml) in a medium containing 0.6% (v/v) sodium cholate as described in 
Chapter 2 for 5, 10, 15, 20 and 25 min at 37°C. Fig 3.7 (a) shows the typical 
chromatographic profile of the extract of the mixture after a 10 minute incubation while 
Fig 3.7 (b) shows a time course relating peak area to length of incubation time.
Conversion of 7a-hydroxycholesterol (62pmoles/20|il) into peak area units of 7 a-
hydroxy-4-cholesten-3-one was linear up to 10 min incuation with cholesterol oxidase, 
approximately. The time chosen for the assay - 10 min, where upon, the reaction has 
reached completion.
The optimal number of washes/extractions for recovering the cholesterol-oxidase 
generated metabolites from the reaction mixture was next established. After incubation of
730 pmoles 7a-hydroxycholesterol/20|il final resuspension, with 40fil cholesterol 
oxidase (25U/mg, lmg/ml) in a medium containing 0.6% (v/v) sodium cholate for 10 
min at 37oC, the 7 a-hydroxy-4-cholesten-3-one product was extracted from the assay 
medium with varying volumes of petroleum ether (HPLC grade) as described in Chapter 
2. Extraction of products of the cholesterol oxidase reaction was shown to be dependent 
on the number of washes with petroleum ether. The optimum volume of petroleum ether
required for the final extraction of 7a-hydroxycholesterol from the assay buffer was 
found to be 18ml (Fig 3.8).
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Fig 3.7 (a) A typical chromatographic profile obtained upon conversion of 7 a -
hydroxycholesterol (62 pmoles/2 0 |il) and cholesterol (400nmoles/20(j,l) to 7a-hydroxy- 
4-cholesten-3-one (16.48min) and 4-cholesten-3-one (36.8min), respectively. Assay 
conditions as in Chapter 2. The peak observed at 14.06 min is that of 2 0 a- 
hydroxycholesterol, the internal standard.
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(62 pmole/20|il) to 7a-hydroxy-4-cholesten-3-one using 1 unit Cholesterol oxidase 
(Nocardia erythropolis). Conditions for assay were as described in Chapter 2.
Fig 3.7 (b): Time course asssay for the conversion of 7a-hydroxycholesterol
TIME (mins)
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Fig 3.8: The optimal volume of petroleum ether required for the final extraction 
of 7a-hydroxycholesterol (730 pmoles/20fil) from the assay buffer. Assay conditions as 
described in Chapter 2.
PETR O LEU M  E T H E R
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I3.2.3 Measurement of performance characterisitics of HPLC assay
Method validation is a very important aspect of method development. This section
describes the criteria for assessing validation of the HPLC procedure for 7 a- 
hydroxycholesterol assay.
3.2.3.1 L inearity:
Fig 3.9 is a calibration curve for the conversion of 7a-hydroxycholesterol to its enone
derivative - 7a-hydroxy-4-cholesten-3-one. Varying amounts of 7 a-hydroxycholesterol
(25 to 992 pmoles in final resuspension of 20|il) were incubated with 1 unit of 
cholesterol oxidase at 37oC for 10 min. After termination of the reaction, the product was 
extracted with 3x6 ml aliquots of petroleum ether (HPLC grade). An aliquot (20(il) was 
injected onto a column and monitored at 240nm. It is apparent from Fig 3.9 (a) that the
method was able to produce a response proportional to the concentration of 7a-
hydroxycholesterol. Regression analysis for this sterol was Y = -112.49 + 9.8200x, with 
a correlation coffecient of= 0.999. Fig 3.9 (b) shows the calibration curve for the
above conversion, but in the concentration range of 25.00 to 62.00 pmoles 7a-
hydroxycholesterol/20|il injection. Regression analysis yielded the equation :
Y = 0.87887 + 7.7746x and correlation coffecient 0.999. Linearity of the method was 
also established for the conversion of cholesterol to 4-cholesten-3-one. Fig 3.10 is a 
standard curve relating peak area to cholesterol concentration in the range 51.7 to 129.3 
nmoles/20|il injection. Regression analysis for this curve yielded the equation:
Y = -248.69 + 1810.8x, r= 0.997.
Fig 3.11 compares the selected method of analysing 7 a-hydroxycholesterol (by its 
conversion to its enone derivative and subsequent detection and measurement at 240nm) 
to a method whereby 7a-hydroxycholesterol is injected directly onto the HPLC column 
and measured at 214nm. Peak areas of 7a-hydroxy-4-cholesten-3-one after enzymatic
conversion by cholesterol oxidase are greater than those for 7 a-hydroxycholesterol 
injected directly and monitored at 214nm, by about 4.4 fold. Regression analyses were
Y = 1.3143 e-2 + 1.7460x, r = 1.000 (A240nm) and
Y = 1.2716 + 7.769x, r = 0.999 (A2i4nm).
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Fig 3.9: Standard curve for the conversion of 7a-hydroxy cholesterol to 7 a - 
hydroxy-4-cholesten-3-one using 1 unit Cholesterol oxidase (Nocardia ertythropolis)
(a): Standards ranging from 25.00to 992.00 pmoles/20p.l
[7a-HYDROXYCHOLESTEROL] (pmoles/20ul)
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Fig 3.9 (b) Standards ranging from 25.00 to 62.00 pmoles/20|xl
[7a-HYDROXYCHOLESTEROL] (pmoles/20^1)
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Fig 3.10: S tandard curve for the conversion of cholesterol to 4-cholesten-3-one, 
using 1 unit of Cholesterol oxidase (Nocardia erythropolis), in the range of 51.7 to 129.3 
nmoles/20(Xl. Assay conditions as in Chapter 2.
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Fig 3.11: Standard curves for 7a-hydroxycholesterol monitored at
a) 214nm, after direct injection onto the C18 column
b) 240nm, after conversion to 7a-hydroxy-4-cholesten-3-one.
[7a-HYDROXYCHOLESTEROL] (pmoles/20^1)
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3.2.3.2 Recovery:
This is an important part of the validation procedure as it gives the analyst some idea of 
the efficiency of the procedure. Table 3.3 demonstrates the % recovery of 7 a - 
hydroxycholesterol from rat serum across the range 40 to 120 pmoles. Concentrations of 
7 a-hydroxycholesterol in a series of spiked serum samples (containing 40, 80 and 120 
pmoles), taken through the full procedure described in Chapter 2, were extrapolated from 
the standard curve (Fig 3.9). Mean ± SD concentration of 7 a-hydroxycholesterol in 
two unspiked serum samples was 121.3±1.2 pmoles/0.5ml serum. Addition of 40 
pmoles of 7a-hydroxycholesterol standard to the two samples resulted in a 1.25 fold 
yield (151.6±0.5 pmoles) representing a 75.6% recovery. Addition of 80 and 120 
pmoles 7a-hydroxycholesterol to the serum samples resulted in a 1.5 fold (183+3.4 
pmoles) and 1.78 fold (216.4+4.7 pmoles) return respectively. % recoveries on adding 
80 and 120 pmoles 7a-hydroxycholesterol were 77.1 and 79.3% respectively. Fig 3.12
demonstrates that the slope of the processed standard curve for the recovery of 7 a- 
hydroxycholesterol from rat serum was Y=120.55+0.79179x; r=1.00.
3.2 .3 .3  P recision:
Precision, made up of two components, repeatability and reproducibility, was 
determined by means of an intra assay (Table 3.4) and inter-assay (Table 3.5). 0.5, 
0.75 and 1ml aliquots of bovine serum were analysed in quadruplicate for intra assay 
(within day) variation and the concentration determined from a standard curve, 
constructed on the same day. The coefficient of variation was shown to range from 1.59 
to 3.69%. These low values are indicative that the method is excellent for same day repeat 
analysis. Quadruplicate analysis of 0.5ml serum yielded 231.8±3.7 pmoles/ml while 
quadruplicate analysis of 0.75ml and 1ml aliquots returned mean concentrations of 
224.9±8.3 pmoles and 219.4+6.6 pmoles/ml respectively.
Repeatability of the chromatographic procedure as assessed by quadruplicate analysis 
of different volumes of serum was shown to be satisfactory. Inter-assay (between day) 
variation was also examined and evaluated by analysis of 0.5, 0.75 and 1ml aliquots of 
bovine serum, in quadruplicate over a period of four days. The concentrations were 
determined from a standard curve constructed daily and results (Table 3.5) once again 
show that due to low coefficients of variation obtained that this is an excellent method for
repeated analysis of 7a-hydroxycholesterol. Mean±SD concentration of 7 a -
hydroxycholesterol in 0.5ml serum measured over 4 days was found to be 227.9±2.3 
pmoles/ml. This compares with similar values obtained when 0.75ml and 1ml aliquots of 
serum were assayed similarly over 4 days (223.9±3.76 and 222.5+5.48 pmoles/ml) 
respectively.
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Table 3.3: Percentage recovery of 7a-hydroxycholesterol from rat serum was 
determined across the linear range, following the extraction as described in Chapter 2.
Xo represents the amount of endogenous 7 a-hydroxycholesterol present and Na the 
amount added to 0.5ml control rat serum (n=6 )
SAMPLE AMOUNT AMOUNT RECOVERY
ADDED FOUND (%)
(pinoles) (pmoles)
Xo 0 120.12
Xo 0 122.45
Xo + a 40 151.08 74.38
Xo + a 40 152.08 76.87
Xo + 2a 80 186.35 81.33
Xo + 2a 80 179.61 72.90
Xo + 3a 120 221.13 83.20
Xo + 3a 120 211.65 75.30
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serum with known concentrations of 7oc-hydroxycholesterol standard, from 40 to 120 
pmoles per sample. Assay conditions as described in Chapter 2.
Fig 3.12 Plot of amount of 7 a-hydroxycholesterol recovered after spiking 0.5ml rat
7a-OHCHO ADDED 
(pmoles/ml)
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from serum (n=4). Analyses were carried out in quadruplicate for volumes of control 
bovine serum ranging from 0.5-1.0ml, over one day. % C.V.obtained is indicative of 
precision.
Table 3.4: Intra-assay variation for 7a-hydroxycholesterol following extraction
SERUM VOL.
(mis)
CONC.
(pm oles/m l)
CONC.
M EAN±S.D
(pm oles/m l)
C .V .
(%)
229.94
0.50 236.22227.80
233.02
231.75 ±3.67 1.59
0.75
230.26
212.57
227.83
229.10
224.94 ± 8.31 3.69
1 .00
225.73
211.15
217.16 
223.65
219.42 ± 6.61 3.01
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Table 3.5: In ter-assay  varia tion  for 7a-hydroxycholesterol following extraction 
from serum (n=4). Analyses were carried out in quadruplicate for volumes of control 
bovine serum ranging from 0.5-1.0ml, over a period of 4 consecutive days. % 
C.V.obtained is indicative of precision.
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The HPLC procedure was also suitable for measurement of serum cholesterol, which 
was apparent from each chromatogram obtained. Retention time of 4-cholesten-3-one 
was approximately 34 min. The accuracy of the described method was further tested, by 
comparing serum cholesterol levels as measured by HPLC with those obtained using the 
standard cholesterol assay kit (Randox). Table 3.6 tabulates the values obtained using 
both methods for serum cholesterol in control and hypercholesterolemic human sera and 
in control, diabetic and cholestyramine-treated rat sera. Excellent agreement (r=0.998) 
between values was found in all sera, when comparing both methods of analyses, as can 
be seen in Fig 3.13, where the equation obtained from plotting the information in 
Table 3.6 is Y=0.14696+0.91148x, thereby further validating the use of the HPLC
analytical procedure for the assay of cholesterol and also of 7a-hydroxycholesterol.
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Table 3.6: Comparison in the values obtained for the measurement of serum 
cholesterol, using the above described reverse HPLC method to those obtained using a 
standard assay kit (Randox).
SUBJECT CONC. 
CHOLESTEROL 
((imoles/ml) 
TEST KIT
CONC
CHOLESTEROL
(|imoles/ml)
HPLC
RAT:
CONTROL 1.544±0.021 1.509+1.02
CHOLESTYRAMINE-
TREATED 0.915±0.061 0.953+0.96
DIABETIC 1.014±0.731 1.121±0.90
HUMAN:
CONTROL 3.790+0.423 3.911±0.96
HYPERCHOLESTEROLEMIC 8.110±1.01 7.400±1.09
70
Fig 3.13 Comparison between the described procedure for the extraction and analysis 
of serum cholesterol and that of a commercial kit (Randox) for the measurement of 
cholesterol in biological samples.
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Discussion
HPLC is a popular method for steroid separation, due to its rapidity and non­
destructive nature (Heftmann and Hunter, 1979). By contrast, TLC may not be 
considered a method of choice because it allows the samples to become susceptible to 
potential oxidation due to large surface area and also be deemed unsuitable due to low 
loading capacity (Csallany et al. , 1989). It has been reported that extraction followed by 
gas chromatography produced a number of peaks suspected to be oxidation products 
(Van Lier and Smith, 1967); however some of them were found to be artifacts (Smith and 
Van Lier, 1970) due to the exposure of the samples to air and high temperature. 
Koopman et al., (1987) reported difficulties in setting up a GC determination for 
hydroxycholesterols, which he reported to be a result of the close structural similarity and 
the large concentration differences in these compounds (i.e. hydroxycholesterols) in 
comparison with cholesterol. He therefore removed cholesterol from the assay.
The reverse-phase HPLC method described here is that of Hylemon et al., (1989), 
where it was used in the analysis of liver samples. We used this method in the analysis of
7a-hydroxycholesterol in serum, having set up an efficient method for its extraction and
hydrolysis (in samples where the total amount of 7 a-hydroxy cholesterol is to be 
measured).
The first step in the analysis of lipids is the selective extraction of the lipids out of the 
biological matrix (Nissen, 1990). As natural lipids possess a high proportion of 
polyunsaturated fatty acids and are subject to autoxidation, appropriate precautions were 
taken during the analysis. These included the addition of an anti-oxidant (BHT) to serum 
and the work was carried out as much as much as possible under an atmosphere of 
oxygen-free nitrogen.
The procedure described here uses reverse phase HPLC for the analysis of 7 a-
hydroxycholesterol and cholesterol in sera samples. The mobile phase employed is 
acetonitrile:methanol (70:30 (v/v)). It has previously been found that eluent systems 
containing an alcohol (methanol, ethanol, 2 -propanol) resulted in broader 
chromatographic peaks, while an eluent based on acetonitrile gave a satisfactory 
chromatogram (Kasama et al., 1987) in the analysis of sterols in serum by HPLC. 
However, as observed in the obtained chromatograms, the peaks obtained were well 
separated and sharp.
The method involved the Folch extraction, which was found to be the most efficient, 
having examined the efficiences of different solvents in the extraction of cholesterol and
7a-hydroxycholesterol from serum. An enormous problem connected to deproteinisation 
is the possibility of the analyte adsorbing on - or clustering of the analyte in - the 
precipitate. This effect has been reported to be minimised by addition of the homogenised
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sample to the deproteinising agent (solvent) and not the reverse way. With certain 
compounds, it was found that a further increase in recovery could be obtained by 
agitating the solvent in an ultrasonic bath during the addition of the homogenised sample 
(Uihlein, 1986). Thus, this may be of due consideration in future work, as our results 
show that the main loss that occured during the developed procedure was at the initial 
step, the Folch extraction.
The solvent system chosen- chloroform / methanol (2:1 v/v), was selected as the 
analyte was found to be highly soluble, thus this should help avoid adsorption on or 
coprecipitation with the protein during the organic solvent - protein precipitation step. It 
has been suggested (Lim, 1991) that sometimes it may be necessary to use a mixture of 
two solvents to attain a recovery which is quantitative. Other workers also found that the 
chloroform/methanol (2 :1, v/v) was the most suitable solvent for the extraction of total 
lipids and cholesterol (Kaneda et al. , 1980). Methanol has an additional advantage of 
inactivating many phosphatases and lipases present in animal tissues, but it also extracts 
contaminants such as sugars, salts, amino acids etc. However, these are removed by 
washing the crude lipid extract. The sample analyte was not found to adhere to the glass
tube, as results indicate that there was no significant difference between recoveries of 7 a - 
hydroxycholesterol from tubes which had been silanised with SigmaCote, to those which 
had not been silanised.
The sample was then subjected to alkaline hydrolysis in order to hydrolyse the esters of 
cholesterol and 7a-hydroxycholesterol, when total amounts of each was required.
Koopman (1987) and Oda (1990) reported the stability of 7a-hydroxycholesterol during
alkaline hydrolysis. Sample was re-extracted with n-hexane three times and then washed 
twice with water/ethanol (1:1, v/v). Such a step is carried out because although hexane is 
nonmiscible with water, there is a possibility that polar compounds may easily be 
transferred into the organic phase together with the dissolved water (possible solubility of 
water). Thereby, the extract is washed several times with small volumes of aqueous 
phase.
Other extractions and washes were carried out, the sample extract was then reacted with 
cholesterol oxidase (an enzyme which is specific for the 38-hydroxyl group) to convert
cholesterol and 7 a-hydroxycholesterol to enone derivatives, which were detected more 
sensitively at 240nm, as opposed to 214nm direct measurement. Cholesterol oxidase (EC 
1.1.3.6) can modify certain sterols by converting them into enones which are conjugated 
(Smith and Brooks, 1976). The 313-hydroxyl group of cholesterol or related sterols is 
oxidised to a keto group by dioxygen and the isomérisation of the A5-bond to yield this 
conjugated double bond which, in turn acts as a chromophoric group (oc,J3-unsaturated
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ketone; E240nm= 16,000 M-1 cm-i) (Lee and Biellmann, 1988). This results in an increase
in sensitivity in the detection of the oxide, as they absorb UV light more readily in this 
form. This enzyme conversion allows the separation of closely related sterols. This 
increase in sensitivity was demonstrated and shown to be more sensitive than direct 
detection at 214nm. This is an advantage if using an enzyme reagent system, as they 
allow sensitivity and specificity (Flegg, 1973).
The method developed was validated and the coefficient of variation for inter- and intra­
assay were determined. Also, the percentage recovery was determined by the addition of
known amounts of 7a-hydroxycholesterol standard to sera samples. In general,
extraction methods do not yield 100% recoveries. Over a chosen concentration range 
yields may vary. Thus, it is necessary to construct standard curves which are based on 
known amounts added to the sample and are carried through the whole extraction and 
analytical procedure as well as the sample. Quantities added should (and did) cover the 
expected range of analysis, as extrapolations from the standard curve may not result in 
true values.
The overall values obtained for the validation suggest that this described method is a 
suitable, reliable and reproducible method for the analysis of serum cholesterol and 7 a- 
hydroxycholesterol. When cholesterol concentrations measured were compared to those 
measured by means of a commercial kit- there was a highly significant correlation found, 
r=0.998. Such a value is greater than that reported by Dadgar and Smyth (1986), who 
reported that the correlation of the developed method to another reliable method 
(commercial kit) by linear regression analysis (r > 0.98) is the most acceptable form of 
validation.
2 0 a-hydroxycholesterol was added as internal standard and brought through the 
complete procedure. However, it should be noted that the extraction of the internal 
standard may not be exactly the same as for the analyte, even if it is a homologue. A 
suitable internal standard minimises errors by compensation. In theory, the best internal
standard should elute closely with the analyte band, which was observed here- 2 0 a -
hydroxycholesterol eluted at approximately 14 min, while 7a-hydroxycholesterol eluted 
just after that, with a retention time of 16.5 min.
Altogether, the results obtained for the validation of this method indicate that it is a 
reliable, sensitive and precise method (comparing well to a standard commercial kit when 
measuring serum cholesterol content), for the simultaneous measurement of serum
cholesterol and 7a-hydroxycholesterol. Others have reported problems related to
autoxidation during analysis. We however did not experience this, as results indicate that
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upon addition of BHT and working under the conditions stated, there was no significant 
increase in the levels of 7B-hydroxycholesterol or 7-ketocholesterol, which are the 
reported major autoxidative products of cholesterol (Smith, 1987, Bergstrom and 
Wintersteiner, 1961).
Having set up and validated this method, sera samples from human control subjects and 
from subjects being treated for hypercholesterolemia were analysed, as were sera samples 
of control, diabetic and cholestyramine-treated rats. As will be illustrated in later chapters,
the method was found to be satisfactory for an investigation of 7 a-hydroxycholesterol
metabolism.
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CHAPTER 4 
SERUM 7a-HYDROXYCHOLESTEROL IN  
HUM AN AND ANIM AL M ODELS OF ALTERED  
CHOLESTEROL M ETABOLISM
Introduction
The most important pathway for the metabolism and excretion of cholesterol in 
mammals is the formation of bile acids. Over the last decade the enzymes and proteins 
involved in this pathway have been major points of research focus. In 1989, cDNAs for 
two key enzymes of bile acid biosynthesis were isolated and several more have been 
reported since. These advances have provided a wealth of insight and tools for examining 
this pathway. Here, I have reviewed the main regulatory step in the pathway of bile acid 
biosynthesis. Also included is an overview of defects in bile acid biosynthesis and of 
alterations in cholesterol metabolism in hyperlipidaemic conditions.
Modem advances in spectroscopy and chromatography have provided new tools for 
studying the complex chemistry and physiology of these bile acids. The final part of this 
section will review the instrumentation that has been in use lately for monitoring 
alterations in bile acid flux in the various human and animal models of cholesterol 
metabolism.
4.1.1 Bile Acid Metabolism
There are considered to be two pathways in the formation of bile acids from 
cholesterol. The first of these is that which involves the enzyme- sterol 27-hydroxylase in
the initation step, the other involves cholesterol 7cc-hydroxylase. The former pathway
differs mainly to the latter in that it is a widely distributed mitochondrial enzyme with
high activity in vascular endothelial cells (Javitt, 1994), while cholesterol 7a-hydroxylase
is a liver enzyme.
Sterol 27-hydroxylase has an important role in the degradation of the side-chain of 
cholesterol. The product of this reaction, 27-hydroxycholesterol, is a potent inhibitor of 
the overall regulation of cholesterol biosynthesis. Recently, it has been suggested, by 
Bjorkhem etal., (1994) that conversion of cholesterol into 27-hydroxycholesterol and 
3B-hydroxy-5-cholestenoic acid represent a general defense mechanism for macrophages 
and for other peripheral cells which are exposed to cholesterol. Such cholesterol oxides 
are efficiently converted into bile acids in human liver.
When the enterohepatic circulation is disrupted, the cholesterol 7a-hydroxylase
pathway is preferred Javitt (1994). The pathway which is initiated by sterol 27- 
hydroxylase, originates in vascular endothelium and thus provides a mechanism for 
reverse cholesterol transport, ending with the synthesis of chenodeoxycholic acid, 
predominately. The pathway which is discussed and examined below is that of hepatic
cholesterol 7a-hydroxylase.
The conversion of cholesterol into bile acids involves almost all of the conceivable 
mechanisms for conversion of a lipophilic compound into an excretable water-soluble
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product. Of the more than 14 different enzymes participating in the conversion, 
hydroxylases, oxidoreductases and conjugating systems are of particular importance for 
increasing the polarity. The major primary bile acids synthesised in the human, the 
hamster and the rat are cholic acid and chenodeoxycholic acid (Danielsson and Sjovall, 
1975), however the synthesis and metabolism of bile acids may differ significantly 
between different vertebrate species. There are two main categories of steps which lead to 
their formation: those reactions in the endoplasmic reticulum and cytosol which modify 
the cyclopentanoperhydrophenanthrene ring structure or nucleus (Fig 4.1) and those in 
mitochondria and peroxisomes that oxidise and shorten the 8 carbon atom side chain of 
the sterol. These divisions are for explanatory convenience only as many of the enzymes 
exhibit substrate promiscuity leading to uncertainty with regard to the exact order of 
biosynthetic steps (Bjorkhem, 1985).
In reaction 1 (Figure 4.1) a hydroxyl group is inserted in the axial (a) configuration
at position C-7 of cholesterol, resulting in the formation of 7a-hydroxycholesterol. This
reaction is catalysed by a unique cytochrome P-450 enzyme, microsomal cholesterol 7 a- 
hydroxylase (EC 1.14.13.17), one of three cytochrome P450s (the others being sterol 
12a-hydroxylase and sterol 27-hydroxylase) that participate in bile acid biosynthesis and 
belongs to a class of enzymes known as “mixed-function” oxidases. This term, 
introduced by Mason in 1965, refers to a reaction, catalysed by an enzyme, whereby an 
atom of molecular oxygen is incorporated into the substrate molecule, while the other is 
reduced to water. The reduction requires a coenzyme, usually NADPH.
RH + NADPH (or NADH) + H+ + 0 2
 ► ROH + NADP+ (or NAD+) + H2O where RH is the substrate.
This enzyme requires oxygen as its activator and cytochrome P450 as a substrate. The
7a-hydroxylation of cholesterol resembles other hepatic microsomal mixed-function
oxidation reactions in that it does not require adrenodoxin (an iron-sulphur protein), 
which is essential for cytochrome P450-dependent hydroxylations occuring in the adrenal 
mitochondria (Myant and Mitropoulos, 1977).
This first step involves the formation of a reversible complex between cytochrome 
P450 in the oxidised form ( F e 3 + )  and the substrate. The F e 3 +  of the cytochrome P450- 
substrate complex is then reduced to the F e 2 +  state, by NADPH transferring one electron. 
Molecular oxygen then reacts with this reduced complex, resulting in the formation of a 
ternary complex of F e 2 +  cytochrome P450, substrate and O2.
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Fig 4.1 Routes of synthesis of cholic and chenodeoxycholic acids, the major bile acids 
of human bile acids. Steps 1 and 2 are numbered in bold type.
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Another electron is then transferred to the ternary complex, an atom of oxygen is 
introduced into the substrate, water is expelled from the complex and the resulting 
hydroxylated substrate and oxidised cytochrome P450 are released (Myant and
Mitropoulos, 1977). Cholesterol 7 a-hydroxylase catalyses the rate-limiting step in bile
acid synthesis and the expression and activity of this enzyme are subject to multiple 
regulatory inputs which will be discussed below.
The second step in this pathway results in the reduction of 7 oi-hydroxycholesterol to
7oc-hydroxy-4-cholesten-3-one. This step (reaction 2 Fig 4.1) is catalysed by a
microsomal 36-hydroxy-steroid oxidoreductase isoenzyme specific for C-27 steroids 
This reaction uses NAD+ as a cofactor. Although this 3B-hydroxy-C-27-steroid 
oxidoreductase was the first bile acid biosynthetic enzyme purified to homogeneity by 
Wikvall in 1981, a eDNA encoding this isoenzyme has not yet been reported.
It is at this stage of the bile acid biosynthetic pathway that a divergence occurs. Such a 
branching point is thus, of potential regulatory importance (Russell and Setchell, 1992). 
The two primary bile acids formed are cholic and chenodeoxycholic acid. These two 
acids, differing in only a hydroxyl-group at C-12 have never been shown to be
interconverted. The 7a-hydroxy-4-cholesten-3-one product of 3B-hydroxy-C-27-steroid
oxidoreductase can take one of two paths in bile acid biosynthesis (Fig 4.1). If this 
intermediate is acted upon by the second microsomal cytochrome P-450 enzyme of the
pathway, sterol 12a-hydroxylase then the resulting product is ultimately converted to
cholic acid. 7a-hydroxy-4-cholesten-3-one can alternatively serve as a substrate for a
soluble A4-3-oxosteroid 58-reductase to yield a steroid intermediate that is ultimately 
converted into chenodeoxycholic acid. This enzyme also catalyses the identical reaction
on 7a,12a-dihydroxy-4-cholesten-3-one, the product of 12a-hydroxylation. Cholic acid
and chenodeoxycholic acid, as well as their secondary and tertiary metabolites, have 
different physicochemical and physiological properties (Carey et al., 1982).
The idea that 7-hydroxylation commits cholesterol to bile acids seems sound (Fielding 
and Fielding, 1985). However, while the later intermediates for synthesis of the common 
bile acids are well known, there is little agreement on the regulation of the steps that 
produce the intermediates. An example of this is where 12-hydroxylation commits the 
sterol nucleus to the synthesis of cholic rather than chenodeoxycholic acid (Fig 4.1).
Once the nucleus has been hydroxylated at positions C-7 and C-12, the hydroxyl group 
at C-3 is inverted from the 6 - to the a- orientation. This inversion seems to precede the 
saturation of the double bond. Once the nucleus has been elaborated, the side chain
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degradation may proceed leading to C-24 acids. The enzymes responsible for converting 
cholesterol into 3a, 7 a, 12a-trihydroxycoprostane are located in the microsomal fraction 
of rat liver cells. They require cofactors such as ATP, NAD and glutathione for optimal 
activity. Synthesis of bile acids begins in the endoplasmic reticulum and from here, 
intermediates follow a cytoplasm~>mitochondria—>cytoplasm
—>endoplasmic reticulum—>peroxisome—>endoplasmic reticulum—>bile route (Russell 
and Setchell, 1992).
4.1.2 The enterohepatic circulation of bile salts
The two bile acids primarily formed in human liver are cholic acid and 
chenodeoxycholic acid, the ratio between the synthesis rates being about 1.5-2. Bile salts 
are secreted by the liver in conjugated form, together with free cholesterol. In animals 
possessing a gall bladder, most of the bile secreted by the liver during fasting is diverted 
into the gall bladder via the cystic duct where it is concentrated and stored until the gall 
bladder contracts in response to feeding. When this occurs, the bile is secreted into the 
duodenum through the common bile duct. In the lower ileum and colon, the conjugated
bile acids are acted upon by enzymes of the intestinal flora, with deconjugation and 7a- 
dehydroxylation as the major reactions, resulting in the formation of deoxycholic from 
cholic acid and of lithocholic acid from chenodeoxycholic acid. After participating in the 
adsorption of lipids in the jejunum, the bile salts pass down the ileum, where at least 95% 
of the total secreted is reabsorbed, the unabsorbed fraction escaping into the faeces (Fig 
4 .2 ).
The bile acids reabsorbed from the intestine enter the portal vein and are rapidly and 
efficiently extracted from the portal blood by the hepatocytes; only a minor proportion 
passes through the liver into the peripheral blood circulation. Within the hepatocytes, the 
unconjugated bile acids are reconjugated with glycine and taurine. Fasting bile acid 
concentrations in the systemic circulation at 2-3 (iM are around 6-fold higher than those in 
the portal circulation, reflecting the efficient extraction of bile acids by the liver under 
normal physiological conditions (Ceryak et al., 1993). In some species, including rats,
deoxycholic acid is 7a-hydroxylated to cholic acid, however, in man the 7 a- 
hydroxylation of deoxycholate is incomplete, resulting in the presence of conjugated 
deoxycholic acid in human bile.
The enterohepatic circulation of bile salts is so efficient that each day the relatively small 
pool of bile acids (about 3-5g) can be cycled through the intestine 6-10 times with only a 
small amount lost in the feces (approximately 1% per pass through the enterohepatic 
circulation). Each day, an amount of bile acid equivalent to that lost in the feces is 
produced from cholesterol by the liver, so that a pool of bile acids of constant size is 
maintained. This occurs as a result of a feedback control system.
80
Fig 4.2 Enterohepatic circulation of bile salts and the digestion of lipids.
Dashes represent enterohepatic circulation of bile salts. TG, triacyl glycerol; MG, 
monoacylglycerol; FA, long chain fatty acids (Harper, 1982).
H.P.V* : Hepatic portal vein.
4.1.3 Regulation of Cholesterol 7a-hydroxylase
The rate-limiting step in bile acid biosynthesis was shown in the late 1960’s to be 
catalysed by cholesterol 7 a-hydroxylase (Danielsson et al., 1967; Shefer et al., 1970).
These and subsequent investigations have shown that once 7a-hydroxycholesterol is 
formed in liver primary bile acid synthesis soon results. Various studies have 
demonstrated that cholesterol 7 a-hydroxylase activity is induced by blocking the return 
of bile acids to the liver either by surgical interruption of the enterohepatic circulation
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(Danielsson etal., 1967) or by dietary administration of anion-exchange copolymers that 
bind bile acids in the small intestine and thereby prevent their uptake. Conversely, 
infusion or dietary administration of bile acids leads to a decrease in enzyme activity 
(Shefer etal., 1970). Thyroid hormone was shown to induce the amount of cholesterol
7a-hydroxylase mRNA and protein in the liver (Ness et al. , 1990). Other physiologic 
up-regulators of this enzyme include glucocorticoids, cholesterol (Straka et al., 1990) and 
metabolites of cholesterol. Recent work by Doerner etal., (1995) found that cholesterol
and not oxysterols regulate cholesterol 7a-hydroxylase. Expression is also governed by a 
hormone-mediated circadian rhythm (Chiang et al., 1990; Sundseth & Waxman, 1990).
Recent studies by Chiang et al., (1990) using reverse phase HPLC and a highly 
sensitive immunoblot procedure showed parrallel changes in enzyme activity and
concentration of cholesterol 7a-hydroxylase in microsomes of rats maintained under
different lighting conditions, in rats treated with cholestyramine-supplemented and 
cholestyramine-depleted diets, in genetically obese Zucker rats and in groups of rats 
treated with different cytochrome P-450 inducers. The study provided the first direct 
evidence that the bile acid feedback regulation and circadian rhythm of microsomal
cholesterol 7a-hydroxlase activity involved the induction of cholesterol 7a-hydroxylase
enzyme level.
It is now widely believed that regulation of cholesterol 7 a-hydroxylase activity is
mainly controlled at the transcriptional level. Cholesterol 7 a-hydroxylase activity, protein 
mass and mRNA levels have been shown to increase in response to partial and complete 
biliary diversion; conversely, continuous intraduodenal infusion of taurocholate in rats
with chronic bile fistula leads to a decrease in cholesterol 7 a-hydroxylase specific 
activity, protein mass, mRNA levels and transcriptional activity (Pandak et al., 1991). 
These findings provided direct evidence that taurocholate, a relatively hydrophobic bile
salt regulates cholesterol 7 a-hydroxylase at the level of gene transcription. It has been 
shown in some studies that posttranscriptional regulation of the enzyme may occur 
(Shefer et al., 1991) adding a possible additional level of control.
In 1988 Sundseth et al., established that cholesterol 7 a-hydroxylase is regulated in
response to long-, mid- and short term control factors, referred to above, at the 
pretranscriptional level and suggested that this regulation was of greater importance than
the allosteric effects of bile acids on the P-450 cholesterol 7a-hydroxylase protein, 
reversible phosphorylation, or the availability of cholesterol as substrate, which are other 
proposed mechanisms. Long-term regulation is mediated by feedback inhibition of bile
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acids, mid-term regulation through the diurnal cycle and finally, the short-term regulatory 
factors are hormones and dietary factors.
Short term regulation of the enzyme has also been well documented.The inhibition of 
cholesterol 7 a-hydroxylase by phosphatase and stimulation by cAMP-dependent protein 
kinase has been demonstrated in a reconstituted enzyme system (Tang and Chiang,
1986).
Dietary factors, such as cholesterol feeding are also known to influence the regulation
of cholesterol 7 a-hydroxylase. The activity and specificity of cell surface bile acid
transport proteins in the small intestine and the liver may also contribute to the regulation
of cholesterol 7a-hydroxylase (Russell and Setchell, 1992). The transcription factors and
cis-acting regulatory elements involved in the regulation of this enzyme have not been 
fully elucidated. Although there is about 70-80% homology in the first 250 bp of the 5 ' 
flanking sequence of rat, hamster and human gene, there is much divergence in the 
upstream sequence- thereby possibly accounting for the differences in regulation of
cholesterol 7 a-hydroxylase between different species. It is clear that the regulation of
cholesterol 7a-hydroxylase, and hence cholesterol catabolism, occurs at multiple levels
and may even rival that of HMG-Co A reductase, the other major regulatory enzyme of 
cholesterol metabolism in its complexity.
4.1.4 Regulation of bile acid synthesis:
As a result of these extensive studies on cholesterol 7a-hydroxylase activity in the rat, 
it has been generally accepted that bile acid synthesis is regulated by bile acids returning 
to the liver. However, recent studies in vitro and in vivo are not in agreement with the 
classical concept of negative feedback of bile acid and so, regulation of bile acid synthesis 
has become an area of controversy. For example, several groups of investigators could 
not demonstrate the inhibition of bile acid synthesis in bile fistula rats (whereby there is a 
diversion of bile acids from the bile duct by means of a fistula which results in the 
upregulation of bile acid biosynthesis), suggesting that bile acids may not regulate
cholesterol 7 a-hydroxylase directly (Davis et al., 1988). Intravenous (unlike
intraduodenal) infusion of taurocholate did not down regulate cholesterol 7a-hydroxylase
(Pandak et al., 1994). However the degree to which bile acids repress cholesterol 7a- 
hydroxylase activity does appear to parallel the relative hydrophobicity of bile acids in 
portal blood; specifically, hydrophobic but not hydrophilic bile acids are effective down 
regulators. A recent study in primary cultures of rat hepatocytes has indicated that the
repression of cholesterol 7a-hydroxylase transcription by hydrophobic bile acids may be
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mediated by protein kinase C isozymes (Stravitz et al., 1995). Another example of 
discrepancy is the failure to demonstrate negative bile acid biofeedback in cultured or 
freshly suspended hepatocytes following the addition of high concentrations of different 
bile salts to the culture medium (Kubaska et al., 1985). By contrast, manipulations that 
increase or decrease hepatocyte cholesterol were observed to up- or down-regulate bile 
acid synthesis in vitro. These observations suggest that bile acids may regulate their own 
synthesis indirectly by altering the concentration of cholesterol in a critical microsomal 
regulatory pool. A recent publication by Fukushima et al., (1995) reported that bile acid 
synthesis in the rat model was not regulated directly by the portal bile acids returning to 
the liver, which differ to the biliary bile acids, the former being more concentrated when 
in circulation.
4.1.5 Cholesterol supply for catabolism
The role of cholesterol in the regulation of cholesterol 7a-hydroxylase and the 
interrelationship between the cholesterol and bile acid biosynthesis pathways has also 
been an area of concentrated research. There are two alternative sources of cholesterol 
available for bile acid synthesis: cholesterol that is newly synthesised in the adjacent 
hepatic rough endoplasmic reticulum and the free and esterified cholesterol of the plasma 
lipoproteins, interiorised via different pathways. Cholesterol may be supplied from 
varying lipoproteins such as that from the HDL fraction, LDL and also possibly from the 
uptake of cholesterol form chylomicron remnants (Fry et al., 1990).
Early studies carried out on rats indicated that newly synthesised cholesterol was the 
preferred (but not the only) substrate for bile acid biosynthesis (Balasubramaniam et al. ,
1973), as their results indicated that the pool of cholesterol that 7 a-hydroxycholesterol 
was synthesised from did not equilibrate rapidly with the plasma cholesterol. Bjorkhem et 
al., (1975) provided further evidence which was in agreemeent with this theory.
However, in favour of the argument that cholesterol substrate for cholesterol 7a- 
hydroxylase is derived from plasma lipoproteins, whole-body turnover experiments with 
human subjects reported that such a pool of cholesterol provided about two-thirds of the 
cholesterol substrate for the enzyme (primarily free cholesterol of lipoproteins). 
(Schwartz et al., 1982).
Under most experimental conditions, the activity of the rate limiting enzyme in 
cholesterol biosynthesis, HMG Co A reductase changes in parallel with the activity of the
cholesterol 7a-hydroxylase. This linkage is most important for cholesterol homeostasis 
and an increased synthesis of cholesterol always causes a compensatory increase in 
degradation of cholesterol.
Evidence for transcriptional regulation of the enzyme by cholesterol or related sterol
84
came from in vivo studies with lovastatin and mevalonate. Under circumstances in which 
cholesterol is present in excess, cholesterol 7 a-hydroxylase transcriptional activity is up- 
regulated and removal of cholesterol from hepatocytes is facilitated by an increase in bile 
acid synthesis. When cholesterol availability is decreased, cholesterol l a -hydroxylase 
transcriptional activity is down- regulated leading to a decreased elimination of cholesterol 
via bile acid synthesis. In both instances, hepatic cholesterol homeostasis is effectively 
maintained via the link between the pathways of cholesterol supply and catabolism.(Jones 
et al., 1993).
However the nature of the link between these two enzymes is still unknown. The fact 
that bile acids are able to downregulate both enzymes in a similar way may be important 
for the coordination of the two enzymes. Coordinate regulation of the two pathways can 
be readily demonstrated in the rat by dietary manipulation. Feeding animals bile acid 
binding resins leads to a decrease in the return of bile acids to the liver and a consequent
increase in cholesterol 7a-hydroxylase and of de novo bile acid synthesis. This increase
in turn depletes intracellular cholesterol pools, causing an increase in the synthesis of 
enzymes in the cholesterol biosynthetic pathway and of low density lipoprotein receptor. 
Conversely, when cholesterol is included in the diet, enzymes in the supply pathway are
suppressed and cholesterol 7a-hydroxylase is induced. This induction in turn leads to an
increase in bile acid production and to an increase in excretion in this species (Bjorkhem,
1991). When primary bile acids are fed, both cholesterol 7 a-hydroxylase and enzymes in
the supply pathways are suppressed. This response of the supply pathways can be 
explained by an increased absorption of dietary cholesterol mediated by cholic or 
chenodeoxycholate and a subsequent increase return of the sterol to the liver in the form 
of chylomicron particles (Spady et al., 1986). In addition, down regulation of cholesterol
7 a-hydroxylase decreases de novo synthesis of bile acids and further increases the
suppression of cholesterol synthesis and uptake.
4.1.6 Disorders associated with defects in the bile acid biosynthetic 
pathway.
Several liver and intestinal diseases are associated with a changed production of bile 
acids (Axelson etal., 1991). Since bile acids are major excretion products of cholesterol 
(Bjorkhem, 1985) such changes will affect the turn-over rate of cholesterol in the body 
(Axelson etal., 1991). The liver employs many strategies in the coordinate regulation of 
cholesterol metabolism, in an attempt to prevent the pathological consequences of a 
disruption in overall cholesterol homeostasis. These tacts include physiological 
occurrences that link the activities of different regulatory enzymes in each of the pathways 
and also a shared negative feedback regulatory mechanism at the transcriptional level. 
Many inherited diseases have been discovered, in which an enzyme deficiency is present
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in the synthetic pathway of bile acids (Russell and Setchell, 1992). Three of these 
inherited diseases have been described to date.
The first was identified by Salen in 1974. It was observed that subjects with the rare 
autosomal recessive disease, cerebrotendinous xanthomatosis (CTX), which results in a 
defect in the degradation of the side-chain of cholesterol, excreted abnormal C27 bile 
alcohols (urinary and faecal) and reduced levels of C24 bile acids, notably 
chenodeoxycholic acid (Setoguchi et al., 1974). This disorder is characterised by an 
increase in the level of cholestanol and a decreased level of 26-hydroxycholesterol (Javitt 
etal., 1982). Such products are then found to build up in the tissues of the affected 
individual and when accumulation occurs in the central nervous system, progressive 
neurological dysfunction and eventual death result (Menkes, 1968). The molecular basis 
of CTX has recently been established (Cali et al., 1991) by cloning the normal sterol 27- 
hydroxy las e cDNA. The gene was localised to the distal long arm of chromosome 2. 
Diagnosis, if made at early stages, may result in treatment by oral primary bile acid 
therapy, which act by feedback inhibition, thus preventing further accumulation of 
cholesterol and bile alcohols (Salen et al., 1975). 27-hydroxylase results in the
conversion of 5B-cholestane-3a,7a,12a-triol to 56-cholestane-3a,7a,12a,27-tetrol.
The second disorder recorded by Clayton et al., (1987) was identified as a defect in the 
enzyme- 3B-hydroxy-C27-steroid oxidoreductase, which oxidises 7a-hydroxycholesterol
to 7a-hydroxy-4-cholesten-3-one.
Finally, the third defect has been identified in infants with neonatal hepatitis and 
cholestasis, by Setchell etal., 1988. The enzyme that is defective here is A4-3-oxosteroid
58-reductase (involved in the step whereby 7 oc-hydroxy-4-cholesten-3-one is reduced to
7a-hydroxy-58-cholesten-3-one, which subsequently proceeds with the side chain 
oxidation of cholesterol). This results in the elevation in the levels of C24 bile acids that 
retain the A4-3-oxo configuration of the sterol substrates. The cause of liver disease in 
such patients is thought to be the accumulation of potentially cholestatic and hepatotoxic 
atypical bile acids, worsened by the fact that primary bile acids, which are required for 
the generation of bile acid-dependent bile flow, are lacking. Treatment of such disorders 
by bile acid therapy results in the normalisation of liver dysfunction (Russell and 
Setchell, 1992).
The pathogenesis of human cholelithiasis has been ascribed to abnormal hepatic 
cholesterol metabolism. An important discovery was that bile acid pools were diminished 
in such a disease (Vlahcevic et al., 1970). Gallstone subjects have been shown to have a
decreased activity in cholesterol 7 a-hydroxylase (Salen et al., 1975). Other reports have
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described changes in bile acid metabolism which may contribute to hypocholesterolemic 
(Kern, 1991) or hypertriglyceridemic (Angelin, 1987) states.
4.1.7 Hereditary hyperlipoproteinemias
Polymorphism and mutations at the numerous sites of metabolic control in lipoprotein 
homeostasis impart a distinct biochemical individuality. Thus, there is a wide range of 
serum lipoprotein profiles in the general population. For clinical convenience, the 
systems of classifications are based on combinations of the following: HDL cholesterol, 
plasma apoprotein levels, total levels of serum cholesterol and triglycerides, lipoprotein 
phenotype, family history, mode of transmission and presence of other disorders known 
to affect the metabolism of lipoproteins. Such classifications are represented in the 
following two tables, Table 4.1 and Table 4.2.
The major aims when treating hyperlipidaemias are the prevention of de novo 
development of coronary heart disease and other atherosclerotic disorders, as well as 
retardation and regression of such disorders, if already manifest (Tikkanen, 1990).
Pharmacologic intervention with the liver plays an important role in the treatment of 
such patients, as the liver possesses more than half the total body complement of LDL 
receptors. So, any event leading to a perturbation of hepatic cholesterol metabolism 
would be expected to have a profound effect on plasma LDL cholesterol levels (Shepherd 
and Packard, 1992). The sterol pools of hepatocytes may be depleted by the inhibition of 
cholesterol biosynthesis or by stimulating the conversion of cholesterol to its oxidation 
products, the bile acids.
Lipid-lowering drugs, used in such treatments, are usually differentiated by their 
actions. Such drugs can be divided into two main groups- the HMG-CoA reductase 
inhibitors, which reduce lipid production by the liver and the bile acid sequestrants, 
which prevent dietary lipids from being absorbed.
4.1.8.1 HMG-CoA reductase inhibitors/Statins:
These agents act by suppressing cholesterol synthesis in the liver cell, by acting as 
competitive inhibitors of HMG-CoA reductase. Alkaloids were isolated from Penicillium 
citrinum and found to be powerful competitive inhibitors of the rate-limiting enzyme in 
cholesterol biosynthesis, HMG-CoA. They are capable of inhibiting the enzyme when 
present in very low concentrations. As a result of decreasing the concentration of 
intracellular cholesterol, there is an associated increase in the number of LDL receptors 
which are produced and expressed on the surface of hepatocytes. Thus, the removal of 
lipoprotein cholesterol from the plasma is promoted. They include such drugs as 
lovastatin, pravastatin and simvastatin. They lower plasma triglyceride by reducing the 
circulating level of VLDL.
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Tables 4.1 & 4.2: Typical classifications of hyperlipoproteinemia 
(Khachadurian, 1990)
Table 4.1 PHENOTYPIC CLASSIFICATION OF 
HYPERLIPOPROTEINEMIAS
PHENOTYPES LIPOPROTEINS THAT ARE 
ELEVATED
II LDL
III IDL
rv VLDL
V and I Chylomicrons and VLDL
TABLE 4.2 LIPOPROTEIN PHENOTYPES IN MAJOR FORMS OF 
HYPERLIPOPROTEINEMIAS
PRIMARY HYPER­
LIPOPROTEINEMIAS
Phenotypes 
II III IV V & I
Lipoprotein lipase deficiency - - ± +
Familial Dysbeta lipoproteinemia - + ±
Familial Hypercholesterolemia + ± ±
Familial Combined Hyperlipidemia + ± +
SECONDARY HYPER­
LIPOPROTEINEMIAS
Diabetes + + +
Hypothyroidism + + + +
Dysglobulinemias + + +
+ = frequent 
± = occasional 
- = absent
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Pravastatin and simvastatin are new HMG CoA reductase inhibitors that have promise 
in the treatment of elevated serum cholesterol. Lovastatin has a very high affinity for 
HMG-CoA reductase (K; of ~lnM while the Km of ~ 10|±M). Lovastatin and simvastatin
are administered as prodrugs. They are in a lactone form that is inactive and become 
active, as the 13-hydroxyacid form, upon metabolism in the liver. However, pravastatin is 
delivered as an open acid. The most frequent reason requiring that therapy with 
pravastatin be stopped was asymptomatic elevation of liver transaminase levels and non­
specific gastrointestinal complaints with a frequency similar to that seen with lovastatin 
(Milander et al., 1992). The efficiency of statins in FH (apart from the rare homozygous 
patients who have no functioning LDL receptors) is explained by this mechanism. In 
milder (non-FH) forms of hypercholesterolaemia another mechanism may be of 
importance. The increase of LDL receptor activity also causes enhanced removal of 
VLDL and VLDL remnants (precursors of LDL) via these receptors in the liver (Grundy,
1988), resulting in a decreased production of LDL as in Fig 4.3. (Tikkanen, 1990).
Overall, lovastatin and the other HMG-CoA reductase inhibitors are very well tolerated 
with few known adverse side-effects. The major being abnormalities in liver function 
tests (Shepherd e ta l , 1992) and also the occurrance of myopathy. As referred to above, 
statins reduce the circulating levels of VLDL, thus, the moderate elevation in HDL 
cholesterol observed in several patients during statin treatment may be partly explained by 
the reciprocal relationship commonly observed between HDL and VLDL. It is not caused 
by alterations in lipoprotein lipase or hepatic lipase activities (Tikkanen, 1990).
Recently developed drugs which act in the suppression of cholesterol biosynthesis 
include the squalestatins- developd by Glaxo and the zaragozic acids- developed by 
Merck Sharp and Dohme, in 1992. They act as potent inhibitors of mammalian and 
fungal squalene synthese, an enzyme involved in the biosynthesis of cholesterol (Kelly 
and Roberts, 1995).
4.1.7.2 Bile acid sequestrants:
Previous studies have shown that treatment with bile-acid-binding resins, which bind 
bile acids in the intestine and prevent their reabsorption, increases fecal bile acid excretion 
(Grundy, 1988), thereby, stimulating bile acid synthesis. Cholestyramine and colestipol 
are unabsorbable resins, the former acts as a potent inducer of HMG-CoA reductase and
cholesterol 7a-hydroxylase (Cighetti etal., 1983). The interruption of the recirculation of 
bile acids results in a triggered production of LDL receptors and accelerated receptor- 
mediated removal of LDL from circulation. However, the therapeutic response is blunted 
by a compensatory stimulation of hepatocellular cholesterol synthesis (Fig 4.4) 
(Tikkanen, 1990)
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Fig 4.3 Mechanism of action of HMG CoA reductase inhibitors 
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Brown and Goldstein (1984 and 1986) suggested that as statins and resins stimulate 
LDL receptor activity and that the resulting increase in cellular cholesterol synthesis is 
blocked by the statin, that a combination of both the statin and resin would be ideal in the 
treatment of severe cases of hypercholesterolaemia (Tikkanen, 1990). Thus, combined 
drug therapy is thus warranted in such circumstances and can be used to control the high 
LDL cholesterol levels seen in the worst affected heterozygotes (Shepherd and Packard, 
1992).
Cholestyramine has been frequently used in treating human patients for 
hypercholesterolaemia and begins to reduce cholesterol and LDL after 4 to 7 days of 
administration. However, the maximum effect is not noted until two weeks after therapy 
has started (Milander and Kuhn, 1992). It has also been used in studies carried out in rats 
(Song et al., 1991, Kogaire et al, 1992), whereby the latter group reported that 
cholestyramine feeding stimulated pancreatic growth and exocrine pancreatic secretion in 
rats. In parallel to a reduction in LDL cholesterol concentrations, there is a fall in 
apolipoprotein B values, the former being much greater than the latter, as a result of 
change in lipoprotein composition (Shepherd and Packard, 1992).
As resins are not absorbed from the intestine, they are thought to be among the safest 
lipid-lowering drugs. However, due to their ion-exchange properties, they may interfere 
with the absorption of other anionic drugs, such as thyroxine, warfarin and pravaststin. 
In addition, gastrointestinal symptoms and problems such as bloating are reported 
(Tikkanen, 1992 and Milander and Kuhn, 1992). Based on the efficacy of these 
sequestrants and also due to the lack of any long-term adverse effects, bile acid 
sequestrants remain the drugs of first choice in the initiation of therapy of 
hypercholesterolemia after failure of dietary restriction (The Expert Panel, 1988).
4.1.7.3 Fibrates
Gemfibrozil, Bezafibrate and fenofibrate are commonly used fibrates whose mechanism 
of action has not been clearly understood. Various studies have shown that these act by 
accelerating the catabolism of VLDL and VLDL remnants. Such remnants are produced 
by the action of lipoprotein lipase (whose activity is known to increase during fibrate 
therapy) on VLDL (Tikkanen, 1990). Lipoprotein lipase cleaves the triglyceride 
molecules from VLDL and IDL (Milander and Kuhn, 1992). Thus, the major action of 
the fibrates is to reduce triglyceride levels.
HDL cholesterol levels are found to be elevated in patients being treated with fibrates 
due to two main reasons; firstly, there is an increased flow of liberated surface 
components from VLDL (degraded by lipoprotein lipase), which may be utilised in the 
synthesis of HDL (Nikkila, 1984 and Tikkanen, 1989). Secondly, there is less of a 
transfer of triglyceride from VLDL to HDL (reduction in VLDL levels), thereby less 
esterified cholesterol from HDL to VLDL.
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Bezafibrate therapy in hypertriglyceridaemics results in an increase in the average size 
of LDL and a change in the conformation of apolipoprotein B, so that it exhibits a higher 
affinity for receptors. A possible explanation for these results is that the drug reduces the 
proportion of LDL-I to LDL m  (differing sizes in LDLs) in the patient’s plasma.
Side effects of fibrates include an associated increase in size and number of gallstones 
(Millander et ai, 1992). This may be attributed to an increase in conversion of cholesterol 
to bile acids in the liver. They result in slight gastrointestinal disturbances.
Thus, from results of various trials, it has been suggested that gemfibrozil may be 
recommended as a first-line agent in the treatment of hypertriglyceridemia and as a 
secondary agent for several other hyperlipidemias (Shepherd and Packard, 1992).
4.1.7.4 Nicotinic acid
This is a lipid-lowering agent, an effect that is separate to its effect as a vitamin 
(Milander and Kuhn, 1992). Again, there is an associated drop in VLDL levels, which 
are thought to be responsible for a corresponding drop in triglyceride levels. This acid 
works primarily in adipose tissue, where it causes a rapid suppression in lipolysis with a 
fall in circulating free fatty acids. Receptors on the cell surface facilitate the mode of 
action of nicotinic acid, which in turn are coupled to inhibitory G proteins. Thus, its 
mode of action involves the inhibition of adenylate cyclase and decreasing accumulation 
of cAMP.
In treatment, it is rapidly absorbed from the intestine, as it is part of the water-soluble 
vitamin B complex. It is the only hypolipoproteinemic agent to date that has been 
associated with a decrease in overall mortality (Shepherd and Packard, 1992). Its use in 
therapy may result in elevated levels of alkaline phosphatase and transaminase (hepatic 
dysfunction)- which may in turn be associated with jaundice, which are just a few of the 
many adverse effects of the use of this agent. It results in a cutaneous flush within a short 
period of its administration. A deterioration of glucose tolerance is also observed in 
patients, with preexisting impaired glucose tolerance (Shepherd and Packard, 1992).
4.1.7.5 Probucol
Due to the fact that it lowers HDL more than it does LDL, this drug is not as prescribed 
as frequently as others (Milander and Kuhn, 1992). Its mode of action is by decreasing 
the amount of apolipoprotein A-I and A-II which results in a decline in HDL cholesterol. 
Studies have indicated that the probucol-induced fall in LDL cholesterol is due to 
increased catabolism of LDLs via non-receptor mediated pathways. Such pathways may 
not effect the production of LDLs. It is a synthetic lipophilic antioxidant, which is 
incorporated into lipoproteins, thereby preventing their oxidation. It also distributes into 
adipose tissue. Such properties may have important implications in the therapy of 
atherosclerosis. Although its mode of action does not involve affecting the production or
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degradation of LDL, it does, however, alter the ratio of protein:cholesterol of HDL. Due 
to its former effect on LDL, probucol ie presently regarded as a secondary agent in the 
treatment of hypercholesterolemia. It has few side effects, some of which include- 
gastrointestinal disturbances, mainly diarrhea and nausea (Milander and Kuhn, 1992).
4.1.8 Abnormalities in cholesterol metabolism in diabetes mellitus
Although diabetes is by definition a disorder of carbohydrate metabolism, it has been 
apparent for some time that abnormalities of lipid metabolism occur commonly in patients 
with this syndrome. Furthermore, it has been generally assumed that the defects in lipid 
metabolism seen in diabetes help explain why these individuals are at increased risk of 
developing atherosclerosis (Chen et al., 1987). High levels of plasma cholesterol are 
frequently found in human diabetes and also develop in the alloxan diabetic rat (Wong 
and Bruggen, 1960). Such associations with diabetes mellitus- as hyperlipidaemia and 
premature atherosclerosis, may result due to alterations of plasma lipoprotein composition 
and/or to changes in cholesterol synthesis (Devery et al., 1987). Kraemer (1986) reported 
that abnormal cholesterol metabolism resulted due to a deficiency in insulin in animal 
models such as the mouse, while O’Meara et al., (1986) reported such results for the 
rabbit model.
The liver can direct fatty acids into one or other of two fundamentally different 
pathways: triglyceride synthesis for transport to the periphery and fuel storage and 
oxidation to ketone bodies as instant energy source for muscle or brain (Ireland et al., 
1980). Hormones determine which pathway will be taken. Insulin has a large role in the 
balance between storage and release of fat and it promotes the conversion of carbohydrate 
into triacylglycerols. When insulin is lacking, as in severe diabetes, ketogenesis will be 
the major metabolic pathway. VLDLs are frequently increased in mild diabetes due to a 
combination of hepatic synthesis and lack of sufficient insulin in the periphery to allow 
lipoprotein lipase to metabolise them. Abnormalities of HDL metabolism also exist in 
patients with diabetes. Obesity and hypertriglyceridemia have been shown to be 
associated with low plasma HDL-cholesterol levels (Albrink et a l ., 1980, Philips et a l . , 
1981 and Schaeffer et al., 1978).
Non-insulin-dependent diabetes mellitus patients (NIDDM- Type 2) have high levels of 
VLDL and LDL and low levels of HDL. Insulin therapy leads to raised HDL-cholesterol 
levels in patients with type 1 diabetes, the predominant rise occuring in HDL2-cholesterol
(Bergman et al., 1986). Although a fall in lipoprotein lipase activity has been reported to 
be responsible for the low plasma HDL concentration with insulin deficiency, it has also 
been suggested that the evidence is circumstantial and that decreased lecithin:cholesterol 
acyltransferase (LCAT) activity could also be involved (Chen et al., 1987). Cholesteryl 
esters are transferred to LDL and VLDL by cholesterol ester transfer protein, after LCAT 
has esterified cholesterol in HDL 3, thereby converting these particles to HDL2 (Glomset
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and Norum, 1973 and Eisenberg, 1984), which is cholesterol ester rich.
Varying results have been reported for the amount of LCAT activity in diabetic 
subjects. Misra etal., (1974) reported the activity of LCAT was increased in experimental 
diabetes. Their study showed that administration of insulin did not have any effect on the 
activity of the enzyme. However, it must be noted that the substrate used in their 
experiments was that obtained from normal individuals pooled together. Finally, they 
showed that the enzyme activity was depressed in certain cases where diabetic ketosis or 
uraemia occured. Upon correction of acidosis however, the activity of the enzyme was 
found to be normal.
In relation to the use of suitable substrate for the LCAT assay, Chen et al., (1987) 
suggested that in studies on type 1 diabetics, that are poorly controlled, the use of the 
subjects own plasma as source of substrate would aid in the study of LCAT activity in 
such individuals. Meanwhile, Weight etal., (1993), found that there was no significant 
difference between LCAT activities in control subjects and poorly controlled type 1 
diabetics. The activity of the latter was shown to increase with improved metabolic 
control. Other reports in support of the fact that LCAT activity is unchanged in diabetics 
include Schemthaner et al., (1983), who reported that the activity did not change 
irrespective of age, sex or type of diabetes.
On the contrary, Mattock et al., (1979) reported that LCAT activity was slightly, but 
significantly, higher in IDDM and NIDDM subjects studied, than in controls. Regarding 
diabetic rat models and LCAT studies, Kudchodkar etal., (1988), reported that upon 
feeding dietary caesin to diabetic rats, there was a decreased fractional rate of plasma 
cholesterol esteification, which may be indicative of changes in the nature of substrate 
lipoproteins, as the plasma LCAT activity measured using an exogenous substrate was 
not affected. This result, in the case of the caesin fed rat, may be attributed to the fact that 
there was an associated increase in the levels of apo-E rich HDL subclass, which is of a 
lower substrate potential than apoA-rich HDL (Kudchodkar et al., 1988).
LCAT is one enzyme associated with the esterification of cholesterol, which is found 
in plasma- another esterifying enzyme is acylcoenzyme A:cholesterol-0-acyltransferase 
(ACAT), which is found in the liver and intestine. As the latter enzyme is present in the 
intestine, chylomicrons secreted from the intestine are relatively low in free cholesterol 
and have a high cholesteryl ester content proportional to the rate of uptake of cholesterol 
from the intestinal lumen. The level of ACAT in the liver in some species (including 
humans) is very low (Fielding and Fielding, 1985). Thus, it is likely that human hepatic 
lipoproteins contain little, if any cholesteryl esters when secreted (Fielding and Fielding, 
1985).
The activity of ACAT is affected by a number of factors including dietary fat, 
cholesterol and ethanol, the availability of its cholesterol substrate, the concentrations of
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LDL, progesterone, 25-hydroxycholesterol and possibly the phosphorylation / 
dephosphorylation mechanism (Suckling and Stange, 1985). ACAT activity is reported to 
increase in rabbit aorta during diet induced hypercholesterolaemia (Brecher and Chan, 
1980), while in humans being treated for gallstones, its activity has been shown to be 
reduced (Smith et al., 1986). Devery et al., (1987), reported intestinal ACAT activity, 
while reduced in diabetic rabbits, was unchanged in diabetic rats. Their results also 
propose that the decrease in hepatic ACAT activity of the poorly controlled diabetic rats 
(by 10% , P<0.01), may reflect a decreased esterification of free cholesterol within the 
liver or a greater ability of liver to secrete cholesterol out of the liver in the form of VLDL 
particles. Owens et al., (1991) also reported that ACAT levels were found to be 
significantly increased (55±18%) in mononuclear leukocytes of diabetic patients after 
treatment with simvastatin. The significance of this decrease in enzyme levels in diabetics 
may suggest that more free cholesterol is available for transport leading to a higher pool 
of circulating cholesterol (Tomkin and Owens, 1991).
4.1.9 Methods for the measurement of 7a-hydroxycholesterol
Recent advances in spectroscopy and chromatography have permitted measurement of 
various cholesterol biosynthetic pathway intermediates, which covary with rates of 
cholesterol biosynthesis. Many of these methods have also been used to measure
intermediates of the bile acid biosynthetic pathway, including 7a-hydroxycholesterol not
only in biological samples but also in foodstuffs. Such methods include the following:
4.1.9.1 Incorporation of [14C] cholesterol.
Here, radioactive cholesterol is incubated with liver microsomes. The enzyme,
cholesterol 7 a-hydroxylase converts cholesterol into 7a-hydroxycholesterol, the first
step in the bile acid biosynthetic pathway. The product of this reaction is 7 a -
hydroxy[i4C]cholesterol. The radioactive 7a-hydroxycholesterol is then isolated from
the reaction medium and assayed for radioactivity. The initial methods developed for the
analysis of 7a-hydroxycholesterol used the principle of this method. Thin-layer
chromatography is frequently used to isolate the product as decribed by 
Balasubramaniam et al., (1975) and more recently, Bascoul et al., (1988). However, one 
cannot be sure that the behaviour of the enzyme towards exogenous substrate is 
analogous to that towards endogenous cholesterol.
4.1.9.2 Colormetric assay
7 a-hydroxycholesterol may be detected and estimatedby the Lifschutz colour reaction,
as decribed by Bergstrom and Wintersteiner (1942). As 7 a-hydroxycholesterol is known 
as an azurosteroid, the presence of a hydroxy group at position at C-7 results in an
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intense blue colour being produced in acidic or dehydrating medium (SO4H2/H2O, (5:5,
v/v)), or in the presence of antimony chloride (Bascoul et al., 1990). 7 a -  
hydroxycholesterol is also detectable in the ultraviolet-visible region of the spectrum 
(Hutton and Boyd, 1966).
4.1.9.3 Isotope dilution-mass spectrometry
A sensitive and accurate assay was developed by Bjorkhem et al., (1981) for the 
measurement of various intermediates in the bile acid biosynthetic pathway, including
7a-hydroxycholesterol. The radioactive extracts from the assay were subjected to HPLC 
(preparative), peaks of interest were collected, converted to trimethylsilyl ether and 
subjected to analysis by gas-liquid chromatography-mass spectrometry.
4.1.9.4 Capillary gas-liquid chrom atography-selected ion m onitoring  
(GLC-SIM)
Oda et al., (1990) described a method for the analysis of 7 a-hydroxycholesterol using
this method. Samples which were cleaned up using Sep-Pak columns were treated with 
TMSI-H, 1% pyridine-n-hexane and analysed by GLC-SIM. In the SIM mode, the
selected ions were scanned for TMS ether derivatives of 7a-hydroxycholesterol.
4.1.9.5 HPLC
This technnique has been used frequently in recent years. Efficient HPLC separations 
of mixtures of oxygenated sterols has been described (Ansari and Smith, 1979) and 
HPLC separation in combination with enzymatic detection has been suggested (Ogren et 
al., 1980). This is reported to improve the detection of sterols in the low UV absorption 
range. Both normal (Ogishima and Okuda, 1986) and reverse-phase HPLC (Hylemon et 
al, 1989) are reported for such analysis.
Aims of “Serum 7a-hydroxycholesterol in human and animal models of 
altered cholesterol metabolism”:
* To measure levels of 7a-hydroxycholesterol in the serum of humans- control and 
hypercholesterolaemic
* To measure levels of 7a-hydroxycholesterol in the serum of rats- control, cholestyr­
amine-treated and streptozotocin-induced diabetics
* To examine the possible correlation between the levels of 7a-hydroxycholesterol in the 
serum and liver of the rat models as an indicator of hepatic bile acid synthesis
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Results
Having shown that the HPLC method is a reliable, sensitive and precise method for the 
measurement of 7a-hydroxycholesterol and cholesterol in serum, a species survey of its 
levels in both human and animal sera, its biological significance in serum and its route of 
metabolism required further investigation.
This chapter describes data obtained when serum samples from normolipidaemic and
hypercholesterolaemic human subjects were analysed for 7 a-hydroxycholesterol. Since
the liver plays a major role in the regulation of whole body cholesterol metabolism and is
the sole organ for bile acid synthesis in the body, it was decided that 7 a-
hydroxycholesterol, the bile acid precursor metabolite should also be determined in liver 
of experimentally-induced animal models of altered cholesterol metabolism using
essentially the same HPLC analytical technique as was used for the analysis of 7 a-
hydroxycholesterol in serum.
4.2.1 Levels of 7a-hydroxycholesterol in human sera
0.5ml aliquots of serum from 4 control normocholesterolaemic subjects and 6
hypercholesterolaemic patients were analysed for 7a-hydroxycholesterol as described in
Chapter 2. Typical HPLC chromatographs obtained from these samples are depicted in 
Fig 4.5(a) and (b). Table 4.3 depicts the range, mean and standard deviation in
levels of 7 a-hydroxycholesterol obtained in these two groups. No overlap was observed
in the range of serum levels in normal subjects (153.3-216.6 pmoles/ml) and 
hypercholesterolaemic (260-563 pmoles/ml) patients. Hypercholesterolaemic patients
showed significantly higher levels of 7 a-hydroxycholesterol (371.1+126.5 (6 )
pmoles/ml) (p<0.05) than control subjects (185.4±26.4 (4) pmoles/ml). The relatively 
large standard deviation in the level of analyte obtained in the hypercholesterolaemic 
group, may in part, be attributed to the fact that the patients from which serum was 
obtained were being treated for varying medical disorders such as diabetes, 
hypothyroidism, obesity, hypertension, colitis and euthyroidism. Drugs treatments in 
some of the above patents included simvastatin, pravastatin and probucol. The serum 
levels of cholesterol ranged from 4.6mM to 10.3mM, averaging 7.26+2.4mM.
Fig 4.6 represents the profile of serum which has not been enzymatically treated with 
cholesterol oxidase. This was carried out in order to determine whether or not
endogenous amounts of 7a-hydroxy-4-cholesten-3-one were present.
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Fig 4.5(a) and 4.5(b) Typical HPLC chromatographs of (a) normal human serum 
aliquot (0.5ml) and (b) hypercholesterolaemic human serum (0.5ml). Procedure for 
sample preparation and analysis is as in methods.
The positions for 20a-hydroxycholesterol, 7a-hydroxycholesterol and cholesterol are 
indicated below.
Fig 4.5(a)
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Table 4.3: Concentrations of 7a-hydroxycholesterol in serum of control human 
subjects and subjects being treated for hypercholesterolemia. Data represents: The range 
of values obtained and Mean ± S.D.
SUBJECT SERUM LEVEL OF 
7a-OHCHO 
(pmoles/ml)
CONTROL 
* HYPERCHOLESTEROLEMIC
153.30 - 216.60 
185.43 ± 026.40 (n=4)
260.00 - 563.00 
371.06 ± 126.49 (n=6)
* p<0.05
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Fig 4.6 HPLC chromatographic representation of human serum, which has not been 
treated with cholesterol oxidase, indicating the presence of endogenous enone derivatives 
of cholesterol.
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Serum 7 a-hydroxycholesterol was determined in 6 control rats (Fig 4.7(a)), 7 
cholestyramine-treated rats (Fig 4.7(b)) and 6 diabetic rats (Fig 4.7(c)). Table 4.4 
and Fig 4.8 show the concentration of serum 7 a-hydroxycholesterol in the three rat 
groups. The levels of the sterol in serum were similar in control rats and in diabetic rats 
(mean concentration 259.3±63 (n=6 ) and 202.1±66 (n=6 ) pmoles/ml respectively) but 
were significantly elevated (p<0.01) in the cholestyramine-treated rat (591.4±143.9
(n=7) pmoles/ml). The range of 7a-hydroxycholesterol showed no overlap with either
the control (186-335 pmoles/ml) or the diabetic group (115-279.9 pmoles/ml), while 
only one of the cholestyramine levels (257.22 pmoles/ml) overlapped with the control 
values.
For reasons of comparison, hepatic levels of 7 a-hydroxycholesterol, the product of
endogenous cholesterol catabolism by cholesterol 7 a-hydroxylase, were determined by
J.Quinn, another post-graduate student in this laboratory. As expected, the levels of 7 a- 
hydroxycholesterol were elevated in rats treated with 3% cholestyramine. Treatment with 
cholestyramine resulted in a 2.7 fold increase in the concentration of hepatic 7a- 
hydroxycholesterol (17.2+3.7 (n=3) nmol/ml) relative to control rats (6 .2+1.6 (n=6 ) 
nmoles/ml). Streptozotocin-induced diabetes resulted in a significance decrease (p<0.05)
in the concentration of hepatic 7a-hydroxycholesterol (2 .8±0.8  (n=6 ) nmoles/ml).
Paired data for liver and serum levels of 7a-hydroxycholesterol in 6 diabetic and 3 
cholestyramine-treated rats and random matched data for control rats showed that there 
was a correlation between hepatic and serum levels of 7 a-hydroxycholesterol (Fig 4.9). 
This correlation was shown to be significant (even in the absence of control data) 
(r=0.67, p<0.05). Although the % of 7a-hydroxycholesterol in rat serum relative to liver
in all groups was <10%, there were indications that leakage of 7a-hydroxycholesterol 
from liver into serum was higher in the diabetic group (7.3%) relative to the 
cholesytyramine-treated group (2.3%) and control group (4.2%).
4.2.2 Levels of 7a-hydroxycholesterol in rat serum
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Fig 4.7 HPLC chromatograms of serum obtained from (a) control (b) cholestyramine- 
treated and (c) streptozotocin-induced diabetic rats.
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Fig 4.7 (b) Cholestyramine-treated rat serum
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Fig 4.7 (c) Streptozotocin-induced diabetic rat serum
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Table 4.4 & Fig 4.8: Serum levels and hepatic levels of 7a-hydroxycholesterol in the 
control, streptozotocin-induced diabetic and cholestyramine treated rat models. 
p<0.05 for hepatic 7a-hydroxycholesterol levels in the streptozotocin induced diabetic 
rats with respect to controls; and also in the cholestyramine-treated rats with respect to 
controls.
p<0.01 for serum 7 a-hydroxycholesterol levels in the cholestyramine-treated rats with 
respect to the controls.
Table 4.4:
Control Streptoz­
otocin induced 
diabetic
Cholesty­
ramine
treated
Serum
7a-hydroxy-
cholesterol
(pmoles/ml)
Value range 186.0 - 335.0 115.0 - 279.9 433.9 - 791.0
Mean ± S.D 259.3 + 63.9 
(n=6)
202.1 ±66.5  
(n=6)
591.4 ±  143.9
(n=6)
Hepatic 
levels of 
7a-hydroxy- 
cholesterol 
(nmoles/ml)
Value range 4.62-8.61 1.55-3.63 14.87-21.5
Mean ± S.D 6.18+1.57
(n=6)
2.83±0.71
(n=6)
17.1±3.72
(n=3)
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Serum Levels of 7oc-Hydroxycholesterol 
in control, diabetic and cholestyramine-treated
Diabetic Control Cholestyramine
Treated
Hepatic Levels of 7oc-Hydroxycholesterol in 
control, diabetic and cholestyramine-treated rats
Diabetic Control Cholestyramine
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Fig 4.9 : Correlation between levels of 7 a-hydroxycholesterol in serum (total) and liver 
(free) of rats. Rat models included a streptozotocin-induced diabetic model and also the 
cholestyramine treated rat.(r=0.67). Hatched area indicates values obtained for random 
matched hepatic and serum data from control rats (n=6 ).
Diabetic (n=6)
Cholestyramine (n=3) treated models.
(nmoles/ml)
1 0 8
4.2.3 Free and esterified levels of 7a-hydroxycholesterol in human and 
animal serum
0.5ml aliquots of sera from 3 control and 3 hypercholesterolaemic human patients, 3 
control and 3 experimentally-induced diabetic rats were assayed for both free and
esterified 7a-hydroxycholesterol. Esterified 7a-hydroxycholesterol levels were
computed as the difference between free and total 7a-hydroxycholesterol, the former
being determined by the analytical procedure described in Chapter 2 but in the absence of 
alkaline hydrolysis. The procedure facilitated simultaneous measurement and comparison
of free and total levels of both 7a-hydroxycholesterol and cholesterol. Table 4.5
demonstrates that a large proportion of total 7a-hydroxycholesterol in normal human
serum is esterified (78.12%). Mean free 7a-hydroxycholesterol levels in control sera was
found to be 42.93+4.21 pmoles/ml. A slightly higher level of esterified 7 a -  
hydroxycholesterol was observed in hypercholesterolaemic patients (83.72%) with 
respect to controls (78.12%). Mean free 7a-hydroxycholesterol level in the latter was 
61.50±14.38 pmoles/ml. The % esterification of cholesterol was slightly lower than that 
of 7a-hydroxycho leste ro l (71.46% in control sera and 72.37%  in 
hypercholesterolaemic sera).
Levels of free and esterified 7a-hydroxycholesterol were calculated for rat sera also
(Table 4.5). Free 7a-hydroxycholesterol levels were 41.95 pmoles/ml in control and
27.22 pmoles/ml in diabetic rats. However, the total levels of 7a-hydroxycholesterol in 
the former group were 247.83±55.29 pmoles/ml and 145.0+30.64 pmoles/ml for the 
latter. Thus, as can be calculated, the % esterification of 7 a-hydroxycholesterol in 
controls was 74.91%, while in diabetics was found to be 81.23%. The % esterification 
of cholesterol was slightly lower than that of 7a-hydroxycholesterol in control rats 
(64.12%) and diabetic rats (77.32%).
In summary, this chapter provided a comparison of the levels of 7 a -  
hydroxycholesterol in human and rat sera and indicated a species difference in levels of 
both total and esterified 7 a-hydroxycholesterol. In addition, there is some evidence to
support the current literature that analysis of serum 7a-hydroxycholesterol may be a 
convenient method for evaluating the relative rate of bile acid synthesis in vivo.
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(7a-OHCHO) in the various groups studied. Results obtained are those by HPLC 
analysis (n=3). Free and total measurements tabulated below are expressed as pmoles/ml 
serum for 7a-OHCHO, while CHO figures are as fimoles/ml serum. (Hypercholest*: 
hypercholesterolaemic subjects).
Table 4.5 Percentage esterification of cholesterol (CHO) and 7a-hydroxycholesterol
SUBJECT 7a-OHCHO CHO
free total % esterified free total % esterified
HUMAN:
CONTROL
HYPER­
CHOLEST.*
42.93
61.50
196.2
377.8
78.12+7.5
83.72±22.4
1.27
2.28
4.46
8.26
71.46±10.57
72.37±9.00
RAT:
CONTROL
DIABETIC
41.95
27.22
247.8
145.0
74.91+16.1
81.23±12.7
0.431
0.235
1.20
1.04
64.12±0.83
77.32±1.01
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Discussion
parameter for establishing disorders involving the metabolic conversion of 7 a- 
hydroxycholesterol towards bile acids (Koopman et al., 1987), whether acquired, 
inherited or brought about by medical treatment. Previous methods for the identification
and quantitation of 7 a-hydroxycholesterol in serum and in the liver have utilised TLC ,
Gas-liquid chromatography (Bascoul, 1990), a combination of these with mass 
spectrometry (Bjorkhem and Kallner 1976; Einarsson et al., 1986) and recently reverse 
phase HPLC for liver analysis (Hylemon et al., 1989).
Having set up and validated this method, serum samples from human control subjects 
and from subjects being treated for hypercholesterolemia were analysed. It was found that 
the range of measures found in control samples were from 153.3 - 216.6 pmoles/ml, 
which compares well with values of 49 - 410 nmoles/1 - (Koopman et al., 1987)- analysis
by gas chromatography. There was a significant increase in the levels of 7 a - 
hydroxycholesterol in the serum of the patients being treated for hypercholesterolaemia, 
with respect to controls (p<0.05). This is in accord with other findings (Koopman et al.,
1987) and (Bascoul etal., 1990). The latter reported on Familial hypercholesterolemia 
which is associated with a defect in LDL receptor activity. Elevations in both enzymes-
HMG-CoA reductase and cholesterol 7a-hydroxylase activity were reported in Yoshida
rats, which are animal models of spontaneous hyperlipidemia (Fantappie et al., 1992). As 
referred to in the introduction (4 .1 .7: Tables 4.1 and 4.2), diabetes and 
hypothyroidism are classified as secondary hyperlipoproteinemias, having altered 
lipoprotein patterns. All the hypercholesterolaemic patients in this study had cholesterol 
levels above 7.2mM.
Results of 7a-hydroxycholesterol measurement in rat serum, indicate that the levels
found were higher than those of control humans (rat values = 259.33 ± 63.86 pmole/ml, 
human values = 185.43 + 26.4 pmoles/ml). This is in accord with the report by Einarsson
et al., (1986), who showed that the activity of cholesterol 7 a-hydroxylase in human liver 
was found to be lower than in the rat (one magnitude). However, the observation that rats 
do not possess a gall bladder and have an unusually long small intestine, may account for 
high levels of bile acid metabolism in these animals. Such anatomical and biochemical 
differences coupled with the different manner by which the rat metabolises endogenous 
and exogenous cholesterol (Turley and Dietschy, 1982) suggest that not all of the results 
obtained in the rat may be extrapolated to other species. Nevertheless, most mammals 
share the same rate-limiting step in bile acid biosynthesis and in this regard, the rat is an 
exemplary species (Russell and Setchell, 1992).
Studies carried out on rats included the administration of cholestyramine, an anion
It has been suggested that the 7 a-hydroxycholesterol concentration in serum is a good
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exchange resin (a gritty polymer carrying many positively charged chemical groups), in 
the diet. As the resin is not absorbed from the intestine, it is excreted, carrying the bound 
bile acids with it. This drug, as it binds negatively charged bile acids in the intestine and
prevents their reabsorption, releases the feedback inhibition of cholesterol 7a-hydroxylase
activity by enterohepatic recirculating bile acids (Myant and Mitropoulos, 1977), thus 
stimulating the enzymatic conversion of cholesterol towards bile acids. Cholestyramine
treatment resulted in a significant elevation (p<0.01) in circulating levels of 7 a-
hydroxycholesterol in serum of treated rats. A corresponding increase in the hepatic levels
of 7a-hydroxycholesterol were also observed (a 2.7 fold increase relative to controls:
Quinn, unpublished results). These results are in accord with others (Song 1991), who 
reported a 5- to 6 -fold increase in enzyme activity in rat liver microsomes of animals 
treated with cholestyramine. The animals studied by Song et al., had 3% cholestyramine 
administered for at least 2 weeks ad lib , compared to the same concentration for a period 
of 7 days, as with our models.
It also has been reported (Balasubramaniam et al., 1972 and Mayer, 1972) that there is
a marked fall in the activity of cholesterol 7a-hydroxylase during fasting, the amplitude of
the diurnal rhythm in activity being much reduced but not completely abolished. Einarsson 
etal., (1991), reported results of a study carried out on gallstone patients treated with 
cholestyramine for three weeks and also of untreated patients. They concluded that the
significant increase in the activity of cholesterol 7a-hydroxylase in such treated patients,
was probably not explained by an increase in substrate availability, but possibly due to 
changes in the turnover of specific species of cytochrome P-450 of the enzyme. Chiang et
al., (1990) indicated that microsomal cholesterol 7a-hydroxylase enzyme levels were
increased in parallel with cholesterol 7 a-hydroxylase activity upon the treatment of rats 
with diet supplemented with cholestyramine.
Results here indicate that an increase in circulating levels of 7 a-hydroxycholesterol
mirrored an increase in the level of hepatic 7 a-hydroxycholesterol. The measurements of
serum 7 a-hydroxycholesterol reported here are for total amounts. This matter has been 
previously examined in human patients undergoing treatment for cholelithiasis, where Oda 
et al., (1990) found that esterified and total 7 a-hydroxycholesterol were more highly
correlated with the enzyme activity than the free form, even when cholesterol 7a- 
hydroxylase is not induced, i.e. bile acid synthesis is decreased by treatment with 
chenodeoxycholic acid. Bjorkhem et al., (1987) showed that serum free 7 a -  
hydroxycholesterol reflected cholesterol 7a-hydroxylase activity when bile acid synthesis
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was induced by cholestyramine. Yoshida et al., (1993), recently reported a significant 
correlation between plasma-free 7a-hydroxycholesterol levels and cholesterol 7 a - 
hydroxylase activity in patients with cholelithiasis or early cancer of the gastrointestinal 
tract.
The liver has been found to be capable of converting 7 a-hydroxycholesterol to 7a- 
hydroxy-4-cholesten-3-one, which may be an intermediate formed during the 
epimerisation of the 3B-hydroxyl group to 3a-hydroxyl with migration of the double bond 
in its biosynthesis (Hutton and Boyd, 1966). It has also been suggested by Axelson et al., 
(1991) that the circulating levels of 7a-hydroxy-4-cholesten-3-one, present in plasma, 
reflect both the total production of bile acids in man and the activity of hepatic cholesterol 
7 a-hydroxylase. Literature findings indicate that the circulating levels of 7 a -
hydroxycholesterol are higher than those of 7a-hydroxy-4-cholesten-3-one. A recent
study by Pettersson and Eriksson (1994), found that the concentration range of serum 7 a - 
hydroxy-4-cholesten-3-one (2-35 ng/ml (~5-87pmoles/ml)) was considerably lower than 
the levels of 7a-hydroxycholesterol (19.7-165ng/ml (50-410 pmoles/ml)) reported by 
Koopman et al., (1987). As presented by means of a HPLC chromatograph in Fig 4.6, 
such a form of 7a-hydroxycholesterol was not detected in this study.
Studies carried out on the cholestyramine-treated rat suggest that an increase in the 
activity of hepatic cholesterol 7a-hydroxylase accounts for the increase in newly 
synthesised 7 a-hydroxycholesterol in the liver. The significant positive correlation
between the serum and hepatic levels of this oxide suggests that when 7 a -
hydroxycholesterol accumulates in liver, it may subsequently leak from hepatocytes into 
the systemic circulation.
Although there was a significant decrease in the levels of 7 a-hydroxycholesterol in liver 
of control and diabetic rats, there was, however, no significant difference between the 
levels of 7a-hydroxycholesterol in the serum of diabetic rats with respect to controls. As 
there are no corresponding liver and serum data for control rats, this study may only 
conclude that a significant correlation is only found when cholesterol 7 a-hydroxylase 
activity is stimulated as referred to by Bjorkhem et al., (1987).
Although rats, the most commonly used animal model in diabetes research, are normally 
resistant to dietary cholesterol-induced hypercholesterolemia and atherosclerosis (Mahley
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and Holcomb, 1977), they become susceptible to this dietary stress following 
streptozotocin-induced diabetes (Russell et al., 1962). However, it has been reported that 
the restriction of food intake by diabetic rats prevents hypercholesterolemia (Young et al.,
1982). The levels of cholesterol in the plasma of rats has been shown to be proportional to 
the fraction of cholesterol in plasma originating in the diet (Young et al., 1985). Recently, 
work carried out by Maechler etal., (1992), disagreed with this theory, saying that 
hyperphagia and intestinal hypertrophy could be excluded as triggering factors for the 
hyperresponsiveness of diabetic rats to cholesterol feeding.
The level of circulating cholesterol in the diabetic model here, was found to be lower than 
that of non-diabetic rats. This may be due to the fact that the daily diet was monitored and
rationed in order to prevent hyperphagia. Levels of 7a-hydroxycholesterol in the liver, 
being lower than non-diabetics, will be discussed elsewhere and may be attributed to 
changes in size of the endogenous cholesterol substrate pool used in the assay (Quinn, 
unpublished results).
Morel and Chislom (1989), reported increased peroxidation products in VLDL and LDL 
of streptozotocin-induced diabetic rats. However, this was not observed in the present 
study, as it is evident from the chromatographs that there was no significant difference
between the levels of 7a-hydroxycholesterol in the serum of control and diabetic rats. In 
addition, there was no significant increase in the serum levels of 7J3-hydroxycholesterol or 
7 -ketocholesterol, which are two other prevalent oxidative products of cholesterol.
Oxysterols have been reported to have known effects on enzymes involved in 
cholesterol metabolism: Kandutsch etal., (1977), reported that oxidised cholesterols at a 
concentration of between 10~6 and 10-9 M in vitro and in vivo inhibit cholesterol 
synthesis (i.e., inhibits HMG-CoA reductase), consequently, the cholesterol concentration 
in cells and their membranes decreases resulting in “leaky” cells. 2 2 -hydroxycholesterol 
has been shown to block cholesterol esterification and cholesterol synthesis (Bates et al. ,
1983).
That more than 75% of 7 a-hydroxycholesterol is carried in LDL raises the question of
whether an increase in the circulating level of 7a-hydroxycholesterol affect all cells with
LDL receptors? (Bascoul et al., 1990). Such effects may result in inhibition of HMG- 
CoA-reductase activity, the principal enzyme in the biosynthesis of cholesterol and may 
also have an effect on the synthesis of LDL receptors (Dueland et al., 1992). 
Alternatively, it may affect cholesterol metabolism as a result of its cytotoxic nature
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(Crastes de Paulet et al., 1988).
7a-hydroxycholesterol in diabetic rats was found to be esterified only to a slightly 
greater extent than in control rats. The sterol was also found to be only slightly more 
esterified in human hypercholesterolaemic patients than in control subjects. As regards the 
esterification of cholesterol, there was no significant difference in the amount esterified 
between the two human groups, however, there was a significant difference between the
rat groups. No result was obtained for the esterification of 7a-hydroxycholesterol in 
cholestyramine-treated rats.
As referred to above, Bascoul et al., (1990) reported that more than 75% of 7 a-
hydroxycholesterol, found in circulation, was found carried by LDLs, with approximately 
75% being esterified at the 313-position (Oda et al., 1990). Little is known about the
metabolism of esterified 7 a-hydroxycholesterol or its formation- although studies have
been carried out on the metabolism of the free form in vitro (Anaki and Yamasaki, 1970) 
and in vivo. (Anderson et al., 1972). Recently, metabolic studies were carried out on the
further metabolism of 7 a-hydroxycholesterol-313-stearate in the hamster, by Kishinaka et
al., (1992), which had been intravenously infused and it was effectively taken up by the
liver, to be excreted in the bile. However, some of this esterified 7a-hydroxycholesterol
may be hydrolysed prior to hepatic uptake. Such studies suggest that the microsomes
might be the first subcellular organelle in which esterified 7 a-hydroxycholesterol is
metabolised within the hepatocyte.
The formation of esterified 7 a-hydroxycholesterol also poses questions-is it esterified 
by LCAT or ACAT, or does it result from the hydroxylation of esterified cholesterol? Part 
of 7a-hydroxycholesterol which, when formed in the hepatocyte and is not oxidised
further to 7a-hydroxy-4-cholesten-3-one, may be esterified by ACAT (Sakamoto 1968).
Free 7 a-hydroxycholesterol may leave the hepatocyte and enter the systemic circulation
and be esterified by LCAT in the plasma, along with free 7 a-hydroxycholesterol which
may be the result of the action of cholesterol esterase on esterified 7a-hydroxycholesterol.
Thus, the results of such studies of the esterification of 7a-hydroxycholesterol, in vitro, 
will be discussed in Chapter 5.
In summary, the developed method proves to be an efficient, reproducible and precise 
method for the analysis of serum 7 a-hydroxycholesterol. The results suggest that the
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analysis of 7a-hydroxycholesterol in serum is a sensitive and convenient method to 
determine relative rates of bile acid production, as there was shown to be a positive 
correlation (p<0.05) between levels of 7 a-hydroxycholesterol in serum and liver in the 
two treated groups. Furthermore, despite an interspecies difference in levels of both total 
and esterified 7 ot-hydroxycholesterol, it is apparent that the % esterification of 7a- 
hydroxycholesterol was similar in both species.
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CHAPTER 5 
REACTIVITY BETWEEN 
7a-HYDROXYCHOLESTEROL AND 
CHOLESTEROL ACYLTRANSFERASE 
ENZYMES IN SERUM AND LIVER
Introduction
Interest in the hydrolysis of cellular cholesteryl esters is relevant to both normal and 
pathologic situations since hydrolysis of cholesteryl ester is a necessary prerequisite to 
further metabolism of the cholesteryl moiety, either intracellulary, for steroid synthesis or 
membrane biosynthesis, or via efflux to the plasma compartment for delivery to the liver. 
Apart from cells that secrete lipoproteins and the flux of intact cholesteryl ester from cells 
to plasma cholesteryl ester transfer protein, most other cells do not secrete intact 
cholesteryl esters (Glick, 1990). Thus, due to the fact that cholesteryl esters may be 
deposited and have pathological consequences- as seen in atherosclerosis, characterised 
by the retention of cholesterol within the peripheral vascular bed (Reichl and Miller, 
1989), where cellular cholesteryl esters are deposited in macrophages and smooth muscle 
cells of the vessel wall (Small, 1988; Ross, 1984)- there has been much interest shown in 
the metabolism of such esters.
5.1.1 Lecithin-cholesterol acyltransferase (LCAT)
An enzyme central in the extracellular metabolism of plasma lipoproteins is lecithin- 
cholesterol acyltransferase (LCAT- E.C. 2.3.1.43). It is secreted by the liver, into the 
plasma, bound to lipoproteins or in the free form (Jonas, 1991). Early data showed 
cholesteryl esters in all the major plasma lipoprotein fractions. Fielding and Fielding
(1985), reported that due to the low level of hepatic acyl CoA-cholesterol acyltransferase 
(ACAT) in humans, the major part of cholesteryl ester of VLDL and LDL is derived from 
the LCAT reaction. The absence of almost the entire plasma cholesteryl ester moiety in 
congenital LCAT deficiency indicated that cholesteryl esters in human plasma are derived 
from LCAT activity. This enzyme has become of interest for several reasons, which 
include the following:
Biochemically- LCAT is a serine hydrolase, whose three dimensional structure and 
mechanism have been studied. It has both phospholipase (or esterase) and acyltransferase 
activities. Both such activities are dependent on the presence of an apolipoprotein 
coprotein (Fielding, 1990).
Physically/chemically- the substrate specificity of LCAT, as a function of the physical 
properties of the lipids, has been studied. Its transferase activities result in the transfer of 
acyl groups to many alcohols, including sterols and long-chain alcohols (acceptors with 
free -OH groups).
Due to the role of LCAT in the metabolism of plasma lipoproteins and subsequently in 
the process of “reverse cholesterol transport”, whereby peripheral cell cholesterol can be 
returned to the liver for catabolism, LCAT studies have been of major importance. This is 
also evident in the number of reports on its clinical significance in various diseases 
(Jonas, 1991).
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5.1.1.1: MECHANISM OF ACTION OF LCAT
The reaction catalysed by LCAT is depicted in Fig 5.1 below.
I
Fig. 5.1 Reaction catalysed by LCAT
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An acyl group is transferred from phosphatidylcholine (PC) to free cholesterol. Under 
physiological conditions LCAT reacts with cholesterol derived from the membranes of 
blood cells or vascular cells, or with that from the plasma lipoproteins (Fielding, 1990). 
Jonas (1986b) found that, in general, mixed chain PC particles are the preferred 
substrates of LCAT, followed by disaturated PCs of increasing chain length and by long 
chain polyunsaturated-PC particles. Much published work on the acyltransferase activity 
of LCAT reports that it is specific for the sn-2 position of PC, however, recent work by 
Subbaiah et al., (1994) showed that LCAT derived a significant percent of acyl groups 
from the sn-1 position of certain PC species. They also found that the positional 
specificity was determined at the formation of acyl-enzyme intermediate and that such 
specificity is influenced by the structure of PC, especially the chain length of the sn-2 
acyl group.
The mechanism of action of LCAT is as for chymotrypsin and trypsin, as it is 
considered to belong to the same family of serine hydrolases. Fielding (1990) proposed 
such a mechanism, which is shown below in Fig 5.2.
Fig 5.2 Mechanism of action of LCAT
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The proposed triad comprises of Asp-Ser-His which are linked by a charge relay 
system. This triad, according to Fielding (1990), is involved in the deacylation of 
phospholipid substrates, formation of a Ser-O-acyl intermediate and subsequent transfer 
of the acyl chain to cholesterol or water. Jauhianinen and Dolphin (1986), demonstrated 
that a single serine and histidine residue within the active site of human LCAT, catalysed 
the cleavage of lecithin with the formation of a fatty acyl-enzyme intermediate (oxyester) 
involving serine, that is- the phospholipase A 2 step of the reaction. They also postulated 
that the two Cys residues participate in the cholesterol esterification step only (forming a 
thioester), Fig 5.3. Various results conclude that the rate-limiting step is in one 
involving the phospholipase activity (Yogoyama et al., 1980).
Although the reaction involving LCAT occurs on the surface of HDL particles, the 
reactants (PC and cholesterol) and the products (lyso-PC- which binds serum albumin for 
removal and cholesteryl esters) of this reaction are widely distributed (Jonas, 1986b). 
This results from HDLs interacting with other lipoproteins- where free cholesterol and 
phospholipids are transferred into HDLs from LDL and VLDL and also the exchange of 
triglycerides in the other direction- into VLDL and LDL from HDL. This overall catalytic 
reaction is considered to be only partially reversible.
Once synthesised, cholesteryl ester moves into the interior of the HDL particle and 
some of it is exchanged for triglyceride in other lipoproteins by cholesteryl ester transfer 
protein. This form of cholesterol accumulates in LDLs and cells which require free 
cholesterol take up the contents of these LDL particles via the LDL receptor pathway. 
Thus, LCAT plays an important role in the metabolism of cholesterol by helping HDL to 
accept additional free cholesterol from other lipoproteins or from cell membranes. Larger 
HDL particles then deliver their cholesteryl ester content to the liver for metabolism. This 
concept is explained in more detail in Chapter 1.
5.1.1.2: Interaction of LCAT with HDLs
As referred to above, this reaction takes place on the surface of HDLs. The number of 
apolipoprotein A-I molecules that are present on the lipoprotein has been reported to be 
proportional to their activating effect (Yokoyama et al., 1980). LCAT requires apo A-I 
and apo A-IV for optimal activity and seems to act preferentially on the smaller high- 
density lipoprotein particles, including pre-beta HDL and HDL3 (Gillett and Owen,
1992). It is also stimulated, to a lesser extent, by apo C-I and apo-E. Chen and Albers
(1986) found that apo A-II must be incorporated together with apo A-I into lecithin- 
cholesterol liposomes to exert its stimulatory effect on LCAT activity and that apo A-II in 
HDL may play an important role in the regulation of LCAT activity. Present in high 
concentrations, apo A-II and serum amyloid A inhibit the LCAT reaction by apparently 
displacing apo A-I from the liposome substrates or from HDL in plasma (Steinmetz et al.,
1989).
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formation of the serine-fatty acyl intermediate and possibly in the subsequent transacylaiion reactions.
Fig 
5.3 
LCAT 
triad 
(Jauhianinen 
and 
D
olphin, 
1986)
It appears that the interaction of apolipoproteins with different PCs produces different 
interfaces which are recognised differently by the enzyme. Evidence which highlights the 
importance of a) the structure and conformation of apolipoprotein and b) the interface 
between it and the lipid, comes from various results and observations, which include the 
following:
* chemical modification of certain lysine residues in apo A-I, which did not affect the 
overall structure of apo A-I, did not lower the overall LCAT activation process. 
However, charge interactions and structural changes of apo A-I were found to be 
responsible for the observed decrease in activating capacity. Such results indicate that the 
activation of LCAT by apo A-I in vivo depends on the structure and charge of the 
apolipoprotein, which may be altered by mutations, changes in HDL size and 
composition, or by interactions with macromolecules or ions (Jonas et al., 1985).
* Various apolipoproteins of HDL, reacted with LCAT resulted in different levels of 
activation of the enzyme
* Synthetic substrates for LCAT may be synthesised in different sizes, thus having 
varying structures of apolipoproteins associated with the complex.The smallest sized 
particle, as studied by Jonas and McHugh (1984), was found to be the most reactive 
toward LCAT.
5.1.1.3: Transformation of lipoprotein by LCAT
Upon LCAT interacting with apolipoprotein on the surface of the HDL particle, 
morphological changes occur in the appearance of the latter. It changes from being 
discoidal in shape to taking on a spherical appearance, forming small, mature HDL 
particles. Observations made by Jonas (1991), upon reaction of LCAT with rHDL, 
containing two or more apo A-I molecules, involves the formation of cholesteryl esters, 
their accumulation in the central hydrophobic core of the complex, rearrangement of the 
surface components and also major fusion and disproportionation occurences which 
involve the protein and lipids of the complex.
When nascent HDLs are synthesised by the liver (Fig 5.4) and intestine (the HDLs of 
the latter contain only apolipoprotein A, while the former also contain apolipoprotein C) 
they are discoidal phospholipid bilayers containing apolipoprotein and free cholesterol. 
They acquire unesterified cholesterol on efflux from peripheral cells. After reaction with 
LCAT, the nonpolar cholesteryl esters move into the hydrophobic interior of the bilayer, 
the reaction continues to generate a nonpolar core that pushes the bilayer apart until a 
spherical pseudomicellar HDL is formed, covered by a surface of polar lipids and 
apolipoproteins.
Thus, it is evident that due to the fact that there are several different sizes and shapes of 
HDL particles, it is extremely difficult to study the reactivity of LCAT toward them, 
therefore the synthesis of particles of defined chemical composition, having the overall 
size and density of HDL was developed (Jonas, 1986), to study LCAT activity.
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Fig 5.4 Synthesis of discoidal HDL in extracellular fluid.
PL: phospholipid, FC: free cholesterol, LCAT: lecithin-cholesterol 
acyltransferase (Fielding and Fielding 1995)
Peripheral
cells
pre 11-1 
HDL
FC
FC T
Lymph
Extracellular space
e n d o t h e l iu m
Plasma
Spheroidal 
HDL
122
5.1.2: Measurement of serum LCAT activity
Various methods have been used in the analysis of serum LCAT activity, which use 
natural substrates (Glomset and Wright, 1964) and also synthetic substrates (Chen and 
Albers, 1982 and Jonas and McHugh, 1984). These methods are:
* the endogenous self-substrate method and
* the exogenous common-substrate method.
5.1.2.1: The endogenous self-substrate method
Such experiments use the subjects plasma as a substrate and enzyme source in 
measuring the esterification of cholesterol. Early studies carried out on plasma 
esterification involved measuring the extent of esterification occuring over a prolonged 
period of incubation. A decrease in unesterified cholesterol is measured by GLC after 
incubation of the plasma itself or LCAT activity is measured upon incubation of sample 
with [14C]cholesterol and subsequently measurement of the incorporation of radioactivity 
into cholesteryl esters (Stokke and Norum, 1971). Nagasaki and Akanuma (1977), 
developed a colorimetric method for measuring LCAT activity, using cholesterol oxidase 
and peroxidase.
The above are a few examples of self-substrate methods and have certain draw-backs. 
Long preincubation and equilibration times may result in an alteration of the substrate 
properties of the plasma and labelled exogenous cholesterol may not be in complete 
equilibration with endogenous cholesterol (Chen and Albers, 1982).
5.1.2.2: The exogenous common-substrate method
The substrates- artificial liposomes (Batzri and Korn, 1973) or heated plasma (Glomset 
and Wright, 1964) are used in the measurement of LCAT activity, where radiolabelled 
cholesterol ([14C] or [3H]) is converted into cholesteryl ester. A small quantity of sample 
plasma is used in such assays. However, it has been reported by Blomhoff (1974) that 
when different inactivated substrate sources are used, the resulting LCAT activity 
measurements differ. Also, the use of heated plasma is not ideal (Albers et al., 1981) as it 
is a less efficient substrate than unheated serum and cannot be readily standardised.
5.1.2.2.1: Reconstituted high-density lipoproteins/M icellar complexes Vs 
vesicles
The main components for most reconstitution experiments have been purified 
apolipoproteins (A-I, A-II, E or Cs), synthetic or natural phosphatidylcholines and free 
cholesterol (Jonas, 1986b). Micellar, discoidal complexes (non-aqueous internal 
compartment) were prepared as substrates for LCAT in this study. Preparation of such 
complexes and their formation is controlled, kinetically, by such factors as the 
temperature at which the synthesis is carried out; the concentration of cholesterol in the 
lipid bilayer; the type of apolipoprotein and PC; the PC vesicle size and composition
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(Jonas, 1986a).
The temperature at which the PC is incubated with sodium cholate (in discoidal 
complexes prepared by detergent-mediation), equilibrated with apolipoprotein and the 
various stages of dialysis should be as close as possible to the gel to liquid-crystalline 
phase transition temperature (Tc) of the PC. 40C is an acceptable temperature to work
with when using PC such as egg-PC. Matz and Jonas (1982), described a method for the 
synthesis of discoidal complexes based on the dispersal of lipids in sodium-cholate 
(which allows for the incorporation of many types of phospholipids into the complexes) 
and the subsequent removal of detergent in the presence of apolipoprotein.
Much evidence exists on the surfactant-like action of apolipoprotein A-I on 
multilamellar or unilamellar vesicles to produce micellar complexes, resembling HDLs 
(Swaney, 1980 and Atkinson et al., 1976). Apolipoprotein may intercalate with lipid 
vesicles by: cosonication of all the components (products are not very reproducible); 
spontaneous interaction of the lipid vesicles and the apolipoprotein (this method may only 
be used with certain PCs and there are restrictions due to the nature of the lipid vesicles) 
or finally, by the commonly used detergent-mediated method. The last method has the 
added advantage over the “spontaneous” method as it allows, due to the dispersion of the 
lipids, apolipoprotein to penetrate the bilayer of the complex. The resultant product 
consists of a bilayer disc surrounded by a peripheral ring of protein which is mostly
present in the a-helical structure. Micellar complexes, formed when apolipoprotein
interacts with vesicles, differ to the latter in that vesicles have aqueous inner 
compartments, their inner phospholipids being protected from external influences, while 
the phospholipid head groups of micellar, discoidal complexes are fully exposed. 
Another main difference between these two substrate vehicles is that there are associated 
problems with vesicle stability, while discoidal complexes are reportedly more stable. 
Differently sized particles may be synthesised by varying the proportion of PC to apo A- 
I.
However, it must be remembered that there are certain ratios that must be selected 
carefully, such as the molar ratio of sodium cholate/PC, which ideally should be from 1/1 
to 2/1, yielding a suggested sodium cholate concentration of 3 mg/ml (Jonas, 1986a). 
Work carried out by Matz and Jonas (1982), on the synthesis of micellar complexes, 
consisting of egg-PC, apo A-I and cholesterol, showed that when their results were 
examined in light of others, that when the molar ratio of PC/cholate was below 1/2, the 
major resultant products were small spherical micelles; ratios from 1/2 to 2/1 yielded 
bilayer discs of PC and cholate which were stabilised by an annular arrangement of 
cholate molecules and finally, ratios above 2/1 yielded PC mutilamellar compexes which 
allowed the intercalation of cholate. This, combined with the use of the correct Tc,
usually improves the micellisation of the process.
124
Physical and chemical analysis may be carried out on these complexes. Determination 
of their size and structure by gel filtration, transmission electron microscopy, gradient gel 
electrophoresis, analytical ultracentrifugation, static fluorescence polarisation and 
quasielastic light scattering have been described, in brief by Jonas (1986a).
5.1.3: Requirements for LCAT activity
The enzyme, when studied with artificial substrates, seems to show a preference for 
the sn-2 position of phosphatidylcholine, while recent studies also indicate that LCAT 
derived a significant percent of acyl groups from the sn-1 position of certain PC species 
(Subbaiah etal., 1994). On the basis of their work, it was postulated that the active site 
of human (and pig) LCAT was not sufficiently large to accomodate the long chain 
polyunsaturated acyl groups (PC 16:0-20:4), thereby utilising the group at position sn-1 
instead, whereas rat and mouse LCAT preferentially derived their acyl groups from the 
sn-2 position. Subbaiah et al., (1994), concluded that the substrate and positional 
specificities of LCAT are controlled by the central domain of LCAT protein, 
corresponding to the amino acid residues 130-306.
Kitabatake et al., (1979) found LCAT specificity to be broad, whereby sterols and long 
chain primary alcohols exhibited acceptor activity. Tilvis and Miettinsen (1980), 
concluded that sterols without the methyl group at position 4 of the steroid nucleus were 
esterified by LCAT. Piran and Nishida (1979), recorded that LCAT required that the 
sterol acyl acceptor possess a 36-hydroxyl group and a trans configuration of the A/B 
rings.
5.1.4: Acyl CoA:cholesterol acyltransferase: Intracellular cholesterol 
esterification
The regulation of cholesterol homeostasis in cells appears to be vital for their proper 
functioning. The cholesterol of lipoproteins entering the cell, the rate of intracellular 
cholesterogenesis, also the rate of cholesterol excretion from the cell by means of bile 
acid synthesis and by lipoproteins, are all processes which are balanced within liver cell. 
Acyl-coenzyme A:cholesterol acyltransferase, (ACAT), is an intracellular enzyme 
responsible for the esterification of cholesterol, the storage form.
The most important function of this enzyme is to act in conjunction with hydroxy-3- 
methylglutaryl-coenzyme A (HMG-CoA) reductase and the low-density lipoprotein 
(LDL) receptor system to minimise free cholesterol fluctuations in the cell (Szanto et al., 
1994). ACAT is an integral protein of the rough endoplasmic reticulum. The metabolic 
role of ACAT was first studied in cultured skin fibroblasts. When cholesterol uptake by 
receptor-mediated endocytosis take place, the result is that cholesterol synthesis is 
reduced and its esterification with fatty acids, catalysed by ACAT, takes place, 
accompanied by down-regulation of receptor expression and decreased synthesis of free 
cholesterol.
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5.1.4.1: Location of ACAT
ACAT has been identified in various tissues, apart from the liver. These tissues include 
the adrenal cortex (and other steroidogenic tissues); the arterial and venous tissue and 
finally, in the intestine (Suckling and Stange, 1985). Billheimer and Gillies (1990), 
concluded that the activity of ACAT in these tissues is found to vary greatly, with specific 
activities being greatest in those organs which play a major role in cholesterol 
metabolism. The tissue with the highest activity was the liver, which was similar to the 
intestine, the decreasing order was ovary, mammary gland, aorta, placenta, endometrium 
and finally, the gallbladder.
5.1.4.1.1: ACAT activity in the steroidogenic tissues
The importance of the intracellular pool of esterified cholesterol varies between steroid 
hormone-producing tissues (Suckling and Stange, 1985). Relatively little ester is found 
in the Leydig cell of the testis, while much ester is located in the adrenal cortex of the rat. 
However, measurements of the cholesteryl ester pools in such tissues is somewhat 
distorted by the presence of cholesteryl ester hydrolase. Most of the tissues referred to 
here, utilise cholesterol from lipoproteins, which is thought to be the main source for 
long term steroidogenesis, but the intracellular pool of esterified cholesterol also partakes, 
when the trophic hormone stimulates the tissue (Boyd et al., 1983). Thus, the above 
steroid-hormone producing tissues demonstrate a complex metabolism of cholesterol. 
The resulting stored cholesteryl esters in these tissues may be hydrolysed by a hormone- 
sensitive cholesteryl ester hydrolase and the mobilised free cholesterol transferred to 
mitochondria where steroid hormone synthesis is initiated (Gillett and Owen, 1992).
5.1.4.1.2: ACAT activity in the venous and arterial tissues
Cholesterol metabolism in the arterial wall is predominantly a function of three 
enzymes, ACAT, and acidic lysosomal cholesteryl ester hydrolase and a neutral 
cholesteryl ester hydrolase (Billheimer and Gillies, 1990). Other enzymes include LCAT 
and cholesterol esterase (Ross and Glomset, 1973), ACAT being the one of most 
significance, quantitatively (Billheimer and Gillies, 1990). In atherosclerosis, there is a 
documented increase in the accumulation of cholesteryl esters in the arterial wall. Some 
argue this statement, suggesting that the increase in ACAT activity and subsequent 
increase in cholesteryl ester deposition is just a consequence of the increased availability 
of cholesterol, as a substrate for ACAT. The arterial tissue is also capable of synthesising 
its own cholesterol. The activity of aortic ACAT is similar to the intestinal and liver forms 
in that it is preserved by reducing agents and inhibited by detergents (Proudlock and Day, 
1972; Morin et al., 1974).
From the order of ACAT activities in varying tissues, referred to above, it is noted that 
the activity of ACAT in arterial tissue is not very high. This may be attributed, in part, to 
the fact that ACAT, assayed microsomally, in liver preparations having high levels of 
endoplasmic reticulum, is of a high activity, whereas aortic microsomal preparations
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which are rich in plasma membrane and poor on endoplasmic reticulum, have 
significantly lower activities of the enzyme (Billheimer and Gillies, 1990).
5.1.4.1.3: ACAT activity in the intestine
ACAT is known to catalyse the esterification of cholesterol in the intestine of many 
different animals (Field and Salome, 1982) with highest activity found in the jejunum and 
proximal ileum of the small bowel (Field et al., 1982). Human and rat activities are both 
highest in this region, while rabbit intestine is of a higher ACAT activity than rat intestine 
(Devery et al., 1987). Its activity parallels cholesterol absorption in the intestine and 
suggests that the differing activities observed in various intestinal segments is due to 
substrate supply . In contrast to the esterification of dietary or lipoprotein cholesterol, 
there seems to be limited esterification of endogenously synthesised cholesterol by the 
intestinal muscosa (Billheimer and Gillies, 1990). Intervention in the adsorption of 
cholesterol by giving cholestyramine (which increases cholesterogenesis) to experimental 
rats, was shown not to have any effect on the activity of ACAT in the rat intestine (Stange 
etal., 1983). This may be due to cholesterol being preferentially used for bile acid 
synthesis.
The activity of ACAT in the intestine of 3-week old diabetic rats was reported to be 
increased with respect to controls (Jiao et al., 1988). When intestinal ACAT activity was 
suppressed by compound 58-035, there was a resulting malabsorption of cholesterol, 
both in the cholesterol-fed rabbit and in the lymph-fistula rat with a cholesterol bolus or 
infusion into the stomach or duodenum (Stange et al., 1981 and Bennett and Tercyak,
1984). In the intestine, cholesteryl esters that are formed become associated with 
chylomicrons (Burner et al., 1994). Thus, intestinal ACAT activity is actively involved in 
the esterification and in the absorption process of cholesterol.
5.1.4.1.4: ACAT activity in the liver
ACAT has been shown to be located in the rough endoplasmic reticulum (RER) 
(Reinhart etal., 1987). The lack of ACAT activity in the smooth endoplasmic reticulum 
(SER), has been suggested by Billheimer and Gillies (1990), not to be due merely to the 
loss of ribosomes since in vitro agents, which remove the ribosomes from the RER result 
in an increase in ACAT activity. The RER has less cholesterol than SER, thus ACAT 
may play a part in the biogenesis of SER and in protein synthesis by regulating the 
cholesterol levels of the RER. It is an intrinsic protein, which although it has been 
solubilised, has not been purified (Erickson et al., 1994).
Balasubramaniam et al., (1979) demonstrated, with human liver ACAT, that the 
preferred substrate was endogenous cholesterol and that exogenously added cholesterol 
was not well utilised by ACAT. Others report that ACAT, in human liver microsomes, 
can utilise exogenous cholesterol as substrate (Einarsson et al., 1989). In hepatocytes, 
cholesteryl esters synthesised by ACAT are incorporated into VLDL and secreted.
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5.1.5: Mechanism of action of ACAT
The mechanism of action of ACAT is depicted in Fig 5.5.(Gillett and Owen, 1992) 
where an acyl group is transferred to the 36-position of cholesterol, from acylcoenzyme 
A, resulting in the formation of cholesteryl ester and free coenzyme A.
Fig 5.5 Mechanism of action of ACAT
C holeste ro l C h o le s te ry l es le r
5.1.6: Substrate specificity of ACAT
Rat liver ACAT has a high degree of specificity for cholesterol. The ability of sterols 
to be esterified by ACAT declines sharply with either the reduction or extension of the 
length of the side-chain from that normally observed in cholesterol (Billheimer and 
Gillies, 1990), thereby, indicating that the side chain is very important in the binding of 
the substrate in the active site of the enzyme. This would suggest that sterols with an 
oxygenated side-chain, would not be esterified at an appreciable rate by ACAT. 
However, work carried out by Lichtenstein and Brecher, (1983) demonstrated that 25- 
hydroxycholesterol was esterified by a microsomal enzyme with properties similar to 
ACAT. Intestinal ACAT was found to esterify 25-hydroxycholesterol (Field and Mathur,
1983). Sterols with the molecular length of cholesterol, were shown to be optimal in the 
esterification by ACAT (Tavani et al., 1982). Goodman etal., (1964) found that oleoyl- 
CoA was the best substrate followed by palmitoyl-, stearoyl- and linoleoyl-CoA. A part 
of this selectivity may be due to the presence of acyl-CoA hydrolase in the microsomal 
preparations (Billheimer, 1985). The latter enzyme hydrolyse oleoyl-CoA at a rate an 
order of magnitude greater thatn its esterification (Berge, 1979).
ACAT is known to esterify precursors of cholesterol in the liver (Brady and Gaylor, 
1971). Sterols that contain a gem-dimethyl group at position CA (e.g., lanosterol) are not 
esterified by ACAT. The lack of esterification in such a case, may be attributed to steric 
hindrance produced by the positioning of the methyl groups at C-4 on the reactivity of the 
38-hydroxyl group (Tavani et al., 1982). Although these sterols were not found to be 
substrates for ACAT, they had no inhibitory effects on the enzyme. Neither the presence
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of unsaturation in the B-ring, nor the positioning of a double bond at C-5 (as in 
cholesterol) seem to be critical in the esterification by ACAT (Tavani et al., 1982). But, 
deformation of the B-ring, as is observed in 7-ketocholesterol (conjugated ketone), 
reduces the esterification of the substrate by ACAT.
5.1.7: Regulation of ACAT activity
Relatively little is known on the regulation of ACAT, due to limited information on 
such matters as the organisation of the various movements of cholesterol within the cell 
and the communication between processes taking place such as the movement of 
cholesterol that has been newly synthesised from the endoplasmic reticulum; the 
movement of exogenously derived cholesterol out from the lysosome or the transfer of 
cholesterol among various intracellular pools. (Billheimer and Gillies, 1990).
5.1.7.1: Diurnal regulation of hepatic ACAT
Recent work by Szanto et al., (1994) presents evidence for the first time that hepatic 
ACAT exhibits a characteristic low amplitude diurnal rhythm. Their work was 
inconclusive as to whether or not the diurnal rhythm was a direct result due to the 
changes in the availability of endogenous cholesterol substrate or to changes in the 
protein expression of the enzyme. This rhythm of hepatic ACAT activity showed an 
inverse relationship to that of HMG-CA reductase, under physiological conditions. 
Conflicting views argue that these rhythms may, or may not, be dependent on the cellular 
level of free cholesterol.
5.1.7.2: Substrate availability
It is believed that ACAT may not be saturated with cholesterol in the microsomal 
membrane. Experiments carried out on measuring ACAT activity, found that cholesteryl 
ester formation could be significantly increased upon addition of exogenous cholesterol. 
The supply of cholesterol, the effects of cholesterol on the enzyme itself by a possible 
allosteric machanism, the opposing effects of progesterone (Suckling and Stange, 1985) 
are also factors to be considered. Einarsson et al., (1989) concluded from experiments on 
ACAT in human liver microsomes, that the effect of freezing on ACAT activity, which 
resulted in an increase, may be attributed to the fact that the freezing procedure made 
more endogenous cholesterol available to ACAT.
The amount of cholesterol available for esterification is determined by the amount of 
cholesterol in the metabolic pool and also on the movement of this cholesterol by various 
routes. These routes include the delivery of:
Cholesterol synthesised de novo, cholesterol acquired from plasma lipoproteins, that 
from the plasma membrane and that involved in the bile acid/steroidal hormone pathways.
The endogenous pool of cholesterol may be supplemented with exogenously added 
substrate, by means of detergent or organics. The use of Triton WR-1339 was reported 
by Billheimer et al., (1981). More recently, Martin et al., (1993) used cyclodextrin
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vehicles to deliver substrates to microsomal enzym es. Such methods w ill be discussed in
5 .1 .8  
5.1.7.3: Other possible regulating factors
Lichtenstein and Brecher, (1983) found that 25-hydroxycholesterol was esterified by a 
m icrosom al enzym e (in rat liver), w hich w hen com pared to the esterification  o f  
ch olesterol, seem ed to indicate that this enzym e w as A C A T . A n oth er o xid e o f  
cholesterol, 22-hydroxycholesterol w as exam ined b y  B ates e t  al . ,  (198 3). On the 
contrary, 25-hydroxycholesterol was found to stimulate cholesterol esterification, where 
Drevon et  al., (1980) postulated that the effects o f  this oxide m ay be due to its direct 
effect on A C A T . Neither hydrophobic nor hydrophilic b ile  salts w ere found to inhibit 
A C A T  (Heuman et  al.,  1988).
The possible short-term regulation o f  A C A T  by phosphorylation/dephosphorylation 
has been documented. Suckling and Stange (1983), provided data w hich  w as consistent 
with a short-term, in vivo  regulation o f hepatic A C A T  activity, w hile w ork carried out by 
E in arsson  et  a l . ,  (198 9) w ere not in acco rd an ce  w ith  this fin d in g , as no 
activation/inactivation o f  A C A T  by phosphorylation/dephosphorylation w as observed.
5.1.8: Assay of ACAT activity
A C A T  activity, in m icrosom es, is frequently m easured b y  a radiochem ical assay in 
w hich [i4C ]oleoyl-C oA  is converted to [ i4C]cholesteryl ester. Upon com pletion o f  the 
reaction, the products are separated by means o f  T L C . R adioactivity o f  the cholesteryl 
eser is counted in a scintillation counter.
A ssays w hich involve exogenous cholesterol as substrate, suffer from  problem s such 
as incom plete know ledge o f  the extent to w hich  the exogenous cholesterol has m ixed 
w ith  the endogenous substrate. Increasing concentrations o f  fatty a c y l-C o A  in itally 
promote formation o f  cholesteryl esters but, upon reaching the plateau region, the further 
increase in the concentration o f  this fatty acid rapidly inhibit esterification (Suckling et  al.,
1985). Serum albumin is em ployed in order to m inim ise the inhibiting e ffect o f  high 
concentrations o f  o leo y l-C o A  on A C A T  activity, as this fatty acid is a detergent, w hich 
m ay disrupt the microsomal membrane.
The most com m only used assay procedure for A C A T  activity requires a [14C]-labelled 
fatty acyl coenzym e A  as substrate. The addition o f  a radiolabelled internal standard, such 
as [3H] cholesteryl ester, should be added to the assay mixture at the extraction o f  the 
products stage, to account for losses in the procedure and estim ate recovery. The 
products are then run on T L C  plates, under suitable conditions to separate cholesteryl 
ester from free cholesterol, but also from triacylglycerol- which is a potential contaminant 
(Suckling et  al.,  1985).
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A s referred to above, it is believed that A C A T  is not saturated with cholesterol in the 
m icrosom al membrane. The membrane may be dissociated with a detergent, thereby, 
allowing the addition o f  exogenous cholesterol. This procedure allows for the rem oval o f 
the constraining environment around the enzyme. The exogenous substrate may be added 
dissolved in an organic, such as acetone (Billheim er e t a l ., 1981), where no stimulation 
o f the enzym e was observed, while cholesterol, being added under the same experimental 
conditions, except suspended in Triton W R -I339 , resulted in a significant stimulation o f 
A C A T . Cholesterol m ay also be added as cholesterol-rich liposom es (Gillett and Ow en,
1992).
5.1.8.1: The use of Cyclodextrin in studies on choiesterol metabolism
Such “ carrier” m olecules o f fat soluble com pounds (e.g., vitamins and hormones) are 
frequently used to facilitate dissolution. C yclo d extrin s are cy c lic  oligosacch arid es
consisting o f  6 ,7, or 8 glucopyranose units, usu ally  referred to as a - ,  6- or %- 
cyclodextrins respectively. They are naturally occuring compounds which have relatively 
rigid doughnut-shaped structures and act as natural com plexin g agents (Sigm a). The 
overall structure o f  B -cyclodextrin  is shown in Fig 5.6. The arrangem ent o f  C6- 
hydroxyls opposite the hydrogen bonded C2- and C 3-hydroxyls forces the oxygen bonds 
into close proxim ity within the cavity. The number o f  glucopyranose units w hich make 
up the cyclodextrin determine the size o f  the hydrophobic cavity.
Fig 5.6 Structure o f  B-cyclodextrin. In hydroxyethyl B-cyclodextrin (H E B C ), some H ’ s 
o f  the O H  groups are replaced  by C H 2C H 2O H , in hydroxypropyl B -cyclodextrin  
(H PBC D ) by C H C H O H C H 3 (Sigm a information leaflet, 1995).
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The m echanism  o f  action o f  these agents is sim ple. T h e  hydrophobic m olecules are 
incorporated into the central cavity by the displacem ent o f  w ater m olecules. T h is is 
represented in Fig 5.7. The repulsion by w ater, o f  the m olecu le, results in the 
encapsulation o f  the desired molecule- rendering the m olecule water-soluble.
Both bile acids and cholesterol form com plexes w ith  nondegradable derivatives o f  
cyclodextrins (G erloczy et  a l„  1994). B-cyclodextrin has been successfu lly  em ployed in 
the solubilisation o f  m icrosom al cholesterol and also in the delivery o f  cholesterol, as
substrate, in the enzym atic study o f  Cholesterol 7 a -h y d ro x y la se  (M artin e t  a i ,  1993). 
Thus, B-cyclodextrin, due to the size o f  its ca v ity  diam eter, is suitable for use with 
molecules the size o f  hormones or vitamins (Sigm a).
Fig 5.7 Schem atic representation o f  incorporation o f  hydrophobic m olecu le and B- 
cyclodextrin  (Fig A), givin g rise to encapsulated hydrophobic m olecule in low -energy 
cavity o f  B-cyclodextrin (Fig B). The encapsulated m olecule is released w hen the water- 
soluble com plex is dissolved in a large volum e o f  free H 2O m olecules (Fig C ) (Sigm a 
information leaflet, 1995).
FIGURE A
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From  chapter three, it is noted that a substantial percentage o f  7a-hydroxycholesterol w as
found to be esterified in the serum samples examined. This is in accord w ith other reports 
(Streuli e ta l . ,  1981 and O da et  al . ,  1990). Thus, there have been studies carried out on 
the possible m echanism  o f  its esterification. Such studies and their findings w ill be 
discussed in detail in the fo llow ing chapter (chapter 6 ). Earlier w ork w as carried out on 
the possible hydroxylation o f  cholesterol esters, which indicated that this did not result in
the formation o f  7a -h yd ro x y  cholesterol esters. Thus, w ork was then carried out on the
hepatic cholesterol esterifing enzym e- A C A T . H ow ever, to date, it appears that no study
has been carried out on the possible esterification o f  7 a-hyd roxych olesterol by the
plasma cholesterol esterifing enzyme- L C A T .
In the fo llow in g  section, the partial purification o f  L C A T  from  a bo vin e source is 
described. Syn th etic substrates, resem blin g H D L s w ere synthesised, contain ing
cholesterol or 7 a-h yd roxych olestero l as substrates for the enzym e. W o rk  w as also
carried out on the microsomal enzyme- A C A T , with respect to its possible contribution to
the presence o f  esterified 7a-hydroxycholesterol in plasma. A gain , a bovine source o f
enzym e w as used. T he m ethod o f  analysis o f  7 a-hydroxych olesterol, described in
chapter 3, is utilised here also. The results o f  our findings are reported in this chapter, 
w hile the significance o f  our results w ill be discussed in the overall discussion.
Aims of “Reactivity between 7a-hydroxycholesterol and cholesterol 
acyltransferase enzymes in serum and liver”:
* T o  synthesise a suitable substrate carrier, containing 7a-hydroxycholesterol or 
cholesterol for reaction with L C A T  (lecithin-cholesterol acyltransferase)
* T o  partially purify this enzym e from  bovine plasma
* T o examine the possible reactivity o f  A C A T  (acyl CoA:cholesterol acyltransferase) 
with 7a-hydroxycholesterol
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Results
The demonstration that an appreciable amount o f  7ot-hydroxycholesterol w as esterified
in both human and rat serum prompted a study to determine the origin o f  its esterification.
The previous chapter provided evidence that serum  7 a -h yd ro x ych o lestero l m ay be
hepatic in origin. A  possible route o f  m etabolism  m ight be esterification b y  acyl C o A
cholesterol acyltransferase (A C A T ) within the liver o f  any 7a-hydroxycholesterol w hich
had escaped from the bile acid biosynthetic pathway prior to secretion into the circulation. 
A n oth er route m ay be the esterification  o f  any free sterol form  in serum  b y  
lecithin:cholesterol acyltransferase (LC A T).
In order to investigate the esterifying potential o f  the serum enzym e L C A T , a suitable 
substrate vehicle needed to be developed. Thus, proteoliposom e com plexes containing
apo A -I, lecithin and either cholesterol or 7 a-hydroxych olesterol w ere prepared and 
characterised. Furthermore, a partially purified form  o f  the enzym e, L C A T , w as deemed 
a prerequisite for any study o f  the specificity o f  this enzym e w ith respect to acyl group 
acceptors. This chapter describes progress made in the partial purification o f  L C A T  from 
bovine blood and in determining its reactivity with artificial substrates during incubations
in vitro.  The reactivity o f  hepatic A C  A T  activity towards 7a-hydroxycholesterol w ill be 
discussed later.
5.2.1 Characterisation of synthetic substrates for LCAT
5.2.1.1 Characterisation of cholesterol-containing com plexes by gel 
filtration on a Sepharose CL-4B column
In order to develop a w ell defined, standardised and e ffective  com m on artificial 
substrate proteoliposom al vesicles  contain ing apo A -I, p h osp h atid ylch olin e and 
cholesterol (including [14C]-labelled cholesterol) in the m olar ratio o f  1:10 0 :9 .1, were 
prepared by the cholate dialysis method as described in Chapter 2. A  2ml aliquot o f  this 
preparation containing 579(Xg apo A -I, 1.78 5m g phosphatidylcholine and 84.85^ig 
cholesterol w as applied to a Sepharose C L-4B  colum n (2.2 x  50cm) colum n equilibrated 
with lO m M Tris-H Cl buffer pH 7.4, containing 150m M  N aC l, Im M  NaN3 and 0.05% 
E D T A . 110 x2 m l fractions were co llected  and analysed  for protein, lecith in  and 
ch olesterol as described  in C hapter 2. G e l filtration  o f  these v e s ic le s  gave a 
predominantly single peak containing all o f  the micellar components initially introduced to 
the colum n (Fig 5.8). The elution profile show ed peaks for both phosphatidylcholine 
and cholesterol at fraction 79. H owever, although there w as a corresponding peak in the 
protein concentration at fraction 79, there w as also a second higher peak observed at 
fraction  89. T h is m ay indicate the p resence o f  a s lig h tly  sm aller secon d ary 
proteoliposom al com plex. Overall, the three components eluted over the sam e fraction 
nu m bers, in d ic a tin g  that c o m p le x e s  fo rm e d  w h ic h  co n ta in e d  apo A -I , 
phosphatidylcholine and cholesterol.
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Fig 5.8 E lu tion  p ro file  o f  apo A -I, p h o sp h a tid ylch o lin e  (P C ) and ch o lestero l 
com plexes (m olar ratio 1:100:9.1) from a Sepharose C L -4 B  (2.2 x 50cm ) colum n. 2mls 
o f  the preparation, containing 579(ig apo A -I, 1.78 5m g P C  and 84.848|ig cholesterol 
w ere applied to the colum n. The colum n was eluted w ith lOm M  Tris, 150m M  N aC l, 
Im M  N aN 3 and 0.05%  (w/v) E D T A , pH 7.4 buffer. 2m l fractions w ere co llected  at a 
flow  rate o f  0.5ml/min and assayed for protein, cholesterol and P C  as described in the 
methods. Arrow s indicate the following calibration markers:
(1) Thyroglobulin (2) Ferritin (3) Catalase and (4) B S A .
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The Stokes radius o f  the com plexes was calculated to be 58A , b y  extrapolation o f  a 
calibration plot as in Fig 5.9. A  corresponding m olecular w eight o f  approxim ately 3.71 
x  105 daltons w as determined, again by extrapolation o f  V e  from  the calibration curve, 
Fig 5.9.
5.2.1.2: Characterisation of cholesterol- and 7a-hydroxycholesterol- 
containing complexes by gradient gel electrophoresis of proteoliposomal 
com plexes
T he m icellar com plexes o f  apo A -I, p hosph atid ylch oline and cholesterol/7 a -
hydroxycholesterol, in the molar ratio 1:100:9.1 w ere analysed by electrophoresis on a 
native 3 -20%  polyacrylam ide gradient gel, (both com plex types, containing 10 nmoles 
sterol, were prepared by the sodium cholate dialysis m ethod as described in Chapter 2). 
The cholesterol containing com plexes, having passed through the Sepharose C L -4B  gel 
for analytical purposes, were reversed dialysed against PEG-8000 in order to concentrate 
them for electrophoretic studies. Such com plexes w ere run in Lane 1 (Fig 5.10). The 
protein markers- thyroglobulin (6 .6  x  105), ferritin (4.4 x  105), catalase (2.1 x  104) and 
bovine serum albumin (6.7 x  10 4) w ere run in Lane 2. F inally, com plexes containing 
7a-hydroxycholesterol were run in Lane 3. It is apparent from  the electrophoretogram
(Fig 5.10) that both o f  the proteoliposom al com plexes show ed sim ilar electrophoretic 
behaviour. T w o  electrophoretic bands o f  different intensities (Rf=0.28 and 0 .5 1 )  were 
observed in the cholesterol-containing com p lexes. T h eir m o lecu lar w eigh ts w ere 
calculated b y  means o f  a calibration curve o f  relative m obility w ith m olecular w eight o f 
each protein m arker (Fig 5.11). M olecular w eights o f  the upper and lo w er bands 
approximated 6.60 x  105 and 3.85 x  105 daltons respectively (Fig 5.11). The band o f 
higher R f  (M ol. W t., 3.85 x  105) w as the more intense. T w o bands (Rf=0.25 and 0.49) 
were also observed in the 7a-h yd ro xych olestero l-co n tain in g  com p lexes. M olecular 
w eights approxim ated 7  x  1 0 5 and 4  x  105 daltons. A s  observed in the cholesterol- 
containing com plexes, the band o f  higher R f  (M ol.W t., 4 x  105) w as the more intense.
5.2.1.3 Electron microscopy studies
Transm ission electron m icroscopy, using negative staining w ith 4 %  phosphotungstic 
acid (pH 6 .8 ) w as carried out in The Electron M icroscop y Unit, U niversity  C ollege  
Dublin. Prints o f  different fields were made using 3 fold m agnification o f  the negatives. 
The com plexes seen in Fig 5.12 are those containing apo A -I, egg phosphatidylcholine 
and cholesterol in the m olar ratio (1:10 0:9.1). The preparation o f  com plexes was quite 
dilute so only relatively few  com plexes w ere examined. It is apparent that these m icellar 
com plexes are quite heterogenous in size. A rrow s indicate diam eter sizes: 10.908nm, 
14.540nm, 18.180nm  and 25.452nm.
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Fig 5.9 Calibration curve for the measurement o f  m olecular w eight and corresponding 
Stokes radius o f  m icellar com plexes from  their elution volum e, upon passing through a 
Sepharose C L -4 B  colum n. M arkers for calibration as in F ig  5.8- parenthesis refer to 
Stokes radius).
ELUTION VOLUME 
(mis)
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Fig 5.10: A  3-20% native gradient-gel electrophoresis o f  m icellar co m p lexes. The 
markers are indicated in Lane 2 and range from 68-669 kdaltons. C om plexes stained with 
Coom assie Brillant Blue appear to be o f tw o heterogenous sizes.
Fig 5.11 Logarithm ic plot o f  m olecular w eight o f  standards versus their relative m obilty 
through a non-denaturing gradient polyacrylam ide gel (3-20%).
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Fig 5.12: Electron m icrograph o f  discoidal com plexes. D iscoidal com plexes o f  bovine 
apolipoprotein A -I, egg phosphatidylcholine and cholesterol w ere prepared using a 
m olar ratio o f  1:100: 9.09. M icroscop ic analysis w as perform ed as described in the 
experimental section. The bar represents lOOnm.
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Fig 5.13(a) and Fig 5.13(b) show com plexes o f  apo A-I, egg-phosphatidylcholine
and 7a-hydroxycholesterol in the molar ratio (1:100:9.1). Again, this preparation was as
for the cholesterol containing com plexes above. T h e d iscoidal appearance o f  the 
com plexes is m ore evident here. Fig 5.13(a) sh ow s that sligh t stackin g  o f  the 
com plexes has occured, w hile Fig 5.13(b) illustrates this stacking effect from  the side. 
T hese com plexes measure 14.54nm  in diameter by 9.09nm (side view ) and the spherical 
com plexes w ere 10.908nm, the more disc shaped com plexes being 10.908 x 18.18nm.
Thus, size heterogeneity w as also a characteristic o f  the 7 a -h y d r o x y c h o le s te r o l-
containing preparations.
5.2.2 Partial purification of lecithin:cholesterol acyltransferase
Since m ost o f  the L C A T  in plasm a has been shown to be associated w ith  the H D L  
fraction, the strategy used in the present purification (partial) was to first dissociate L C A T  
from  lipoproteins by potassium  brom ide gradient ultracentrifugation. A t  an overall 
density o f  1 .2 1 g/ml, lipoproteins float to the top o f  the tube, plasma proteins precipitate 
to the bottom  w h ile  L C A T , dissociated from  H D L , rem ains in the m iddle layer. 
Butanol/(NH4)2SC>4 treatment o f  the resulting enzym e lipoprotein fraction w as follow ed
by ion-exchange chromatography on DE-52, as described in Chapter 2. A ctivity  o f  L C A T  
w as m easured using proteoliposom al com plexes containing [i4C ]-cholesterol as the 
substrate. 30^1 o f  the proteoliposom al preparation, containing lO nm oles o f  free 
cholesterol were incubated w ith source o f  L C A T  for 30mins at 37°C. The reaction, lipid 
extraction, separation o f  [ 14lC-cholesterol and [ ^CJ-cholesterol ester and determination 
o f  radioactivity were done as described previously in Chapter 2. The rate o f  cholesterol 
esterification is g iven  as nm ole o f  cholesterol esterified/hour and unit o f  enzym e 
designates the esterification o f  ln m ol o f  unesterified cholesterol/hour at 37 0C  under the 
standard assay conditions in presence o f  apo A-I.
T he results o f  a typical procedure for the partial purification o f  L C A T  from  168ml 
bovine plasm a are sum m erised in Table 5.1. U pon ultracentrifugation o f  the density 
adjusted plasm a (5=1.21g/m l), the middle fraction contained 72 .7%  o f  the L C A T , some 
activity was also found associated w ith the low er protein layer. M ost o f  the protein w as 
found to be in the bottom  layer w hile the L C A T  enriched middle layer contained only 
about 2 .12 %  (336.8m g) o f  the total p lasm a protein (15 .8 5g).T h u s, m ost o f  the 
contam inating plasm a lipoproteins w ere rem oved in this initial purification step. A  
significant 34- fold increase in the specific activity (20.15 units/mg) was alw ays observed 
after dialysis o f  the middle ultracentrifugation fraction (d  1.21-1.25g/m l). A fter treatment 
with 1 -butanol in the presence o f  ammonium sulphate, the specific activity was increased 
alm ost 100- fold (58.14 units/mg). This step, as m ay be seen from  the S D S -P A G E  gel 
shown later (Fig 5.15) rem oves a significant amount o f  the low er m olecular w eight 
proteins.
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Figs 5.13 (a) & 5.13 (b): E lectron m icrograph o f  d isco id a l co m p lexes o f  bo vin e
apolipoprotein A -I, egg  phosphatidylcholine, 7  a-hydroxycholesterol in the m olar ratio
1:100: 9.09. M icroscop ic  analysis w as perform ed as described in the experim ental 
section. The bar represents lOOnm in both micrographs.
Fig 5.13 (a)
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Table 5.1: Partial purification o f  Lecithin-Cholesterol Acyltransferase 
from  bovine plasma.
TOTAL
PROTEIN
(mg)
TOTAL
ACTIVITY
(units*)
SPECIFIC
ACTIVITY
YIELD
(%)
PURIFICATION
FOLD
BOVINE
PLASMA
(168ml)
15854.84 9332.4 0.588
d 1.21-1.25 
(g/ml)
336.78 6785.8 20.15 72.7 34.27
(NH4)2 S 0 4 70.57 4102.94 58.14 43.96 98.88
DE-52 11.06 4067.76 367.79 43.59 625.49
* One unit of enzyme activity catalysed the esterification of lnmole
unesterified cholesterol per hour at 37°C with bovine apolipoprotein A-I, 
egg phosphatidylcholine and cholesterol complexes as substrate.
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The final step carried out in the partial purification  o f  the enzym e in volved  the 
application o f  the dialysed ammonium sulphate fraction to an anion exchange column, 
DE-52. The fraction w as dialysed against lO m M  T ris-H C l, pH 7.6  containing 5m M  
E D T A  and 50mM N aC l, w hich was the buffer used for the equilibration o f  the DE-52 
resin. W hen the dialysed ammonium fraction w as applied to the colum n, approximately 
84% o f proteins w ere rem oved Fig 5.14 show s the elution  p ro file  o f  this step, 
indicating the fractions that w ere to be pooled. T hree activ ity  peaks w ere observed 
corresponding to elutions at salt concentrations o f  110 , 135 and 158 m M  N aC l. It is 
apparent that D E-52 chromatography did not change the enzym e yield. A ll o f  the enzyme 
activity that was applied was recovered in 3 peaks o f  activity in 26 fractions (Fig 5.14). 
The final L C A T  preparation, having a sp ecific activity  o f  368 units/mg w as purified 
approximately 625- fold, with 44% yield.
A liquots o f  the various purification stages w ere analysed b y  S D S -P A G E  under 
reducing conditions (Fig 5.15). Lane 1 (left) indicates the positions o f  the markers, 
w hich range from  32 kD al to 195 kDal. Lane 2 shows the electrophoretic pattern o f  raw 
plasma. Lane 3 shows the pattern for the dialysate o f  the middle fraction obtained from 
the ultracentrifugation step, while lane 4 shows the ammonium sulphate fraction and lane 
5 the concentrated D E-52 fraction. A ll o f  these protein samples contained approximately 
lOfig protein per w ell, except for the DE-52 fraction w hich contained approxim ately 8(ig 
protein. The final lane on the right is that o f  the D E-52 fraction. Here, four distinct bands 
and also a fifth  w eaker band were visible. R eference to the m igration o f  the S D S -7B  
prestained m olecular w eight markers (Sigm a) indicated the fo llow in g M r values: 33.5, 
36, 47 and 62.5 kDals.
5.2.3 Kinetic studies of partially purified LCAT
A  time course o f  L C A T  activity in the presence o f  lOnmoles o f  proteoliposom al [14]C- 
cholesterol and 40, 75  and 100p.l partially purified enzym e is shown in Fig 5.16/Table 
5.2. W ith all three enzym e concentrations exam ined, L C A T  activity  w as linear with 
repect to time, up to 60 minutes. A pproxim ately 2 1%  cholesterol w as esterified in the 
presence o f  40|il enzym e after 60 min incubation. This how ever increased to 38% and 
46%  when 75|il and 100|j.l enzym e w ere assayed for 60 min respectively. Data for time 
courses carried out with 40fil, 75(il and 100(il are presented in Table 5.2.
It is apparent that enzym e activity w as also proportional to enzym e concentration. Fig 
5.17 demonstrates the dependence o f  enzym e activity on enzym e concentration. Reaction 
o f  100|ll enzyme with substrate for 30min resulted in approximately 26% esterification.
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Fig 5.14: DE-52 chromatography o f  butanol-am m onium  sulphate fraction. The enzym e 
fraction w as applied to a D E -52 colum n (2.5x6.Ocm), equilibrated w ith  lO m M  Tris, 
5m M  E D T A  and 50mM N aC l, pH 7.6. A fter the sam ple w as applied, the colum n was 
eluted with a gradient o f  75m M  to 200mM N aC l. F lo w  rate w as 1.0ml per minute and 
2 ml fractions were collected.
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Fig 5.15: 7 .5 %  S D S -P A G E  gel d em onstrating the various steps in the partial 
purification o f  L C A T , from  bovine plasma. M olecular weight markers, ranging from  32- 
195kD al are shown in Lane 1. The various stages o f  the sam ple preparation are as 
described in Chapter 2. The low er gel shows a clearer version o f  the (NH4)2S04 step.
kD al
Lane 1 2 3 4 5
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Fig 5.16 /  Table 5.2 Time course assay (10-60 min) for varying LCAT
concentrations (40-100|_ll) in the esterification of cholesterol.
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Table 5.2
Enzym e
(^ )
Tim e
(min)
nmoles
est./hr
%CHO
est/hr
1 0 0.369 3.69
40 30 1.003 10.03
60 2.105 21.05
1 0 0.651 6.51
75 30 1.879 18.79
60 3.813 38.13
1 0 0.857 8.57
1 0 0 30 2.615 26.15
60 4.624 46.24
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Fig 5.17 Plot o f  enzym e activity as a function o f  enzym e concentration, at varying times 
(10-60min). Reaction conditions as described in Chapter 2.
ENZYME ALIQUOT (fxl)
5 . 2 . 4  Reactivity of partially purified LCAT with micellar complexes 
containing cholesterol and 7a-hydroxycholesterol
H aving demonstrated interaction o f  partially purified bovine L C A T  w ith cholesterol- 
containing p roteoliposom es, its reactiv ity  w ith 7 a -h y d ro x y ch o le ste ro l w as next 
exam ined. H ow ever, due to the fact that there there w as no com m ercially  available 
radiolabelled 7 a -h y d ro x y ch o le ste ro l and also due to d ifficu lties  in its synthesis 
(examined in the discussion later) the method o f product analysis w as different to that for 
the radiolabelled cholesterol containing com plexes. Thus, the sam ple preparation and 
analysis b y  H P L C , as described in Chapter 2, is em ployed in this analysis, i .e . ,  
incubation, lip id  extraction, alkaline h ydrolysis, sterol extraction, reaction  w ith  
cholesterol oxidase and H P LC  analysis.
A n  aliquot (30^1) o f  the d isco id a l co m p lexes, co n tain in g  lO n m oles 7 a -  
hydroxycholesterol w as incubated w ith  100|il aliquot o f  enzym e. T L C  w as used to 
separate and compare the products obtained upon reaction o f  the enzym e source with the 
tw o different substrate com plexes. Fig 5.18 is a diagram m atic representation o f  the 
T L C  chromatogram show ing products o f  each reaction. Lane 1 contains the products o f  
the reaction with cholesterol com plexes, w hile Lane 2 shows the products o f  the reaction
with 7a-hydroxycholesterol-containing complexes. T w o distinctive bands w ere observed 
in Lane 1 with R f  values o f  0.26 and 93. These correspond w ith the relative partitioning 
o f  the cholesteryl oleate and the free cholesterol standards in Lanes 3 and 4 respectively. 
A  contam inating band corresponding to cholesterol is also observed in Lane 3. Lane 2 
shows the presence o f  tw o bands, one with an R f value (0.27) sim ilar to ch o lestero l, the 
other with a slightly higher R f  o f  0.32, indicating a less polar structure.
It w as decided to run duplicates o f  the described assays- one set w hich were analysed 
b y  T L C - the others run by H P LC , as described in Chapter 2. This was to account for the
possibility that the R f o f  esterified 7 a-hydroxycholesterol m ay have been higher and that 
such a band m ay not have been visible with the iodine staining method o f  visualisation. 
Table 5.3 demonstrates results obtained when the reactivity  o f  L C A T  towards 7 a -  
h yd ro xych o lestero l and ch olestero l w as com pared. B o th  reaction s sh ow ed  the 
esterification  poten tial o f  L C A T : 5.6  nm oles ch olestero l ester/assay and 3 .54  
nm oles/assay. S p ecific  activ ity  o f  L C A T  towards cholesterol (354.93nm oles/hr/m g
protein) w as observed to be 1.6- fo ld  higher than that towards 7a -h yd ro x ych o lestero l
(224.36nmoles/hr/mg protein). It is apparent from this study that 7 a-hydroxycholesterol 
can, like cholesterol, serve as an acyl acceptor for the transacylation reaction catalysed by 
L C A T .
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Fig 5.18 A  schematic representation o f  a T .L .C . plate indicating positions o f  products 
obtained upon L C A T  reacting w ith  discoidal co m p lexes contain ing a) 10 nm oles
cholesterol (Lane 1) b) lOnm oles 7a-h yd roxych olesterol (Lane 2) as substrate for the
enzyme.
Lane 3: Cholesteryl oleate standard. Lane 4: Cholesterol standard.
M obile phase: Petroleum ether : Diethyl ether : A cetic acid (76 : 20 : 1 ) (v : v: v)
SOLVENT
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obtained when m easuring the activity o f  L C A T  using 10 nm oles cholesterol / 7  a -  
h ydroxycholesterol discoidal com plexes as substrates. A n alysis  w as carried  out by 
reverse-phase H P L C  and values tabulated below  are the corresponding concentrations 
(nmoles) obtained by extrapolation from the standard curves in Chapter 3.
Table 5.3: Typical values of free and esterified cholesterol / 7a-hydroxycholesterol
SUBSTRATE 
FOR LCAT
NMOLES/
ASSAY
FREE
(nmol/
hr/
1 0 0 ^1)
ESTERIFIED
(nmol/
hr/
lOOul)
NMOLES 
ESTERIFIED 
/HR 
/MG PROTEIN
CHOLESTEROL 1 0 . 0 0 4.40 5.60 354.93
7a-HYDROXY-
CHOLESTEROL 1 0 . 0 0 6.46 3.54 224.36
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5 .2 .5  R ea ctiv ity  o f 7a -h yd roxych olestero l with acyl-coenzym e  
A:cholesterol acyltransferase (ACAT)
T he final experim ent in this project was to determine i f  7 a-hydroxycholesterol could 
serve as acyl acceptor for A C A T , the liver m icrosom al enzym e that regulates cholesterol 
esterification. 100(0.1 aliquots o f  microsom al fraction o f  bovine liver containing 3.42|_ig 
cholesterol, prepared as described in Chapter 2, were treated for varying lengths o f  time 
w iith  2-hydroxypropyl-B -cyclodextrin  (final concentration 30m M ) to unsaturate or 
desaturate the enzym e o f  endogenous cholesterol. Fig 5.19 show s the extent o f  
cholesterol rem oval using cyclodextrin after 45 min and after 90 min. Concentration o f  
cholesterol in the m icrosom al fraction after 45 min w as 25.6fig/ml (27.24% ) depletion, 
w hile after a further 45 min it was reduced to 5.5|ig/ml (overall depletion o f  84.21% ).
A n  aliquot o f  this fraction  w as incubated  w ith  va ryin g  am ounts o f  7 a -
hydroxycholesterol and 25 nmoles o f  [14C] oleoyl C o  A  as second substrate and assayed 
for esterifcation as described in the methods chapter. The products o f  the reaction o f the
A C A T  source (alm ost totally  depleted o f  ch olestero l) w ith  24 nm oles o f  7  a -  
hydroxycholesterol as substrate, are depicted in the diagram m atic representation o f  the 
T L C  chromatogram, in Fig 5.20. Lane 1 depicts the presence o f  one band (R f 0 .541) 
for cholesterol oleate, w hile Lane 2 has a band at an R f  o f  0 .113 , the location o f  the 
cholesterol standard. Lane 3 depicts five  bands w h ich  were subsequently scraped and
analysed  by H P L C  for ch olesterol and 7 a -h y d r o x y c h o le s te r o l as w e ll as fo r
radioactivity. The bulk o f  the 7 a-hydroxycholesterol w as found in the bands w ith  R f  
0 .113  and 0.308. The higher R f  o f  the latter w as presumed to indicate the presence o f  the 
more non-polar 7a-hydroxycholesterol oleate species. The strongest band, intensity-wise 
on the T L C  plate, w as that o f  R f 0.233, w hich on H P L C  analysis w as show n to contain 
cholesterol. The proportion o f  cholesterol contam inating, the R f  0 .113  (0.59%  o f  total 
cholesterol present) and R f  0.308 (30% total cholesterol) bands suggest the inability o f  
the cyclodextrin to com pletely solubilise the cholesterol. R adioactivity analysis o f  the 
reaction products indicated a predominantly rich [ 14]C  band at R f  0.233. This band m ay 
be that o f  unreacted oleoyl C oA .
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Fig 5.19 Effect o f  incubation o f 2-H PBCD  w ith bovine microsom al preparation, in the 
depletion/solubilisation o f  cholesterol. 0.1m l o f  m icrosom al preparation, containing 3.42 
fig  ch olestero l and 150 fig  protein w as in cu b ated  w ith  b u ffe r  co n ta in in g  2- 
hydroxypropyl-G -cyclodextrin. M ixture w as incubated at 37°C  for 45 mins per cycle . 
A fter two depletion cycles were carried out, 84.21%  cholesterol w as solubilised.
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Fig 5.20: Schematic representation of a T.L.C. plate, indicating Rf values of products 
obtained upon reacting AC AT source with 7a-OHCHO 
Lane 1: Cholesteryl oleate. Lane 2: Cholesterol standard.
Lane 3: Sample of ACAT reacted with 7a-OHCHO.
Mobile phase: Hexane : Ethyl acetate (95 : 5) (v : v)
HpLC 
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Fig 5.21 shows that ACAT activity was proportional to the concentration of 7 a- 
hydroxycholesterol used as co-substrate. Radioactivity analysis of product bands formed 
after incubation of 4, 8 , 12 and 24 nmoles of 7a-hydroxycholesterol with ACAT source
demonstrated a linear increase in the concentration of 7a-hydroxycholesterol oleate 
formed up to a concentration of approximately 8  nmoles; Vmax was seen to be approached 
at a substrate concentration of 24nmoles/assay.
Thus it would appear that ACAT esterified a proportion of the 7a-hydroxycholesterol 
in this study. Under the given reaction conditions was esterified, the specific activity of 
bovine hepatic microsomal ACAT, towards 7a-hydroxycholesterol was 736.12 
pmoles/min/mg protein. Thus, it is apparent that there was an approximate 5-fold lower 
esterification of 7a-hydroxycholesterol by ACAT relative to its esterification by LCAT.
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nm oles) against the num ber o f  pm oles o f  7 a-hydroxycholesterol esterified/m inAng 
protein, upon incubation with A C A T  source (bovine m icrosom es depleted o f  82%  o f  
endogenous cholesterol). Methods as in Chapter 2.
Fig 5.21 Plot of varying concentrations of 7a-hydroxycholesterol (4, 8, 12 and 24
800
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Discussion
In general, the concentration o f  cholesteryl esters is greatest in serum and in those 
tissues (liver, intestine, adrenal and ovary) w hich play a major role in the anabolism  and 
catabolism  o f  cholesterol (D ’H ollander and C h evallier, 1969). T hese organs (liver, 
adrenal and the ovary) are also found to have the highest concentration o f  L D L  receptors. 
Large amounts o f  cholesteryl ester are known to accumulate in certain tissues as a result 
o f  lipid m etabolism, such as atherosclerosis. Cholesteryl ester formation m ay play a role 
in a number o f  pathological conditions, most notably coronary heart disease (C H D ). This 
disease involves the accumulation o f  lipids-particulary free cholesterol and cholesterol 
ester, in and betw een the vascular bed (Fielding and Fielding, 1985). The ester form  
seems to initally accum ulate in macrophages which, in turn invade the arterial w all to 
scavenge lipid and other cellular debris (Gerrity, 1981). The end result is that cells take 
up large amounts o f  free cholesterol, due to a poorly regulated receptor w hich recognises 
m odified L D L , thereby resulting in the increase o f  cholesteryl ester synthesis by as much 
as 100-fold (Brow n and Goldstein, 1983).
Lecithin:cholesterol acyltransferase (L C A T , E C  2.3.1.43) is an enzym e synthesised in 
the liver, secreted into and acts in the plasma, catalyses the synthesis o f  cholesteryl esters 
and lyso lecith in  from  lipoprotein lecithin and free cholesterol. The p h ysio lo gica l 
consequences o f  this reaction are profound and are illustrated by the pathological changes 
seen in m edical cases where there is a fam ilial deficiency o f  the enzym e (G lom set e t a l . ,  
1983). In such patients as those that are deficient in the enzym e, there is an elevation in 
the level o f  free cholesterol at the expense o f esterified cholesterol. Glom set et  al. ,  (1983) 
reported that there is a predeposition towards premature atherosclerosis in these subjects 
and that there is also an accumulation o f  free cholesterol and phospholipids in different 
tissues. N orum  e t  al.,  (19 7 1) reported that in fam ilial L C A T  deficiency, there are very 
low  levels o f  H D Ls present, w hich are m ostly as discoidal nascent particles devoid  o f  
cholesteryl esters. Thus, studies on L C A T  are deemed to be o f  importance in the study o f 
lipid metabolism.
The study undertaken here, in Chapter 5, involves m easuring the activity  o f  L C A T
toward a m etabolite o f  cholesterol- 7a-h yd roxych olesterol. Previous w ork has been
carried out on the m easurement o f  L C A T  activity toward cholesterol (Fielding and 
Fielding, 19 7 1, D oi and N ishida, 1981). Due to the heterogenity, both chem ically  and 
physically, o f  native high density lipoprotein particles, it has been deem ed necessary to 
rely on more chem ically and physically defined synthetic substrates to investigate the 
reaction between L C A T  and varying substrates.
A s  referred to in the introduction (Chapter 5), there are different types o f  synthetic 
substrates. T he m ain com ponents for m ost reconstituted substrates are purified  
apolipoproteins, synthetic or natural phosphatidylcholines and free cholesterol (Jonas, 
1986b). The type used in these experim ents described here are defined as m icellar,
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discoidal com plexes and were synthesised using the sodium -cholate method as decribed 
by Jonas (1986a). These com plexes, as opposed to vesicles, are reported to be devoid o f  
an internal aqueous com partm ent (Jonas, 1986b). Jonas (1986b) reported that a 
noteworthy difference between vesicles and discoidal com plexes o f  sim ilar composition 
is the discoidal com plexes (egg P C  com plexes) are about 4- fold better substrates for 
L C A T  than the vesicular counterparts. This m ay be due to the fact that there is a higher 
content o f  bound apo A -I in the m icellar com plexes than in the corresponding vesicles. 
Thereby, apo A -I m ay adopt a confirm ation that m akes it a better activator o f  the L C A T  
reaction when present in m icellar com plexes as opposed to being bound to vesicles. The 
com plexes are also capable o f  storing large amounts o f  cholesteryl esters formed: at least 
20 m ole % o f the particle lipid, w hile the vesicle lipid can store 3 m ole % (M atz and 
Jonas, 1982a).They are also reported to be o f  sim ilar size and density o f  H D L  (Jonas, 
1986a). Such com plexes were synthesised using the sodium -cholate d ialysis method 
(Jonas, 1986a). This method allows the incorporation o f  a large variety o f  phospholipids 
into discoidal, H DL-like particles.
Initally, discoidal com plexes w ere synthesised here w hich  contained cholesterol as 
substrate for the L C A T  enzyme. This method w as selected to use for such a synthesis, as 
the kinetic b lock  in the spontaneous reaction o f  p hosphatidylcholine vesicles w ith 
apolipoproteins can be bypassed using com plexes prepared b y  the sodium -cholate 
diaylsis method. This kinetic block occurs as the vesicle bilayer form ed in the initial step 
o f  synthesis must be disrupted in order to allow  the apo A -I to penetrate the structure. 
Thus it w as necessary to w ork strictly at temperatures close  to the T c (gel to liquid-
crystalline phase transition temperature) o f  the lipid (phosphatidylcholine- 40C). Some 
vesicu lar lipid preparations, upon exposure to apo A -I at or above the T c> can be 
transformed into micellar com plexes (Jonas et al., 1980).
The m olar ratios chosen to w ork w ith, being apo A -I, phosphatidylcholine and 
cholesterol, (1:100:9.1), were selected for the follow ing reason- reports show that native 
H D L  are the best substrates for L C A T  (G lom set, 1972), second to these are sm all 
spherical H D L  and then larger H D L  subclasses. The com plexes synthesised here had 
morphological similarities to native H D L. Highest yields o f  m icellar com plexes (Matz and 
Jonas, 1982b), are obtained at cholesterol contents o f  less than 20 m ol%  and at 
incubation temperatures approaching the transition temperature o f  the corresponding 
phosphotid ylcholine, w here ch olesterol m ole%  g iv e s  the num ber o f  ch olesterol 
molecules/100 lipid molecules (Phosphatidylcholine + cholesterol).
Little information is available on the difference between the disc and sphere as regards 
reactivity  w ith L C A T  (Jonas, 19 9 1). N ative spherical (M arcel e t  a l . ,  1980) and 
reconstituted spherical H D L (Jonas e t a l . ,  1990) are considerably less reactive w ith 
L C A T  than the discoidal H D L particles.
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Jonas (1991) suggests that as regards the native particles, the changes in apolipoprotein 
conformation, changes in com position and packing o f  the surface lipids m ay result in a 
decrease in the reactivity with L C A T . Thus by synthesising com plexes in the specified 
m olar ratio the resultant com plexes w ould be relatively sm all in size, thus ressem bling 
native H D Ls in some respects.
T he com plexes synthesised here w ere analysed by gel filtration, gradient ge l 
electrophoresis and electron m icroscopy. A  com bination o f  these three analytical tools 
seems to indicate that the com plexes containing cholesterol, w ere approxim ately 3.71 x  
105 daltons in m olecular w eight and w ith a Stokes radius o f  58A . Further analysis by 
electron m icroscopy revealed they measured approximately 10.908nm in diameter. Thus 
the values obtained for the diameter from  the different means o f  m easurem ent are in 
agreem ent. T hese studies show  that the com p lexes form ed w ere fu lly  associated  
stru ctu res m ade up o f  the three co m p o n en ts apo A - I , c h o le s te r o l and 
phosphatidylcholine. These measurements w ould result in the com plexes being classified 
as “ small discs” , w hich Jonas (1986b) groups as discs having m olecular w eights in the 
range from 1 0 5 to 4 x  105, axial ratios o f  2/1 to 3/1, diametres from  1 0 0  to 140A  and the 
thickness o f  a lipid bilayer. Large discs, on the other hand, have m olecular w eights -1 0 6 , 
axial ratios -4/1 or larger and diametres around 200A.
Others obtained com plexes measuring 123.4 ± 5.1 A  for the apparent vesicle radius, for 
com plexes comprised o f  apo A-I: lecithin: cholesterol in the molar ratio o f  0.8: 250: 12.5 
(Chen and Albers, 1982). Com plexes w ith P O P C  (palm itoyloleoyl phosphatidylcholine), 
cholesterol and apo A -I in m olar ratios o f  80:8.1:80, yie lded  four d ifferently  sized  
products o f  77 , 8 6 , 96 and 109A  (Jonas e t  a l . ,  1989). Such  d isco id al com p lexes 
resem ble very closely  the discoidal nascent H D L  in physical and chem ical properties. 
T hey are remarkably stable entities (Jonas, 1986b). The selected ratios w orked w ith here 
(1:10 0 :9.1; apo A-I:phosphatidylcholine:cholesterol) w ere manipulated in terms o f  the 
ratio o f  phosphatidylcholine:apolipoprotein A-I, in order to alter the size o f  the complex.
The elution profile obtained by passing the com plex mixture over the Sepharose C L -4B  
colum n indicated that there w as a possibility that the preparation w as not hom ogenous, 
which was later confirmed by running the preparation on a native gradient polyacrylam ide 
gel and also by electron m icroscopy. The com plex peaks obtained are occasionally broad 
and often the protein and lipid elutions do not coincide exactly, indicating the presence o f  
chem ical and size heterogeneity in the com plexes (Jonas, 1986a). Contaminants include 
apolipoprotein D. This glycoprotein is found in the V H D L  fraction but is also a consistent 
constituent o f  H D L3. Both H D L 3 and V H D L  are good substrates for L C A T  (Fielding and
Fielding, 1971).
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Thus, these methods for synthesising and characterising such described complexes are 
suitable for the present study. Native HDL particles of humans and animals, which have 
been isolated between densities of 1.063 and 1.210 g/ml have the characteristic discoidal 
make-up diametres of about 130 to 240 A and widths from 40 to 50 A (Jonas, 1986b). 
The cholesterol containing complexes described here had diametres of approximately 112 
A, falling in the lower end of the size scale reported for native HDL.
Having synthesised the required complexes, the enzyme lecithin:cholesterol 
acyltransferase (LCAT) was partially purified prior to reaction with the substrates. The 
reason for the partial purification was to attempt to remove possible major interferring 
compounds such as LDLs, which may, with cholesteryl ester acyl transfer protein, 
further metabolise the product- cholesteryl ester. However, there are still uncertainties of 
a direct association between LCAT and CETP while it has been shown that both are 
involved in the metabolism of plasma lipoproteins and act on HDLs. Nishida et al.,
(1990) found that the lipid transfer activity of CETP was enhanced upon reaction of 
CETP, LCAT and vesicles of apo A-I and egg-PC or with HDL 3 . When discoidal rHDL 
or HDL2 were reacted with LCAT, they did not find that this was the case.
Some workers have reacted plasma as a crude LCAT source, with the substrate 
cholesterol (Chen and Albers, 1982), while others have used a fully purified source 
(Steinmetz and Utermann, 1985). The various steps in the partial purification resulted in 
an overall purification fold of 625.49 and a yield of 43.59% (Table 2.1). The first step 
involved ultracentrifugal centrifugation after adjusting the density to 1 . 2 1  g/ml with solid 
KBr. KBr and NaBr (or a combination of these salts) are routinely used for high-density 
isolations while NaCl is used for low-density work (Beckman, 1989).
Salt, for adjusting the density of the plasma, may be added as a solution or as a solid. 
The latter was selected here as minimal dilution of the sample was required. However, if 
a solution of the salt was to be added, it would generally be added in the ratio of 1 or 2  
volumes of salt solution to 1 of plasma (Mills et al., 1984). The method was tedious as 
the salt was added slowly with continuous stirring. The density of the plasma was 
checked using a density meter. Although expensive, the instrument has the merit that it 
can determine the density of a solution (minimum of 2ml) to 1.999 g.cm-3 with an 
accuracy of ±1x10-3 very rapidly.
The time of centrifugation was 30 hours. As a large proportion of the HDL has an 
apparent flotation rate of less than 3.5 Svedbergs, a long centrifugation is necessary if a 
good recovery of this fraction is to be obtained (Mills et al., 1984). This long time for 
centrifugation also is required if the upper half of the tube is to be adequately cleared of 
protein (Plasma albumin has a significantly reduced sedimentation rate in the presence of 
a highly dense and highly viscous solvent). The reason that this fraction was selected to
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w ork with is that L C A T  in plasm a is m ostly associated w ith high-density lipoproteins 
(1.063 < d  < 1.21 g/ml) and very high density lipoproteins (1 .2 1  < 5 < 1.25 g/ml), 
(Akanum a and G lom set, 1968; Fielding and Fielding, 1971), thus the region obtained 
from  the ultracentrifugation step d =  1 .2 1-1.2 5  g/ml (V H D L ) contained most o f  the 
plasma enzyme activity and only a fraction o f  the total protein.
The next step resulted in a further increase in purification- the am m onium  sulphate 
precipitation in the presence o f  butanol. This step has been reported to reduce the amount 
o f  contam inating protein in the interfacial precipitate wiithout altering the enzym e yield 
and the the addition o f  sucrose also stabilises the enzym e (D oi and Nishida, 1981).
The final step- ion exchange chromatography on D E -52 anion exchange resin resulted 
in an overall purification o f  625.49 fold. The enzym e activity peaks obtained indicate that 
the protein was eluted o ff  at a salt concentration between 1 10-158m M . Previous findings 
for the elution o f  L C A T  by  means o f  a salt gradient include 160m M  N a C l (human 
plasma; D oi and N ishida (1981)), approx. 170 -183m M  N aC l (human plasma; Steinm etz 
and Utermann, (1985)), 120m M  N aC l eluted enzym e w hich w as then subjected to a 
further gradient o f  60-120mM  N aC l (M ahadevan and Soloff, 1983) and finally Jauhianen 
and Dolphin, (1986) found that L C A T  eluted from  a D E A E  colum n betw een 130 and 
150m M  N aC l. Chen and Albers, (1985) purified L C A T  from  different animal species 
including pigs, dogs, goats and rabbits. U pon passing the enzym e fraction through 
D E A E -S ep h aro se  C L -4 B , they found the en zym e a ctiv ity  to elute at an N a C l 
concentration o f  approx. 120-160m M , w hile their earlier w ork on human L C A T  (198 1) 
resulted in an enzym e elution at a N aC l concentration o f  approximately 95-164m M .
Discrepencies in the m olecular w eight o f  L C A T  are reported. Chung et  al.,  (1979) and 
Chong etal., (1983) recorded human L C A T  to be a 60,000 m olecular w eight, single 
polypeptide chain glycoprotein, containing 25%  by w eight carbohydrate. Albers et al ., 
(1976) characterised it as a protein with an apparent m olecular w eight o f  68,000±1,600 
(human source), w hich was similar to 65,000 to 69,000 b y  D oi and N ishida (1981). Pig, 
dog, goat and rabbit L C A T  w ere found to be 66,000:65,000:65,000 and 67,000 
respectively by Chen and A lbers, (1985). M ahadevan (1983) 66,000+2,000 for human 
L C A T . M atz and Jonas (1982a) purified human L C A T  o f  M r = 60,000+4,000.
One o f  the bands obtained in the present study appears to be o f  an approxim ate 
m olecular w eight o f  62,500 daltons. This band m ay be that o f  L C A T . There is also 
another band corresponding to the m olecular w eight o f  47,000 daltons. This m ay be a 
contaminating enzym e- Cholesteryl ester transfer protein (C E T P ), which has a reported 
w eight o f  41,000 (Tall et al., 1983), w hile Hasler et al., (1988) reported it to be o f  a 74  
K dal glycoprotein. In addition, free apolipoproteins and serum am yloid m ay be present 
as proteins o f  molecular w eights o f  less than 45 Kdal.
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Phospholipid tranfer protein (PTP) is another lip id  transfer protein, w h ich  is 
temperature-sensitive with reported apparent m olecular weights ranging between 41,000 
and 75,000 (Tall et  a l . ,  (1983), T ollefson et  al. ,  (1988) and Jauhiainen e t  al. ,  (1993)). 
Interspecies com parisons demonstrated that some species, am ong them rat and mouse, 
lack  the cholesteryl ester and triglyceride transfer activ ities but not the facilitated  
phospholipid transfer activity (Ha and Barter, 1982; Ihm and H arm ony, 1980). Both 
C E T P  and PTP are also present in the 3> 1.21 g/ml infranatant (Lagrost e t  al . ,  1994), 
w hose results showed that L C A T  was separated from  the tw o lipid transfer enzym es 
upon passing the m ixture over a coupled H eparin-U ltragel/B Iue-Trisacryl colum n. 
Groener et  al . ,  (1984) detected most o f C E T P  activity in the H D L 3 fraction (1 .12 5  < d <
1 .2 1 0  g/ml).
Such proteins, i f  actively present in experiments containing varying lipoproteins, could 
transfer phosphatidylcholine between H D L and L D L  (CE TP), as C E T P  is involved in the 
transport o f  cholesteryl ester from H D L  to V L D L  and L D L . Thus, the products o f  the
L C A T  reaction, being esterified cholesterol or esterified 7a-h yd ro xych olestero l, m ay 
when within the discoidal com plex, react further w ith C E T P  to transfer the product to 
L D L  and V L D L . Thus, in the present study the ultracentrifugation step w as undertaken in 
an attempt to elim inate som e o f the lipoproteins from  the study. T he D E -52 anion- 
ex ch an ge  resin w as em p lo yed  in order to rem o ve further p rotein s, such as 
apolipoproteins, as reported b y  Chen and Albers (1985), who also reported that D E A E - 
Sepharose chrom atography separated L C A T  from  lip id  transfer protein activity, the 
former being eluted at a salt concentration o f  approximately 120-160m M , the latter at salt 
concentrations below  115m M . The band obtained on the gel (Fig 5.15) corresponding 
to approxim ately 33.5 K d al m ay be sim ilar to that (33.0 K dal) reported by D o i and 
Nishida (1981) and shown to be a contaminating protein w hich w as rem oved b y  passing 
the fraction over a second D EAE-Sephadex column.
The assay conditions selected to w ork under seem ed to be suitable for the assay o f  
L C A T  activity. The reaction time and amount o f  enzym e used a llo w ed  for a linear 
transformation and approxim ately 26%  esterification o f  substrate in 30 mins. H ow ever, 
with increasing concentrations o f  enzym e, the plot becam e more non-linear.This m ay be 
due to the reaction approaching enzym e saturation. The discs synthesised here contained 
approxim ately 4.35 m ol%  cholesterol. Perhaps further esterification m ay have taken 
place i f  there was a higher m ol%  substrate, as M atz and Jonas (1982a) found that when 
discoidal com plexes o f  egg P C  and apo A-I, containing 20 m ol%  cholesterol were reacted 
with L C A T , alm ost com plete transformation (90%) o f  cholesterol to cholesteryl ester 
took place. Such m icellar com plexes consisted o f  apo A -I:P C :C holesterol (1:23.8:94.4; 
M olar ratio). M atz and Jonas (1982a) also reported that beyond 20-30 m ol%  cholesterol 
content, the reaction decreased markedly.
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The final step resulted in a specific activity  o f  367.79 units. R eacting this L C A T  
source with lOnmoles cholesterol under the conditions specified  resulted in 5.6nm oles 
cholesterol being esterified in 30mins. The K m value for L C A T  towards cholesterol or
7a-h yd ro xych olestero l were not determ ined due to the expense o f  synthesising the 
micellar complexes.
Human plasma L C A T  activity (results not tabulated) towards the com plexes containing 
cholesterol as substrate show that an average o f  62.83nm oles ch olesterol w ere 
esterified/hr/ml plasma. Such values are difficu lt to com pare with other w ork, as L C A T  
activity m ay be measured using either an exogenous (proteoliposom e substrate) assay or 
measuring the cholesterol esterification rate where endogenous cholesterol is converted to 
cholesterol ester. E ven  within these two d ivision s, m any variations appear. L C A T  
activity in control human plasma, as measured by the exogenous method, w as found to 
be 95nmoles/hr/ml p lasm a (Chen and A lb ers, 1985), 122 nmoles/hr/ml plasm a 
(Franceschini et  al.,  1990) and 30 nmoles/hr/ml plasm a (Funke e ta l . ,  1991).
Under the same conditions, 7 a-hydroxycholesterol was reacted with the L C A T  source, 
yielding three noteworthy points:
*Firstly, that 3.54 m oles o f  7 cc-hydroxycholesterol w ere esterified by L C A T  (after 
incubation o f  10 nmoles/reaction). This is com parable w ith the 5.60 nm oles o f  the 10 
nmoles cholesterol w hich were esterified.
^Secondly, the discoidal com plexes synthesised by the sodium-cholate method, using the 
selected molar ratios, were suitable models for such a study.
*Finally, the developed method o f  analysis described in Chapter 2 proved to a valuble 
analytical tool, as the 7 a -h yd ro x ych o le ste ro l used in these experim ents w as not 
radiolabelled, thus a different method for product analysis had to be employed.
The procedure for synthesising radiolabelled 7 a-hydroxycholesterol w ould be difficult
as it may not be possible to label com m ercially available 7  a-hydroxycholesterol, because
the m olecule is labile and could possibly be destroyed b y  exposure to tritium gas or by
chem ical reactions to introduce tritium to 3 a - or 7B- positions. Thus, it seems necessary
to start with labelled cholesterol, according to B jorkhem  (1969). This method involves 
the use o f pyridine and benzene and subsequent reduction with sodium borohydride.
In synthesising esterified 7 a-hydroxycholesterol, it is necessary to protect, as an ester, 
the 313-hydroxyl group o f  cholesterol, because introduction o f  an oxygen m olecule at the 
7- position with chrom ium  reagent w ould result in the oxidation o f 36-hydroxyl group o f 
cholesterol to 3-keto. Such a protecting group m ay be acetyl, form yl or other higher fatty
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acids as stearate, as described by Kishinaka et  al.,  (1992). Sodium  borohydride reduces
the 7-ketocholesterol-3B-ester to the esterified form  o f  7a -h yd ro x ych o lestero l. It has
been suggested (K uroki, 1995- personal com m unication) that reduction w ith lithium  
aluminium hydride would, w hile reducing the 7-keto group, sim ultaneously release the
p ro tectin g  group to y ie ld  m ixtu res o f  free 7 a -h y d ro x y c h o le s te ro l and 713- 
hydroxycholesterol. D ifficu lties, such as hum idity, m ay be encountered and pose 
problems in oxidation reactions. A lthough 7a-h ydroxych olesterol m ay be stable under 
neutral or alkaline conditions, it m ay be destroyed to cholesta-5,7-dien-313-ol under 
strongly acidic conditions. For a non-organic chemist, this m ay becom e a problem, as the 
reduction reaction o f  7-ketocholesterol-3l3-ester to the corresponding 7-hydroxy esterified 
epimers- by sodium borohydride, is carried out in the presence o f  1M  HC1 (Kishinaka et 
a l . , 1992).
Thus, from  these observations, it seems worthwhile to have an assay for measuring the 
activity  o f  L C A T  tow ard a substrate, without the use o f  radiolabelled  com pounds. 
H ow ever, there were some disadvantages to this method. The overall method w as time- 
consum ing and tedious. Further product loss w ould have occured (w hich w as on ly 
validated to the H P L C  stage) after the initial L C A T  reaction, w hen the reacion w as 
terminated by addition o f chloroform/methanol (2 /1  v/v) and the method was continued as 
for the sample preparation for the H P L C  method. H ow ever, the recovery should not be 
much less than that obtained for the H P LC  only, as only one further step was carried out. 
Another factor to be considered is that due to lack o f  discoidal substrate (expense o f  
com m ercial apolipoprotein A-I), the reaction conditions chosen w ere those suitable for
cholesterol as substrate and w ere not optim ised for 7a-h yd ro xych olestero l. Thus, this
could be view ed as a noteworthy shortcoming o f  this study.
A nother enzym e w hich  is to be considered in the p ossible esterification  o f  7 a -
hydroxycholesterol is acyl-coenzym e A:cholesterol acyltransferase (A C A T ). This is an 
intrinsic endoplasmic reticulum protein, which although it has been solubilised (Suckling 
e t  al. ,  1982), it has not been purified (Erickson et  al. ,  1994). T his enzym e m ay be 
assayed, as in earlier assays, using exogenou s lab elled  ch olestero l as substrate. 
H ow ever, an associated draw -back to such an assay w ould be the determination o f  the 
extent o f  exogenous cholesterol m ixing with endogenous m icrosom al cholesterol. The 
m ost w id ely  used A C A T  assay in vo lves a [i4C ]-labelled  fatty acyl coenzym e A  as 
substrate.
[i4C]-labelled oleoyl C o A  was em ployed in this study. This is the preferred substrate, 
as p alm ito yl-C oA  is particularly sensitive to degradation by a second m icrosom al 
enzym e- a c y l-C o A  hydrolase. T his enzym e com petes w ith A C A T  for o leo y l C o A
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substrate (B illheim er et  al.,  1981). O leoyl C o A  itse lf is a detergent w hich can inhibit 
enzym e activity (Billheim er, 1985). The use o f  essentially fatty-acid free bovine serum 
albumin, as was used in this study, prevents the detergent effect o f  oleoyl C o A  disrupting 
the membrane.
A s cholesterol is a w ell defined and studied substrate o f  A C A T , it w as decided to 
attempt to deplete it from  the m icrosom al preparation in order to study the reaction
between A C A T  and 7a-hydroxycholesterol (Einarsson, 1995- personal com unication). 
This was carried out by means o f 2-hydroxypropyl-B-cyclodextrin (2-H PBCD ), which is 
a cy c lic  heptamer o f  glucose capable o f  so lubilising steroids into aqueous solutions 
through the formation o f  inclusion complexes. In such com plexes, the steroid m olecule is 
partially contained in the nonpolar cavity  o f  the m acrocycle  form ed b y  the glucose 
residues o f  B-cyclodextrin (G erloczy et  al. ,  1994). Results by these w orkers conclude 
that h yd roxyp ro p yl B -cyclodextrin  w as c le a r ly  the m ost e ffic ie n t so lu b iliser  o f  
cholesterol, with respect to other derivatives o f  B-cyclodextrin. Such com plexes m ay be 
used therapeutically, in the depletion o f cholesterol, as they also bind bile acids, thus 
preventing their reabsorption, sim ilar to cholestyram ine, but the form er being better 
tolerated than the latter.
M artin et  a l . ,  (1993) reported the successful use o f  this dextrin in the depletion o f  
cholesterol from  ham ster liver m icrosom es (8 1% ) w hile exam ining the activ ity  o f
cholesterol 7a -h yd ro x ylase . The activity o f  the enzym e (m icrosom al) w as found to be
unchanged despite the rem oval o f  its endogenous substrate. The concentration o f  2- 
H P B C D  used here w as in accordance with M artin e t  al.,  (1993) and also D e C aprio e t  
al.,  (1992) reported that the solubility o f  cholesterol in 2-H P B C D  w as 15.5 fimol/ml o f  
0.9% N aC l containing 45%  2-H PBCD , w hich w ould accom m odate the concentration o f  
cholesterol in the m icrosom al preparation. It w as successfully used as it depleted more
than 83% o f m icrosom al cholesterol. 7 a-hydroxycholesterol was added to the reaction 
mixture, suspended in Triton W R -1339. This detergent w as selected as reports have 
indicated that even under optimal conditions, the increase in A C A T  activity obtained by 
suspending cholesterol in acetone w as m uch less than that obtained b y  dispersing 
cholesterol in Triton W R -13 3 9  (Billheim er e t  al . ,  1981). O rganic solvents such as 
acetone containg sterol substrate w ould precipitate out the sterol upon addition to an 
aqueous reaction mixture and the solvent itself may inhibit A C A T . Erickson et  al . ,  (1980) 
and Egan, (1976) reported that such non-ionic detergents as Triton X -100 can disrupt the 
membrane and inhibit A C A T , as their hydrophile-lipophile balance value is betw een 12 
and 15.
7 a-hydroxycholesterol was seen to be esterified by A C A T  under the given  reaction 
conditions. The range o f  7a-h yd roxych olesterol to be added to the assay m ix posed
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another problem. So, it w as roughly calculated from  w ork carried out by Sahlin et  al . ,  
(1994) whereby they added exogenous cholesterol in the concentration o f  50nmol/100jig 
microsomal protein. This is approximately 9- to 10- times the endogenous amount. Thus,
as the endogenous amount o f  7 a-hydroxycholesterol w as found to be approxim ately 4 
nmoles/mg m icrosom al protein, then it was decided that at least a ten-fold substrate 
concentration should be added to the assay. It is apparent from  Fig 5.21 that incubation 
with increasing amounts o f  substrate that was a linear increase in the amount esterified 
between 4 and 8 nm oles substrate added. H ow ever, this linearity seem ed to dim inish
with increasing concentration o f  7 a-hydroxycholesterol, perhaps indicating saturation o f
the enzym e (approachingVm ax at 24nmoles substrate). The amount that w as esterified 
w as in the pmole/min/mg protein range, when nm oles o f  substrate w ere added to each 
assay.
O nce again, the sam ple preparation and reverse-phase H P L C  analysis described in
Chapter 3 proved useful in the identification and quantitation o f  7a-h yd roxych olesterol
present. H aving separated out the products o f  the reaction by T L C , each band w as
analysed separately for the presence o f  7 a-hydroxycholesterol. 7a-h ydroxych olesterol,
being more polar than cholesterol, has a slightly low er R f  value, using a relatively non­
polar m obile phase. Hutton et  al.,  (1966) found that m itochondria, in the absence o f
N AD + (which is required in the conversion o f  7a-h yd roxych olesterol to 7 a-h yd roxy-4-
cholesten-3-one) when incubated with 7 a-hyd roxych olesterol form ed the m ore polar
product cholesten-5-en-36,7a,26-triol. This w as also form ed upon incubation o f  7 a -
hydroxycholesterol and the supernatant fraction o f  rat liver. This triol, being more polar
than 7 a-hydroxycholesterol (Danielsson, 1961) m ay be the band corresponding to the
low est R f  value o f  0.075 (Fig 5.20). Other bands m ay be attributed to unreacted oleoyl
C o A . T he R f  values o f  esterified  7 a -h y d ro x y ch o le ste ro l (0 .31) and that o f  free
cholesterol (0.113) on the T L C  plate o f  A C A T  results, d iffer slightly from  the values for
the esterified 7a-h ydroxych olesterol obtained upon reaction o f  the substrate w ith the
L C A T  source (0.32; Fig 5.18) w hile that o f  free cholesterol was approxim ately 0 .24. 
T w o points m ay be referred to in explaining the slight difference in R f  values in the tw o 
above cases. (1): The m obile phase for L C A T  being petroleum  ether:diethyl ether:acetic 
acid(76:20:l) (v/v/v) w hich  is a slightly more polar m obile phase than that used in the
A C A T  assay: hexane:ethyl acetate (95:5) (v/v). Thus, 7 a -h yd ro x ych o lestero l bein g
relatively more polar than free cholesterol w ill m igrate further with a more polar m obile 
phase. A lso, cholesterol migrated further in this m obile phase relative to the hexane:ethyl 
acetate m obile phase. K uroki, S. (personal com m unication) suggested that the R f  value
o f esterified  7 a -h y d ro x y ch o lestero l is expected  to be very  c lo se  to that o f  free
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cholesterol, as both com pounds have one hydroxyl group. The hydroxyl group ranks 
h ig h ly  in th e o r d e r  o f  i n t e r a c t iv i t y  o f  f u n c t io n a l  g r o u p s :  
R C 0 2H > R C 0 N H 2> R 0 H > R N H 2> R C 0 2C H 3> R H -(C H 3)2> R 0 C H 3>RH . This proved
a very useful tool o f  analysis, as 7a-h yd roxych olesterol-36-o leate w as not available 
com m ercially and its synthesis would have been d ifficu lt to do as it is a long and tedious 
procedure. It involves the esterification o f  cholesterol and the subsequent oxidation with 
chrom ium  trioxide/m ethylene chloride to y ie ld  the esterified  7-keto  form . Further 
reactions are carried out and contaminating 76-hydroxycholesterol-36-oleate is rem oved.
B y  using the preparative extraction  and H P L C  procedures, the e sterifie d  7 a -  
h yd roxych olesterol w as h ydrolysed  and subsequently  m easured after en zym atic  
conversion to 7a-hydroxy-4-cholesten-3-one.
Another advantage o f  the sample preparation and reverse-phase H P L C  m ethod o f  
analysis is that the enzym e for conversion o f  products to enone derivatives detectable by 
H P L C  at 240nm, being cholesterol oxidase, is sp ecific for the 36-position o f  cholesterol 
and seems to require a double bond in the A5- or A4- positions (Richmond, 1973). It does 
not catalyse the oxidation o f  hydroxyl groups at position C - 7 a  and C -76  (Ikaw a e t a l . ,
1979) Thus, i f  7 a-hydroxycholesterol is esterified at position 3 o f  the steroid nucleus,
then in order to analyse it by H PLC , the acyl group at position 3 is hydrolysed and the 
resulting hydroxyl group is converted to an enone derivative by cholesterol oxidase.
Therefore the free and esterified 7a-hydroxycholesterol can be identified b y  means o f  the
characteristic retention time o f  7 a-hydroxy-4-cholesten-3-one. This also show s that the
esterification w hich occured was at position 3 o f  the steroid nucleus. This w ould be in 
accord with Oda e t  al.,  (1990), who recently reported that approxim ately 75 %  o f  serum
7a-hydroxycholesterol w as esterified with fatty acid(s) at the 36-position.
Due to the expense o f  radiolabelled oleoyl C o A , there w ere experiments w hich w ould  
have been beneficial and worthw hile carrying out, but, unfortunately w ere not. These 
include the following:
* M easurement o f  the activity  o f  A C A T  toward cholesterol in the bovine m icrosom al 
preparation, in order to compare it with that obtained for 7a-hydroxycholesterol.
* The activity o f  A C A T  should, ideally, be m easured after cholesterol depletion has 
occured, in order to determine i f  such treatment has harmed the enzym e in any w ay. (A s
referred to above- M artin e t  a l . ,  (1993), found that the activity  o f  cholesterol 7 a -
hydroxylase was unaffected by the depletion o f  cholesterol).
* The assay should be standardised for 7 a-hydroxycholesterol. Such parameters as the
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variations in the concentration o f  oleoyl C o A , m icrosom al protein and time should be 
investigated.
* Studies in v o lv in g  com petition/inhibition  b etw een  7 a -h y d ro x y ch o le ste ro l and 
cholesterol for A C A T  should be carried out. Thus, the addition o f  varying concentrations 
o f  7 a -h y d ro x y ch o le ste ro l, in the presence o f  both  endogenous and ex o g en o u s
cholesterol should be carried out.
* Possible product inhibition studies.
* T w o neutral cholesteryl ester hydrolases have been reported in the liver, a m ore 
quantitatively prominent one, whose activity was detected in the soluble fraction, having 
a pH optimum o f  6 .5-7.5. A  second activ ity  has been  reported, w h ich  accounts for 
approximately 11-32%  o f  the cholesteryl esterase activity o f  the homogenate- this was in 
the microsom al fraction and had a pH optim um  o f  6.1 (D eykin and G oodm an, 1962). 
Whether the activity o f  the latter may affect the products o f  the A C A T  reaction should be 
examined.
* Addition o f  A C A T  inhibitors to the above assay should be considered in order to 
determ ine i f  they have any effect, direct or indirect, on the esterification  o f  7 a -  
hydroxy cholesterol.
H owever, this part o f  the project was only a prelim inary study on the possibilty that 
A C A T  m ay e s te r ify  7 a - h y d r o x y c h o le s te r o l. A s  the resu lts  in d ic a te  7 a -  
hydroxycholesterol w hich was esterified by  A C A T . H ow ever, in relation to the amount 
o f  7a-h yd ro xych olestero l w hich was esterified  b y  L C A T , the am ount esterified  by 
A C A T  was quite small. The overall significance o f  these results w ill be discussed in the 
overall discussion and conclusion.
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CHAPTER 6 
OVERALL DISCUSSION
The w ork reported in this thesis has shown the presence o f  a considerable amount o f
esterified 7a-hydroxycholesterol in the system ic circulation o f  both man and rat. In order
to assess the meaning and validity o f  this w ork it is necessary to address two fundamental 
items; the security o f  the identifications proposed and the potential o f artificial formation
o f  7a-h ydroxych olesterol. W ith respect to the first matter, the identification o f  7 a -
hydroxy-4-cholesten-3-one having an intense absorption at 240nm by the specific action
o f  cholesterol oxidase on 7a-hydroxycholesterol appears to be very sound. Cholesterol
oxidase, being an enzym e that m odifies sterols into conjugated enones w ill oxidise 36 
hydroxyl group o f  cholesterol or related sterols to a keto group and isom erise the À 5 -
bond to y ield  a conjugated double bond w hich  acts as a chrom opheric group ( a , 6
unsaturated ketone; E = 160 0 0 M ~ lcm ‘ l) . T he m ethod has the advantage o f  a llo w in g 
separation and quantitation o f  cholesterol oxidase products by a highly sensitive H P LC . 
Identities assigned solely b y  chromatography are alw ays potentially less secure than those 
made by  brute isolation o f  crystalline material by c lassical methods. N onetheless, the 
validation o f  the method wherein serum samples w hich were spiked with know n amounts
o f  7a -h yd ro x ych o lestero l show ed alm ost 80% reco v ery  and the dem onstration o f  
acceptable low  coefficients o f  variation for both inter- and intra-assays puts the method o f 
identification o f 7a-hydroxycholesterol reported here on a very secure basis.
T he second issu e  o f  im portance is  the p oten tial a rtific ia l orig in  o f  7 a -  
hydroxycholesteryl ester, w hich m ay be an esterified cholesterol oxidation product (i.e. 
7a-h yd ro xych olestero l) , ox id ized  cholesteryl ester or both. I f  the origin is that o f
esterification o f  an oxidised cholesterol derivative such as 7a-hydroxycholesterol, then it
must have occurred as a result o f  a rapid p o s t  mor tem  transestérification o f  traces o f  7  a -
hydroxycholesterol in the presence o f  m assive amounts o f  cholesterol and cholesterol
esters. Alternatively, the requisite 7 a-hydroxycholesterol must be present in v i vo  w here
enzym ic esterification occurs. The latter situation is alm ost certainly the case  for the
esterified 7 a-hydroxycholesterol as analysis was carried out in the presence o f  B H T  and
w as not accom panied b y  the appearance o f  the tw o forem ost m ajor autooxidative
products o f  cholesterol- 76-h ydroxych olesterol or 7-ketoch olesterol. T hough  7 a -
hydroxycholesterol is a quantitatively m inor cholesterol autooxidation product, and
though esters o f 7a-hydroxycholesterol are form ed from  the autooxidation o f  cholesteryl
esters, such air oxidations o f  cholesteryl esters require considerably more exposure in air 
to radiation or heat than for cholesterol and much more than allowed in the present work. 
A s show n in Table 4.5, the concentration o f  serum  cholesterol w as approxim ately
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22000-fold that o f  7a-hydroxycholesterol in humans (approxim ately 6000-fold in rats) 
and minimal autooxidation o f  cholesterol during the sample preparation m ight result in an 
appreciable increase o f  7 a -h y d ro x y ch o le ste ro l. In the present study, h ow ever,
concentration o f  total (free and hydrolysed) 7a-h yd ro xych o lestero l increased rapidly
during alkaline hydrolysis. The levels o f  total 7 a -h yd ro x ych o lestero l after alkaline 
hydrolysis, being sim ilar to those after enzym atic hydrolysis, suggest that there is a form 
o f  7a -h yd ro x ych o lestero l in human and rat serum  w h ich  is readily converted  to 
quantifiable free 7a-hydroxycholesterol.
The hypercholesterolaem ic patients in this study had significantly higher levels o f  total 
7a-hydroxycholesterol than control normolipidaemic subjects. Approxim ately 78-84% o f 
serum 7 a-hydroxycholesterol was esterified w ith fatty acids at the 313 position in both
groups. Despite this, the ratio o f total 7a-hydroxycholesterol to total cholesterol remained
unchanged, suggesting cholesterol-bearing lipoproteins as a possible transport m edium
for 7 a-h yd roxych olesterol in plasma. H igher levels o f  7a -h yd ro x ych o lestero l w ere
found in rat serum relative to human serum, probably reflecting a much greater synthesis
o f  this metabolite in the rat than in the liver. I f  one considers 7a-h yd roxych olesterol as
the major oxidative product o f  cholesterol in the bile acid biosynthetic pathw ay and that 
the r a t , unlike the human has no storage facility  for bile acids it is not surprising that 
such a species difference w ould exist. A  m ajor finding in this study w as how ever the
significantly higher lev el o f  total 7a-h yd roxych olesterol in serum o f cholestyram ine-
treated rats relative to control or diabetic rats. This has previously been demonstrated in 
patients w ith prim ary hypercholesterolaem ia on b ile  acid sequestrant therapy (V an 
Doormaal e ta l . ,  (1989) and B ascoul et  al.,  1990). Furtherm ore, there w as a significant
correlation betw een hepatic levels o f  7 a-hyd roxych olesterol and serum levels o f  7 a -
hydroxycholesterol, indicating that measurement o f  this m etabolite in serum m ay be a 
good means o f  confirm ing high levels o f  bile acid synthesis occurring in liver w hich  
otherwise is difficult to do, being dependent on surgical liver biopsy for measurement o f
hepatic cholesterol 7a-h yd roxylase. There w as no correlation between sterol levels in
liver and serum within each group however. W hether this w as due to the lim ited number 
o f animals within the groups or to other factors is not known. Theoretically, the level o f
7 a-hydroxycholesterol in serum should be dependent upon several factors other than
cholesterol 7a-h yd ro xylase  activity, e.g. rate o f  diffusion/ secretion o f  the sterol into 
blood and rate o f  m etabolism  / elimination. These factors m ay vary between animals and 
contribute to the poor correlation between sterol levels and hepatic levels observed within
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the three rat groups studied. A s mentioned in the introduction to this thesis, only one
other report on levels o f  serum 7a-hydroxycholesterol has been reported but in portal
blood (Fukushima et  al.,  1995). Such measurements by  gas liquid chrom atography were 
found to be circa 800-1000 pmoles/ml w hich w ere sign ifican tly  higher than those
reported in this study (247pmoles/ml serum). Despite the obvious greater concentration 
o f  bile acids (and presumably bile acid precursors) in the enterohepatic circulation, it is
apparent that quantifiable levels o f  7 a-h yd roxych olesterol do leak into the system ic
circulation and that levels mirror levels in liver, potentially its tissue o f  origin.
A  second m ajor outcom e o f  the w ork reported in this thesis w as that 7 a -  
hydroxycholesterol can be esterified by plasma L C A T  and to a lesser extent by the liver 
enzym e, A C  AT. Various studies have been carried out on the possible esterification o f  
oxysterols b y  A C A T  but to date it appears that no corresponding study has been 
published on the plasma esterifying enzyme, L C A T . The findings as described in Chapter 
5 m ay provide answers to some o f  the questions posed by O da e t a l . ,  (1990) w hich  are 
schem atically represented in Fig 6.1.
1) D oes a fraction o f 7a-hydroxycholesterol synthesised in the liver m icrosom es escape 
the bile acid biosynthetic route? 2) Is it esterified by A C A T  in the liver m icrosom es? 3) 
Is it secreted into the system ic circulation as the esterified form  or is it hydrolysed by a 
cholesterol esterase in liver cytosol? 4) Is it not esterified in the liver but rather secreted 
as the free form  into the circulation where it is then esterified by L C A T ?  or 5) m aybe a 
fraction is esterified by both enzym es?
T his study suggests that a p ossib le  m etabolism  o f  7 a -h y d r o x y c h o le s te r o l in
hepatocytes and in serum  w ould  be that in v iew  o f  the sm all proportion o f  7 a -  
hydroxycholesterol in serum (pmoles/ml) relative to rat liver (nmoles/ml), that most o f  the 
hepatic 7 a-hydroxycholesterol is m etabolised to bile acids in the liver and that only a
sm all amount o f  it escapes into the system ic circulation either as free or esterified 7  a -
h ydroxych olesterol. O f  the 7 a -h yd ro x ych o le ste ro l w h ich  enters the circu lation  a 
substantial amount may be esterified by L C A T .
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F ig  6 .1 Schem atic representation o f  the possible m etablism  o f  7a-h ydroxych olesterol in 
hepatocyte and serum. 1= 36-hydroxysteroid dehydrogenase; 2= A C A T ; 3= Cholesterol 
esterase and 4= L C A T . Adapted from Oda et  al.,  (1990).
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IThe significance o f  this finding relates to the transport and further m etabolism  o f  7 a -  
hydroxycholesterol in vivo .  W hen this oxysterol w as presented to L C A T  in com plexes 
w hich resembled H D L ’ s, esterification resulted; this proposes further areas o f  research
such as reacting the esterified 7 a-hydroxycholesterol w ith other lipoproteins and proteins
/ enzym es w hich are involved in the m etabolism and exchange reactions o f  lipoproteins
and tracing their pathway o f  transport and delivery. That transport and m etabolism o f 7  a -
hydroxycholesterol w ould be similar to that o f  cholesterol m ay be inferred from  a recent 
study published by K ishinaka et a l . ,  (1992) w here it w as observed that intravenously
administered esterified 7a-hydroxycholesterol was taken up by the liver and m etabolised
via the normal bile acid biosynthetic pathway. Thus 7a-hydroxycholesteryl ester m ay be
delivered to liver in the form  o f H DL particles for elim ination by the body in the form  o f 
bile acids, as in reverse cholesterol transport. A s  to its mode o f  entry into the system ic 
circulation, it is probable that it m ay be either secreted from  the liver in the form  o f 
nascent H D L ’ s or more likely  as part o f  V L D L ’ s w hich undergo further m etabolism  by
lipoprotein  lip ase. It is w orth m entioning that p o ssib le  equ ilib ratio n  o f  7  a -
hydroxycholesterol from  liver w ith 7a -h yd ro x ych o lestero l from  other non-hepatic 
sources such as heart, lung and kidney (Chiang et  al.,  1990) m ay occur in the circulation. 
R everse transport o f  7a-h ydroxych olesteryl ester by H D L ’s m ay account for the rapid 
hepatic uptake o f  this sterol as reported by Kishinaka e t  al.,  (1990).
The question still remains as to whether 7 a-hydroxycholesterol exerts a regulatory role 
in cholesterol m etabolising pathways or i f  it is an atherogenic oxysterol. H ow ever the 
latter is probably unlikely as it has a very short h alf life  (about 6 hours) when injected as
7a-h ydroxych olesterol-stearate and its hepatic uptake to prim ary bile acids is ve ry  
efficient -at least in hamsters (S. K uroki , K yushu U niversity, Fukuoka, Japan, 1995- 
personal com m unication). L ast month D oerner e t  al . ,  (19 9 5) reported that 7 a -
h yd roxych olesterol in concentrations o f  50 fiM  fa iled  to restore ch olestero l 7  a -  
hydroxylase m RN A  levels in squalestatin (a specific squalene synthase inhibitor w hich 
results in depriving the ce ll o f  endogenously synthesised sterols)-treated rat hepatocyte
cultures. T hey deduced that cholesterol rather than oxysterols regulate cholesterol 7  a -
hydroxylase expression. W hether 7 a-hydroxycholesterol might affect transcription o f  
other genes containing sterol regulatory elements is not yet known.
In vitro  studies carried out over two decades ago show ed that 7 a-hydroxycholesterol, 
713-hydroxycholesterol and 7-ketocholesterol when incubated at concentrations o f  5|iM  or
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more with primary cultured mouse liver cells or L  cells ( a subline o f  N C T C  clone 929 
mouse fibroblasts) markedly inhibited both sterol synthesis and the activity o f  H M G  C o
A  reductase. Another report found 7 a-hydroxycholesterol to be potent in the inhibition 
o f  ch olesterol uptake into aortic sm ooth m uscle ce ll cu ltures b y  up to 5 1 %  at 
concentrations o f 3p.g/ml (7.45 nmoles/ml) (Peng et  a l . ,  1985). These oxysterol studies 
in cultured cells involved  the addition o f  sterols in organic m edia such as ethanol. 
H ow ever Goldstein and Brow n in 1990 reported that ethanol allow s the sterols to enter 
the cyto so l, thereby bypassing the requirem ent for receptors or lysosom es. The 
accumulation o f  such polar sterols in the cytosolic compartment m ay thus account for 
their enhanced potency. Thus future w ork  to be considered in this field  o f  research 
should in volve  presentation o f  such sterols to liver cells as com ponents o f  synthetic 
com plexes which resemble lipoproteins. This w ould facilitate a study o f  how oxysterols 
are taken up by liver cells and m etabolised- whether by means o f  a receptor-m ediated 
pathw ay or whether they directly enter the cyto so lic  or m icrosom al fractions. The 
inclusion o f  serum, serum lipids or serum lipoproteins in m edia is a serious limitation o f  
many in vi t ro  studies (Sm ith and Johnson, 1989). Such  factors m ay influence the 
proliferation, growth and functioning o f  the cell. In addition, the presence o f  undetected 
levels o f oxysterols may also influence the nature o f  the w ork being carried out.
Identification o f oxysterol- binding proteins that regulate oxysterol trafficking between 
membrane compartments is another area for future research.
The significance i f  any o f  the presence o f  fatty acyl esters o f  other oxysterols is a third 
area for future research. The sterol esters m ay be sim ply esterified for further m etabolic 
disposition in the same fashion as is cholesterol. The w ork described in Chapter 5 on
investigating the reactivity o f  7a-h ydroxych olesterol w ith  L C A T  m ay be adapted for 
studying interaction o f  other oxysterols in discoidal com p lexes w ith  serum L C A T . 
Cholestane-313,5a,613-triol, for exam ple is reported to be a toxic m etabolite o f  cholesterol. 
H ow ever, the cytotoxic properties o f  the oxidised sterols suggest that esterification m ay 
be a detoxification mode. The esters m ay be m etabolised nonetheless to y ie ld  the active 
free sterols. M ore speculatively, the hypothesis o f  Kandutsch e t  al. ,  (1978), regarding 
the possible endogenous regulation o f  d e  n o v o  sterol synthesis b y  these oxid ised  
cholesterol derivatives is served b y  findings o f  these p h ysio io lg ica lly  active sterols in 
liver (potentially a tissue o f  origin), plasm a (potentially a transport medium ) and aorta 
(potentially a target tissue).
Thus to conclude, the aims o f  this study being to measure and investigate the biological 
significance and route o f  m etabolism o f 7a-hydroxycholesterol in serum were achieved.
The w ork yielded  a suitable m ethod for analysing serum 7 a-hydroxycholesterol in 
human and rat serum as w ell as in in vi tro  systems com prising reconstituted lipoprotein
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complexes. The method allowed for a correlation between levels of serum and hepatic 
7a-hydroxycholesterol to be investigated and indicated that this may be of significant use 
in diagnosing metabolic disorders of bile acid metabolism. Finally, the resulting 
esterification of this oxysterol by plasma LCAT (involving the synthesis of complexes 
which resembled HDL’s) and also to a lesser extent by hepatic ACAT allows for further
studies on the metabolism of 7 a-hydroxycholesterol and also of other oxysterols 
currently implicated in atherosclerosis.
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